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ABSTRACT 
Erich Vaughn Scheller: Contribution of fimbria and filamentous hemagglutinin in Bordetella 
adherence and immune suppression 
(Under the direction of Peggy A. Cotter) 
 
Pertussis, or whooping cough, is a highly contagious respiratory disease caused by 
Bordetella pertussis. Recent changes to the vaccine against B. pertussis have led to the re-
emergence of this disease. Given the re-emergence of pertussis, it is critical to understand 
Bordetella pathogenesis. Fimbria and filamentous hemagglutinin (FHA), two proposed bacterial 
adhesins and components of the current vaccine, have been shown to be important virulence 
factors required for bacterial colonization of the lower respiratory tract of rats. Bordetella fimbria 
(Type I pili) are generally considered to function as adhesins despite a lack of supporting 
experimental evidence. FHA is a large exoprotein that has been shown critical for Bordetella 
adherence. We developed a novel in vivo adherence assay that confirmed FHA functions as an 
adhesin and we demonstrated a role for fimbria in adherence to ciliated respiratory epithelium. 
We further established that fimbria are required for bacterial persistence in the lower respiratory 
tract of mice and that fimbria contribute to suppression of the immune response. We also 
observed that wild-type and FHA-deficient bacteria induced cellular infiltrate around the major 
airways of the lungs and that FIM-deficient bacteria induced cellular infiltrate in the alveoli. A 
bacterial localization assay established that WT and FHA-deficient bacteria localized to the 
major airways and that FIM-deficient bacteria localized to the alveoli. Together, these findings 
suggest that fimbria mediate the first critical step of localizing the bacteria to the ciliated 
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epithelium of the major airways, and that FHA may mediate tight adherence to these cells. We 
also demonstrated that SCID mice, which contain functional neutrophils and macrophages but 
lack B and T-cells, are unable to clear FIM-deficient bacteria from the lungs. B and T-cells 
adoptively transferred in to SCID mice prior to inoculation partially restored clearance of FIM-
deficient bacteria from the lungs. Collectively, our data suggest that fimbria and FHA mediate 
critical adherence steps necessary for Bordetella to colonize and to modulate the immune system 
and that B and/or T-cells are required to mediate the initial host response to control Bordetella 
infection.  
v 
 
 
 
 
ACKNOWLEDGEMENTS 
 I would like to acknowledge first my advisor Peggy Cotter for her constant support 
throughout my graduate school career and for the training to become a more critical thinker and a 
better writer. I would also like to acknowledge my thesis committee for all of their support and 
advice throughout my graduate school education. I would like to thank all the members of the 
Cotter Laboratory, past and present, for their encouragement throughout my research, for their 
thoughtful discussions and for their tasty lab meeting snacks. I would also like to acknowledge 
Jeff Melvin (primary author of Chapter 3 of this thesis) for his help with animal experiments and 
experimental design throughout my thesis project. I would like to thank my parents, Walter and 
Gina Scheller, for their unconditional love and support, as well as my siblings, Sam, Brett and 
Madyson, who constantly keep me laughing. I would like to thank Pearl, our West Highland 
Terrier, who kept me grounded by making sure I never got to sleep on my own pillow. Finally, I 
must thank my fantastic wife, Shannon, for her unwavering support throughout my graduate 
career. I love you so much and I look forward to our next adventure together. 
  
vi 
 
 
 
 
TABLE OF CONTENTS 
 
LIST OF TABLES ....................................................................................................................... viii 
LIST OF FIGURES ....................................................................................................................... ix 
CHAPTER 
 I. INTRODUCTION ...................................................................................................1 
  References ..............................................................................................................12 
II. COOPERATIVE ROLES FOR FIMBRIA AND FILAMENTOUS 
HEMAGGLUTININ IN BORDETELLA ADHERENCE AND 
IMMUNEMODULATION ....................................................................................19 
 
Importance .............................................................................................................19 
 
 Introduction ............................................................................................................19 
 Results ....................................................................................................................23 
 Discussion ..............................................................................................................32 
 Materials and Methods ...........................................................................................38 
 Supporting Information ..........................................................................................41 
 References ..............................................................................................................51 
III. NEW INSIGHT INTO FILAMENTOUS HEMAGGLUTININ  
SECRETION REVEALS A ROLE FOR PRE-PROCESSED FHAB  
IN BORDETELLA VIRULENCE  .........................................................................55 
Introduction ............................................................................................................55 
Results  ...................................................................................................................59 
Discussion ..............................................................................................................69 
Materials and Methods ...........................................................................................73 
vii 
 
Supporting Information ..........................................................................................76 
References ..............................................................................................................85 
IV. CLEARANCE OF FIM-DEFICIENT BACTERIA REQUIRES 
A COMPONENT OF THE ADAPTIVE IMMUNE RESPONSE ........................89 
Rationale ................................................................................................................89 
Results ....................................................................................................................91 
Discussion ..............................................................................................................94 
Supporting Information ..........................................................................................96 
Materials and Methods ...........................................................................................98 
References ..............................................................................................................99 
V.  CONCLUSIONS..................................................................................................101 
References ............................................................................................................109 
APPENDICES 
A.   BORDETELLA PERTUSSIS PATHOGENESIS: CURRENT  
AND FUTURE CHALLENGES .........................................................................112 
B.  EVIDENCE FOR PHENOTYPIC BISTABILITY RESULTING  
FROM TRANSCRIPTIONAL INTERFERENCE OF BVGAS 
IN BORDETELLA BRONCHISEPTICA ..............................................................161 
C.  AN IMPROVED RECOMBINATION-BASED IN VIVO  
EXPRESSION TECHNOLOGY-LIKE REPORTER SYSTEM 
REVEALS DIFFERENTIAL CYAA GENE ACTIVATION IN  
BORDETELLA SPECIES ....................................................................................215 
  
viii 
 
LIST OF TABLES 
 
Table 
 1.1 Examples of Type 1 pili adhesin proteins and host cell targets……………………...11 
 2.1 Bacterial strains and plasmids used in this study…………………………………….50 
  
ix 
 
LIST OF FIGURES 
 
 2.1 Fimbriae are required for adherence in vivo……………………………………..41 
 2.2 Fimbriae are required for persistence in the lower  
respiratory tract…………………………………………………………………..43 
 
 2.3 Fimbriae are required to modulate the innate immune 
response in mice………………………………………………………………….44 
 
 2.4  Fimbriae do not complement “ in trans ” during coinoculation…………………46 
 2.5 FIM-deficient bacteria localize differently than WT and  
FHA-deficient bacteria in the lower respiratory tract……………………………48 
 
3.1 The FhaB prodomain transits to the periplasm, where  
it is retained during secretion…………………………………………………….76 
 
3.2 The extreme C-terminus (ECT) of the FhaB prodomain  
inhibits prodomain degradation………………………………………………….78 
 
3.3 Figure 3. Properly folded FHA is necessary and sufficient 
for adherence of B. bronchiseptica to the respiratory tract………………………79 
 
3.4 The FhaB proline-rich region and extreme C-terminus 
are necessary for B. bronchiseptica persistence in the  
lower respiratory tract in a manner that is distinct from  
suppression of inflammation……………………………………………………..81 
 
3.5  The persistence defect of the ∆PRR and ∆ECT strains  
cannot be rescued by WT bacteria……………………………………………….83 
 
4.1 SCID mice cannot clear FIM-deficient bacteria from the lungs………………....96 
4.2 Adoptive transfer of bulk splenocytes restored partial 
 clearance of FIM-deficient bacteria from the lungs……………………………...97 
 
1 
 
 
 
 
CHAPTER 1. INTRODUCTION 
Reemergence of Pertussis 
 Pertussis, or whooping cough, is a highly contagious respiratory disease that is 
transmitted by human to human contact (1). The causative agent is the Gram-negative bacterium 
Bordetella pertussis, which accounts for the majority of cases of whooping cough. Bordetella 
parapertussis and Bordetella bronchiseptica, two closely related species of B. pertussis, account 
for the minority of cases (2, 3). Typically, pertussis affects young children and infants, though 
affects older individuals as well (4).  
Pertussis disease is characterized by three phases: the catarrhal phase, the paroxysmal 
phase and the convalescent phase (5) . During the catarrhal phase, the bacteria presumably 
adhere to the respiratory epithelium of the upper respiratory tract and survive innate host 
responses (6, 7). During this phase, symptoms are similar to those of the common cold. After 1-2 
weeks, the disease progresses to the paroxysmal phase. During this phase, which can last for up 
to 10 weeks, the characteristic ‘whoops’ occur, as well as severe spasmodic coughing episodes. 
During the convalescent phase, the adaptive immune response leads to bacterial clearance, 
however symptoms often persist for a month or longer (5). 
In young children (1-9 years old), this disease, while distressing and uncomfortable, is 
not typically fatal. For infants, however, pertussis can often be life threatening, as the bacteria 
may disseminate into the lungs and cause pneumonia (7). Once in the lungs, the infection may 
lead to necrotizing bronchiolitis, intra-alveolar hemorrhage and fibrinous exudate. 
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Lymphocytosis may also occur, which is an influx of lymphocytes in to the bloodstream (7). 
This influx has been shown to correlate positively with pulmonary hypertension, respiratory 
failure and death (7).  
Given the highly contagious nature of pertussis, as well as the severe threat to infants, a 
whole-cell pertussis (wP) vaccine was introduced in the 1940s. This vaccine quickly reduced the 
incidence of pertussis cases per year in the United States. While the wP vaccine was successful, 
there were unfounded  concerns regarding its safety, and public pressure lead to the replacement 
of the wP vaccine with an acellular component vaccine (aP) in the United States and other 
developed nations in the 1990s (8). The aP vaccine contains secreted Bordetella virulence 
factors, such as pertussis toxin, filamentous hemagglutinin, pertactin and fimbrial subunits (9, 
10). Since the introduction of the aP vaccine, pertussis cases have been increasing, with reported 
cases reaching numbers similar to what was seen in the 1950s  (11). Recent studies indicate that 
the incidence of pertussis is significantly higher in children vaccinated with only the aP vaccine 
compared to those that receive even just one dose of the wP vaccine (12). Given the re-
emergence of pertussis, it is important to further the understanding of Bordetella pathogenesis in 
order to develop better vaccines and treatment strategies to reduce morbidity and mortality. 
Bordetella phylogenomics 
 The ‘classic’ Bordetellae (B. pertussis, B. parapertussis and B. bronchiseptica) are the 
three species known to cause disease in mammals (13). Phylogenetic studies indicate limited 
genetic diversity between these three species and suggest that B. pertussis, B. bronchiseptica and 
B. parapertussis are subspecies that have independently evolved from a B. bronchiseptica-like 
ancestor (2, 3). These data are intriguing, given the differences in host range of these subspecies: 
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B. bronchiseptica causes chronic colonization in a wide-range of mammalian hosts, while B. 
pertussis and B. parapertussis are strict human pathogens that cause acute respiratory disease 
(14). Whole genome sequence comparisons indicate that both B. pertussis and B. parapertussis 
underwent gene loss and accumulated insertion sequence elements, events that may have limited 
the host range of B. pertussis and B. parapertussis  (2, 15, 16). Importantly, many of the known 
Bordetella virulence factors of B. bronchiseptica, B. pertussis and B. parapertussis are almost 
identical and functionally interchangeable  (17). Given these similarities, and the fact that B. 
bronchiseptica infects a broad mammalian host range, B. bronchiseptica is often used as a model 
organism as it allows in vivo studies using laboratory animal hosts (17–20). 
Animal Models 
Given that B. pertussis is a human-restricted pathogen, one of the challenges of studying 
the pathogenesis of B. pertussis is developing models that reflect human disease. Using rodent 
models, such as mice, rabbits, rats and guinea pigs, none of which are natural hosts of B. 
pertussis, high numbers of B. pertussis must be delivered directly to the lungs in order to 
establish infection (13). Once the lungs are colonized, the bacteria will multiply for a week post-
inoculation but are eventually cleared. During this time, the host animal will not mount a robust 
pertussis-specific immune response (13). Furthermore, these animals do not present classical 
whooping cough symptoms, and attempts to test transmission have not been fruitful. Taken 
together, these data suggest that rodent models using B. pertussis are not an ideal model system.  
The most recent advance in modelling human pertussis has been the development of a 
baboon (Papio Anubis) model (21). When B. pertussis is inoculated into the nasopharynx of 
weanling baboons, the baboons will develop low-grade fever, paroxysmal coughing, 
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lymphocytosis and produce pertussis-specific protective antibodies (21). Additionally, the 
baboon model allows for study of transmission, as infected baboons have been shown to transmit 
to uninfected baboons by both contact and aerosols (22). Most importantly, this model has 
provided insights into failings of the current aP vaccine, as data suggest that the aP vaccine can 
protect from disease but not colonization or transmission (23).  
While the baboon model provides a promising model for B. pertussis colonization, 
pathogenesis and transmission, using baboons is prohibitively expensive and requires animal 
facilities capable of housing and caring for the animals. As such, rodent models still provide a 
useful model system, and our lab and others have utilized B. bronchiseptica, rather than B. 
pertussis, as our pathogen in this model. As mentioned previously, B. bronchiseptica and B. 
pertussis share similar and functionally interchangeable virulence factors, but B. bronchiseptica 
will naturally colonize rodents (17, 24). While rodents do not present pertussis disease 
symptoms, they are natural hosts of Bordetella, providing insight to the contribution of virulence 
factors for colonization and persistence during a ‘natural’ infection.  This dissertation will focus 
on using B. bronchiseptica in a mouse model of colonization and persistence, which allows for 
understanding the contribution of virulence factors to bacterial survival, as well as tools to 
understand the host response to infection. 
Bordetella adhesins: Fimbria 
B. pertussis, B. bronchiseptica and B. parapertussis all produce type I pili, also known as 
fimbria (FIM). Pili are non-flagellar, multi-subunit surface structures typically involved in 
adherence to other bacteria, host cells or environment surfaces (25, 26). Pili are characterized by 
their assembly pathways, with Type I pili (fimbria) being assembled by the usher-chaperone 
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pathway. Other pili groups include Type IV pili, curli pili, and ‘alternative chaperone-usher 
pathway’ (27).  The Type I pili systems have been the most extensively characterized, with 
Enterobacteriaceae and uropathogenic Escheria coli (UPEC) being the model organisms for 
Type I pili (28). Type I pili consist of a rigid rod composed of pilin subunits extending from the 
bacterial surface with a flexible, adhesive tip (27). These pilin subunits are translocated across 
the cytoplasmic membrane by the sec translocation machinery (28). Once in the periplasm, these 
subunits will complex with the chaperone proteins (29). The chaperone-subunit complex is then 
targeted to the outer membrane usher protein (31, 32), where the complex then dissociates and 
the subunits are added to the base of the pilus by donor-strand exchange, a process by which the 
Ig-like folds of one pilin subunit interacts with the N-terminal extension of a second  pilin 
subunit, non-covalently assembling the pilus (33–35). The usher protein also provides an anchor 
in the outer membrane for the growing pilus as the pilus is exported to the surface of the 
bacterium (36).  
Pathogenic bacteria utilize pili to mediate adherence to mucosal surfaces (26). The tip 
adhesins often mediate this interaction (37), and this protein contains two domains, 1) the C-
terminal Ig-like fold required for donor-stand exchange to assemble the pilus (34, 35) and 2) an 
N-terminal ligand binding domain (37). For example, the FimH adhesin of E. coli has been 
shown necessary for pathogenesis (38). FimH will bind to mannosylated receptors found on 
bladder epithelium (39). This binding then allows the bacteria to bind, invade and form 
intracellular communities and these interactions are necessary for the bacteria to survive during 
the acute stage of infection (40, 41). The roles of pili in bacterial pathogenesis of Gram-negative 
bacteria are broad, as these structures have been shown necessary for adherence, invasion, 
biofilm and inducing host cell signaling (Table 1). However, the common theme surrounding the 
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role of pili is that these structures mediate initial interactions during the early stages of infection 
that allow the bacteria to colonize and proliferate. 
For the Bordetella spp., the fimbrial proteins are encoded by the fimBCD operon, with 
fimB encoding the chaperone, fimC encoding the usher, and fimD the putative adhesive tip (42). 
The major fimbrial subunits are encoded by fim2 and fim3 (43). These genes are located outside 
of the fimBCD operon, are capable of undergoing phase variation (43), and the respective 
proteins, Fim2 and Fim3, are components in the aP vaccine. There are additional, alternative 
major fimbrial subunits identified on the chromosome, such as fimA, fimN and fimX, however the 
expression of these alternative subunits is poorly understood (44–46). While there are no 
reported data showing that the fimbrial components are interchangeable between B. pertussis and 
B. bronchiseptica¸ the amino acid sequences are very similar. When comparing B. pertussis 
(Tohama I) and B. bronchiseptica (RB50), the FimD proteins are 95% identical, while Fim2 and 
Fim3 are 73% and 94% identical, respectively, and it is likely that the fimbria of B. 
bronchiseptica and B. pertussis play similar roles during infection (42, 47, 48).  
Type I pili systems (and fimbria) of different bacterial species have been shown to be 
necessary components in mediating bacterial adherence (27), however in vitro studies using 
Bordetella lacking fimbria have produced varied results. Typically, to study adherence in vitro, 
bacteria will be centrifuged down on to various cell lines of interest (49). These cells will then be 
washed and the number of bacteria remaining will be determined. Using this method, a B. 
pertussis strain containing a TnphoA disruption of fimD was shown defective for adherence to 
monocytes (50). This mutant, however, was also defective for FHA production, and so the 
contribution of fimbria alone in this strain is unknown. A ∆fimBCD strain of B. bronchiseptica, 
which does not produce fimbria and is unaltered for FHA production, will still adhere to any cell 
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type of interest, including epithelial cells and macrophages, suggesting that in these in vitro 
assays, fimbria are not necessary for adherence (49). Assays using tracheal explants, however, 
suggest that fimbria may be required for adherence specifically to ciliated epithelial cells, as a B. 
pertussis strain defective for both FIM and FHA had an adherence defect to baboon tracheal 
explants (51), and B. bronchiseptica defective for FIM had decreased adherence to rabbit 
tracheal explants (6). Attempts to identify a receptor for FIM-mediated adherence showed that 
purified FimD protein adhered to monocytes (52), and purified Fim2 and Fim3 adhered to 
sulfated sugars (53). However, because these experiments used non-ciliated cell lines and 
purified proteins, the receptor for full length, native fimbria is still unclear as purified protein 
interactions may not be reflective of bacterial-associated fimbria.  
While the role of fimbria in bacterial adherence is unclear, various animal models 
indicate an important role for these structures in bacterial colonization and persistence. To 
determine the role of virulence factors in colonization, a rat model, where a small volume 
inoculum is administered into the tip of the nose, has been used. In this model, WT B. 
bronchiseptica will colonize and persist in the nasal cavity and trachea indefinitely (49). When 
rats were inoculated with a B. bronchiseptica stain defective only for fimbria, the FIM-deficient 
bacteria colonized and persisted in the nasal cavity, but were unable to colonize the trachea (49). 
To determine if fimbria were required for the bacteria to migrate from the nasal cavity to the 
trachea, WT or FIM-deficient bacteria were inoculated directly into the trachea.  The WT 
bacteria again were able to colonize and persist in the trachea and nasal cavity, however the 
FIM-deficient bacteria could not colonize or persist in the trachea, despite colonizing the nasal 
cavity (54). Together, these data suggest that fimbria are required to adhere to tracheal tissue, 
resist mucociliary clearance, and possibly to avoid innate immune effectors.  
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While the rat model of infection is useful to determine the role of virulence factors in 
colonization, our lab and others have utilized a mouse model to investigate the host response to 
Bordetella infection. This model uses a large volume, high number of CFUs inoculated 
intranasally. Using this method, bacteria are presumably deposited through the entirety of the 
respiratory tract. While this model has not been utilized to investigate the host response to 
bacteria lacking only fimbria, a study using a B. pertussis strain defective for both fimbria and 
FHA indicated that both fimbria and FHA are required for bacterial persistence and suggested 
that fimbria may contribute to immune suppression (55). 
Bordetella adhesins: Filamentous Hemagglutinin 
Filamentous hemagglutinin (FHA), one of the primary components of the aP vaccine, is a 
large exoprotein secreted by the two-partner secretion (TPS) pathway (56). TPS is a protein 
secretion pathway for Gram-negative bacteria which facilitates secretion of large proteins 
through the outer membrane and to the surface.  Many TPS systems have been shown to 
contribute to bacterial virulence, with roles including adherence, iron acquisition, immune 
evasion and cytotoxicity (19, 57–61). TPS systems have a large exoprotein (generically known 
as TpsA) which is translocated through a cognate outer membrane β-barrel pore protein 
(generically known as TpsB). The secretion mechanism is complex, as secretion occurs in the 
absence of chemical energy and, despite an absence of mechanisms to ensure correct folding, 
results in translocation and proper folding of massive proteins.  For Bordetella, one TpsA protein 
is FhaB, which is synthesized as a ~370 kDa pre-pro-protein, that, when processed, is a ~250 
kDa protein known as FHA (62). The cognate TpsB protein, FhaC, is required to translocate 
FhaB across the outer membrane (56). The C-terminal prodomain is processed by SphB1 and 
other unidentified factors (56, 63). Once ‘mature’, FHA is oriented with the C-terminus distal to 
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the bacterial surface (56, 62). Mature FHA can also be released, as substantial amounts are found 
in culture supernatant in vitro, though the physiological relevance of this release is unclear (56). 
As for many processed proteins, this ‘mature’ molecule is typically considered to be the 
functional form of the protein. 
FHA has been shown both necessary and sufficient to mediate bacterial adherence to a 
broad range of eukaryotic cell lines (64). Additionally, FHA was shown to contribute modestly 
to adherence to ciliated explants, much like fimbria (6), suggesting that FHA alone may not be 
the sole adhesin during infection. Furthermore, studies have shown that FHA molecules 
produced by B. pertussis and B. bronchiseptica are functionally interchangeable regarding 
adherence (17, 20). Studies using non-ciliated cell lines suggest that FHA binds to CR3, VLA-5, 
and leukocyte response integrin-integrin-associated protein (LRI-IAP) complexes (65, 66). 
However, the importance of these interactions has not been shown in vivo.  
FHA has been shown necessary for B. bronchiseptica to colonize the lower respiratory 
tract in a rat colonization model (58), similar to results seen with bacteria lacking fimbria. The 
host response to FHA has been well characterized in the mouse model. FHA-deficient bacteria 
are defective for persistence compared to WT bacteria and induce a more robust inflammatory 
response, characterized by increased pro-inflammatory cytokine and chemokine production, such 
as IL-1β, IL-17, MCP-1 and KC (17, 19, 64). Furthermore, Hemotoxylin and Eosin (H&E) 
stained lung sections indicate increased cellular infiltrate around the major airways when mice 
were inoculated with FHA-deficient bacteria, compared to lung sections from mice inoculated 
with WT bacteria (19). This influx appears to be primarily neutrophilic (19). Together, these data 
suggest that FHA allows B. bronchiseptica to modulate the immune response and establish a 
persistent infection. Interestingly, experiments using B. pertussis lacking FHA in a mouse model 
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indicated that FHA is not necessary for colonization or persistence. However, because B. 
pertussis does not naturally infect mice, the implications of this finding are unclear.  
Research objectives 
Even though fimbrial subunits are included in the aP vaccine, very little is understood 
regarding the contribution of fimbria to Bordetella adherence, colonization and persistence. 
Within the rat model, FIM-deficient and FHA-deficient bacteria appear to have identical 
colonization defects (19, 49, 58), suggesting that FIM and FHA may have similar roles during 
infection. However, the in vitro adherence data suggest that fimbria do not contribute to 
adherence (54), despite fimbria typically acting as adhesins for other organisms.  
The goals of this thesis project were to: 1) Develop an in vivo adherence assay to 
determine if fimbria contribute to bacterial adherence, as we hypothesize that fimbria mediate 
adherence specifically to ciliated epithelium, 2) Characterize the persistence defect of FIM-
deficient bacteria and the host response of mice to FIM-deficient bacteria, as we hypothesize 
fimbria may also contribute to immune modulation. 
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TABLE 
Table 1. Type I pili adhesin proteins and host cell targets 
Organism Adhesin Host Cell Receptor Reference 
E. coli FimH Bladder, kidney 
epithelial cells, 
neutrophils, 
macrophages 
Uroplakin UP1a, 
CD48 
(37, 67, 
68) 
E. coli SfaS Bladder, kidney 
epithelial cells, 
erythrocytes, 
endothelial cells 
Sialic acid 
residues, 
plasminogen 
(69) 
Uropathogenic E. 
coli 
PapG Kidney epithelial cells, 
erythrocytes 
GbO3, GbO4, 
GbO5 
(70) 
Uropathogenic E. 
coli 
DraE Bladder and kidney 
epithelial cells 
CD55/DAF, 
CEACAMs 
(71) 
Uropathogenic E. 
coli 
AfaE Uroepithelium, 
erythrocytes 
CD55/DAF, 
CEACAMs 
(71) 
P. mirabilis PmfF Bladder and kidney 
epithelial cells 
Unknown (72) 
B. bronchiseptica FimD Unknown Unknown (49) 
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CHAPTER 2. COOPERATIVE ROLES FOR FIMBRIA AND FILAMENTOUS 
HEMAGGLUTININ IN BORDETELLA ADHERENCE AND IMMUNE MODULATION1  
Importance 
Although fimbria have been shown to be important mediators of adherence for many 
bacterial pathogens, there is surprisingly little experimental evidence supporting this role for 
Bordetella fimbria. Our results provide the first demonstration that Bordetella fimbria function 
as adhesins in vivo, specifically to airway epithelium. Furthermore, our results suggest that 
fimbria mediate initial interactions with airway epithelial cells that are followed by tight FHA-
mediated binding and that together, fimbria and FHA allow Bordetella to suppress inflammation, 
leading to prolonged colonization. Given the shortcoming of the current aP vaccine in preventing 
colonization, these findings suggest that generation of antibodies capable of blocking fimbria-
mediated adherence could potentially prevent Bordetella colonization. 
Introduction 
The “classic” or mammalian Bordetella species, which include Bordetella pertussis, 
Bordetella parapertussis and Bordetella bronchiseptica, are Gram-negative bacteria that cause 
respiratory infections in mammals (1). B. bronchiseptica colonizes the nasopharynx and trachea 
in a broad range of hosts, including rabbits, rats, mice and occasionally humans, often resulting 
 
_______________________ 
1This chapter was previously appeared as an article in mBio. The original citation is as follows: Scheller EV, Melvin JA, Sheets AJ, Cotter PA. 
“Cooperative roles for fimbria and filamentous hemagglutinin in Bordetella adherence and Immune Modulation” MBio. 2015 May 26;6(3). pii: 
e00500-15. doi: 10.1128/mBio.00500-15 
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in persistent, asymptomatic infections (2). Phylogenetic analyses indicate that Bordetella 
pertussis, the causative agent of whooping cough (pertussis), evolved from a B. bronchiseptica-
like ancestor, narrowing its host range to humans exclusively and typically causing acute 
respiratory disease, particularly in infants and young children (3, 4). Widespread use of a whole-
cell pertussis (wP) vaccine in the 1950s led to a rapid decrease of pertussis morbidity and 
mortality. Safety concerns, however, led to the replacement of the wP vaccine with acellular 
component pertussis vaccines (aP) (5). aP vaccines contain pertussis toxin (PTX) and one or 
more of the putative adhesins: filamentous hemagglutinin (FHA), fimbria (FIM) or pertactin 
(PRN). Coinciding with the switch to using only aP vaccines, cases of pertussis in the United 
States and other countries have increased steadily since the 1990s (6–8). Given the reemergence 
of this disease, it is important to better understand the mechanisms utilized by Bordetella to 
colonize and persist in the respiratory tract.  
Despite differences in host range and disease-causing propensity, B. bronchiseptica and 
B. pertussis are extremely similar and produce a nearly identical set of virulence factors. One 
such virulence factor is a type I pili system, typically called fimbria in Bordetella. The putative 
chaperone, usher, and tip adhesin are encoded by the fimBCD genes, respectively, and are 
required for fimbrial biogenesis (9). Most Bordetella strains characterized produce fimbria 
composed of either Fim2 or Fim3 as the major fimbrial subunit (10). The structural genes, fim2 
and fim3, are unlinked from each other and from the fimBCD operon (10). Additional major 
fimbrial subunit-encoding genes have been identified, including fimX, fimN and fimA (11–13). 
The fimA gene, located immediately 5’ to the fimBCD operon, is a pseudogene in B. pertussis 
(13). Although most aP vaccines contain the major fimbrial subunits, Fim2 and Fim3, whether 
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antibodies against these proteins contribute to protection against colonization or disease is 
unknown. 
Because B. pertussis is a human-specific pathogen that does not readily infect laboratory 
animals, we have been using B. bronchiseptica with its natural hosts to understand the 
contribution of specific virulence factors to Bordetella infection (14–16). The amino acid (aa) 
sequences of the FimD proteins produced by B. pertussis (Tohama I) and B. bronchiseptica 
(RB50) are 95% identical and the major fimbrial subunits, Fim 2 and Fim3, are 73% and 94% 
identical, respectively (9, 17, 18). It is likely that the fimbria produced by B. bronchiseptica and 
B. pertussis play similar, if not identical, roles during infection and we hypothesize that 
information gleaned from studies using B. bronchiseptica and natural-host animal models will be 
applicable to B. pertussis.  
Although fimbria have been shown to be important mediators of adherence for many 
bacterial pathogens, there is surprisingly little experimental evidence supporting this role for 
Bordetella fimbria. A B. pertussis strain containing an insertion mutation in fimD was defective 
for adherence to adherent monocytes in vitro (19). However, as this strain is also defective for 
FHA production, the contribution of fimbria alone could not be determined (9, 19). We 
previously constructed a ∆fimBCD strain of B. bronchiseptica that does not produce fimbria of 
any type and is unaltered for FHA production. Unexpectedly, this strain did not differ from WT 
bacteria in its ability to adhere to various epithelial and macrophage cell lines in vitro (20). 
However, a B. pertussis strain defective for both FIM and FHA had reduced adherence to baboon 
trachea explants and FIM-defective B. bronchiseptica had reduced adherence to rabbit trachea 
explants (21, 22), suggesting that fimbria may be important for adherence specifically to ciliated 
respiratory epithelial cells. Although studies have been conducted to identify host cell receptors 
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for fimbria (23–25), these experiments used purified fimbrial subunits and non-ciliated cell lines 
and whether the interactions identified reflect those which occur with native fimbria in vivo is 
unknown. 
Using a colonization model in which rats are inoculated with a small volume inoculum 
into the tip of the nose, we showed that fimbria and FHA are necessary for B. bronchiseptica to 
colonize the lower respiratory tract, specifically the trachea (20, 26). When inoculated directly 
into the tracheas of rats, FIM-deficient bacteria were unable to persist in the trachea, but 
colonized and persisted in the nasal cavity (20). These data suggest that fimbria are required to 
adhere to tracheal tissue, to resist mucociliary clearance and/or to avoid clearance by the innate 
immune system. Our lab and others have used a large volume, intranasal-inoculation mouse 
model to investigate the host response to Bordetella infection. This inoculation method 
presumably deposits bacteria throughout the nose, trachea and lungs of the animal. Using this 
model, our lab has shown that FHA is necessary for bacterial persistence in the lower respiratory 
tract and that FHA-deficient bacteria induce a more robust inflammatory response compared to 
WT bacteria (27–29). These data suggest that FHA is involved in suppressing the host immune 
response to aid bacterial persistence. Based on the similar tracheal colonization defect of ∆fhaB 
and ∆fimBCD mutants in rats, we hypothesized that fimbria may also contribute to immune 
modulation and bacterial persistence in the lower respiratory tract and we set out to test this 
hypothesis.   
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Results 
Fimbria are required for adherence in vivo 
To investigate the contribution of fimbria to adherence to respiratory epithelium in the 
context of natural infection, we developed an “in vivo adherence assay”. We inoculated mice 
intranasally with 50µl PBS containing 7.5x104 CFU of bacteria, euthanized the mice 30 minutes 
later, cannulated the tracheas, performed bronchoalveolar lavage (BAL) with 1ml PBS, and 
determined the number of CFU recovered. When BAL was not performed, we recovered 
equivalent CFU for all strains tested, approximately 3.0x104 CFU, indicating that all mice 
received similar inocula (Fig 1A). This number also represents the maximum number of CFU 
recoverable from the lungs using this inoculation protocol. When we inoculated mice with wild-
type (WT) bacteria and then performed BAL, we recovered approximately 7.5x102 CFU in the 
lavage fluid (Fig 1A), corresponding to ~1% of the recoverable CFU, which we calculated as the 
mean CFU recovered by BAL divided by the mean CFU recovered from the lungs when BAL 
was not performed (Fig 1B). We homogenized and plated the post-lavage lungs and recovered 
approximately 5x104 CFU (Fig 1A), corresponding to ~75% of the recoverable CFU (Fig 1B). 
Therefore, for WT bacteria, almost all of the recoverable bacteria remained in the lungs 
following BAL, presumably because they adhered tightly to respiratory epithelium.  
When we inoculated mice with a strain defective for production of all known protein 
virulence factors (∆bvgS), we recovered approximately 3x104 CFU in the lavage fluid, 
corresponding to ~55% of the recoverable CFU, while we recovered  7x103 CFU in the post-
BAL lung homogenate, corresponding to ~15% of the recoverable CFU (Figs 1A, 1B). 
Maximum recovery of avirulent bacteria by BAL, therefore, is about 55% of the recoverable 
CFU in this assay (compared with 1% for WT bacteria). When we inoculated mice with a strain 
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deficient for production of fimbria (∆fimBCD), the CFU recovered by BAL was ~55% of the 
inoculum and ~15% of the inoculum was recovered in the post-BAL lung homogenate, 
indicating that FIM-deficient bacteria are as defective for adherence as ∆bvgS bacteria (Fig 
1A,1B). We conclude from these results that fimbria contribute substantially to adherence to 
mouse respiratory tissue. Moreover, as FIM-deficient B. bronchiseptica were not defective for 
adherence to a variety of cell lines in vitro (20), these results suggest that FIM are required 
specifically for adherence to respiratory epithelium and perhaps to ciliated respiratory 
epithelium.  
We also inoculated mice with strains deficient in production of FHA (∆fhaB), pertactin 
(∆prn), both FHA and FIM (∆fimBCD∆fhaB), adenylate cyclase toxin (∆cyaA), or the type 3 
secretion system (∆bscN) and measured adherence. We recovered ~3x104 CFU in BALF from 
mice inoculated with either ∆fhaB or ∆fimBCD∆fhaB bacteria, which is nearly identical to the 
number recovered from FIM-deficient bacteria. By contrast, ∆prn mutants adhered similarly to 
WT bacteria, supporting in vitro evidence that pertactin is not necessary for adherence (30), and, 
as expected, bacteria defective for adenylate cyclase toxin and the type 3 secretion system also 
adhered similarly to WT bacteria (data not shown). These results indicate that both FIM and 
FHA are required for bacterial adherence to mouse respiratory epithelium within the first hour of 
infection. The fact that the number of CFU of ∆fimBCD and ∆fhaB mutant bacteria recovered 
from BAL was similar to that of the ∆bvgS strain suggests that FIM and FHA are the two main, 
if not only, factors that mediate adherence to respiratory tissue and that they function 
interdependently, i.e., both are required. 
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Fimbria are required for persistence in the lower respiratory tract  
We inoculated 6 week old BALB/c mice intranasally with 7.5x104 CFU of either wild-
type (WT), ∆fimBCD, or ∆fimBCD∆fhaB B. bronchiseptica. For mice inoculated with WT or 
∆fimBCD mutant bacteria, we determined bacterial burden in the nasal cavity, trachea and right 
lung lobes at various times post-inoculation (p.i). For mice inoculated with the ∆fimBCD∆fhaB 
mutant, we determined bacterial burden only in the lungs. CFU recovered from tissues harvested 
one hour p.i. (Day 0) were similar among all animals, indicating that consistent inoculation 
between bacterial strains and replicates occurred (Fig 2 A, B, C). There was no difference in the 
number of CFU recovered from the nasal cavities of animals inoculated with WT or ∆fimBCD 
bacteria at any time p.i. (Fig 2A). We also recovered similar numbers of CFU of WT and 
∆fimBCD bacteria from the tracheas one and three days p.i. However, 14 days p.i., no ∆fimBCD 
mutants were recovered from the tracheas, while the number of WT bacteria in the trachea 
remained high at this time point (Fig 2B). Similar to what we have observed in rats (20), 
therefore, fimbria are required for persistence in the tracheas of mice. 
We recovered approximately one log more CFU of ∆fimBCD or ∆fimBCD∆fhaB bacteria 
than WT bacteria from the lungs one day p.i. (Fig 2C). At three days p.i., mice inoculated with 
∆fimBCD bacteria split into two distinct groups: one group had significantly higher bacterial 
burden compared to the burden in mice inoculated with WT bacteria, and were moribund. The 
second group had a similar bacterial burden as mice inoculated with WT bacteria and these mice 
showed no signs of respiratory distress. This “bimodal” phenotype at three days p.i is similar to 
what has been observed in mice inoculated with ∆fhaB bacteria (27–29). For mice inoculated 
with ∆fimBCD∆fhaB mutants, the bacterial burden was not clearly bimodal, but spread between 
105 and 107 bacteria at three days p.i. By seven days p.i., the burdens of both the ∆fimBCD 
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bacteria and ∆fimBCD∆fhaB bacteria were significantly lower than the burden of WT bacteria 
and the mutants were undetectable by 14 days p.i. 
The persistence defect of ∆fimBCD and ∆fimBCD∆fhaB bacteria was similar to that of 
∆fhaB bacteria, indicating that fimbria, like FHA, are required for bacterial persistence in the 
lower respiratory tract (27–29). These data suggest that, like FHA, fimbria may be involved in 
suppressing inflammation.  
Fimbria are required to modulate the innate immune response in mice 
We examined hematoxylin and eosin (H+E) stained lung sections to evaluate 
inflammation in both the major airways and the alveoli during infection (Fig 3A). Lungs from 
mice inoculated with only PBS appeared healthy, with little, if any, evidence of inflammation at 
any time point p.i. Lungs from mice inoculated with WT bacteria contained cellular infiltrates 
around the major airways (black arrows) but the alveoli and alveolar spaces were free of any 
signs of inflammation at three days p.i. The cellular infiltrates around major airways persisted to 
seven days p.i. in mice inoculated with WT bacteria (black arrow), coinciding with the high 
bacterial burden at this time point.  Lungs from mice inoculated with ∆fimBCD bacteria 
displayed some cellular infiltration around the major airways, but also showed substantial 
visually distinct cellular infiltrate within the alveolar spaces at three days p.i (black arrows). This 
histopathology pattern, which was present in the lungs of mice with either high or low bacterial 
burdens at day 3 p.i., differed dramatically from that of the lungs of mice inoculated with FHA-
deficient bacteria, which showed increased cellular infiltrate primarily around the major airways 
and no patches of cellular infiltration in alveoli (27). By seven days p.i., the patches of 
inflammatory cell recruitment in alveoli of ∆fimBCD mutant-inoculated mice was absent and 
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there was decreased cellular infiltrate around the major airways, corresponding with the 
decreased bacteria burden at this time point. Lungs of mice inoculated with ∆fimBCD∆fhaB 
bacteria appeared similar to those of mice inoculated with ∆fimBCD bacteria at both time points 
p.i., with cellular infiltration evident around the major airways as well as distinct cell recruitment 
within the alveolar spaces (black arrows) at three days p.i. At seven days p.i. there were fewer 
inflammatory cells present, coinciding with decreased bacterial burden.   
We also measured cytokine and chemokine levels in right lung homogenates by ELISA 
(Fig 3B). Interleukin-1β (IL-1β) levels were significantly increased in the lungs of mice 
inoculated with ∆fimBCD or ∆fimBCD∆fhaB bacteria compared to WT bacteria one and three 
days p.i. These differences did not correlate with burden, as IL-1β levels were increased in all 
animals inoculated with the mutant bacteria, even those with lower burdens at day 3 p.i.. 
Moreover Monocyte Chemotactic Protein-1 (MCP-1) and neutrophil chemokine CXCL1 (KC) 
levels were significantly increased in lungs of mice inoculated with ∆fimBCD  bacteria compared 
to WT bacteria three days p.i. MCP-1 and KC levels in mice inoculated with ∆fimBCD∆fhaB 
mutant bacteria appeared higher than in mice inoculated with WT bacteria, but the differences 
were not statistically significant. Other cytokines, such as interferon gamma (IFNγ), tumor 
necrosis factor alpha (TNFα), Interleukins-10, 12p70, 22, and 23 (IL-10, IL-12p70, IL-22 and 
IL-23) were measured and no significant difference was found between mice inoculated with 
∆fimBCD or ∆fimBCD∆fhaB bacteria compared to those inoculated with WT bacteria at any 
time point. 
Taken together, these data indicate that fimbria, like FHA, are required to suppress 
inflammation during infection. The dramatically different histopathology, however, suggests that 
FIM and FHA may play different roles in pathogenesis and the fact that the ∆fimBCD∆fhaB 
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double mutant induced a histopathology pattern similar to that induced by the ∆fimBCD mutant 
indicates that the ∆fimBCD mutation is epistatic to the ∆fhaB mutation.  
Fimbria do not complement “in trans” during co-inoculation  
Our data here and from previous studies suggest that WT B. bronchiseptica is able to 
suppress the initial inflammatory response to infection, contributing to decreased pathology and 
increased bacterial persistence (27–29). We have previously shown that when mice are co-
inoculated with WT and FHA-deficient bacteria, the level of inflammation in the lungs is 
decreased compared to that induced by inoculation with the ∆fhaB mutant alone and the ∆fhaB 
mutant persists longer than when inoculated into mice in the absence of the WT strain, 
suggesting that FHA-producing WT bacteria are able to complement “in trans”(29). We 
hypothesized that WT B. bronchiseptica would similarly be able to rescue FIM-deficient bacteria 
from inflammation-mediated clearance. To test this hypothesis, we inoculated 6 week old mice 
with 1.5x105 CFU of WT, ∆fimBCD or ∆fimBCD∆fhaB bacteria alone, or a mixture of 7.5x104 
CFU of each WT and ∆fimBCD bacteria or WT and ∆fimBCD∆fhaB bacteria (so that the total 
number of CFU in each inoculum was 1.5x105) and determined bacterial burden.  
Strikingly, the mutants and WT bacteria were recovered from the trachea and lungs at 
similar numbers from co-inoculated animals as from animals inoculated with WT or mutant 
bacteria alone (Fig 4A); the presence of WT bacteria did not improve the persistence of the 
mutant bacteria, and the presence of mutant bacteria did not lead to increased clearance of WT 
bacteria. These data indicate that, unlike the case with FHA, WT bacteria cannot complement 
∆fimBCD or ∆fimBCD∆fhaB bacteria in trans, further supporting the hypothesis that FIM and 
FHA contribute differently to infection. 
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Lung sections from mice co-inoculated with WT and either mutant strain appeared 
similar to lungs of mice inoculated with ∆fimBCD or ∆fimBCD∆fhaB bacteria alone: there was 
cell recruitment around the major airways as well as in the alveolar spaces (black arrows), 
indicating that the presence of WT bacteria cannot prevent the histopathology seen in lungs 
inoculated with FIM-deficient bacteria (Fig 4B). In general, levels of IL-1β, KC and MCP-1 
were higher in co-inoculated mice compared to mice inoculated with WT alone, although most 
differences were not statistically significant (Fig 4C).  
These data indicate that the presence of WT bacteria in the lungs did not increase the 
survival of FIM-deficient bacteria and did not prevent cellular infiltrate into the alveolar spaces. 
A possible explanation for the inability of WT bacteria to complement FIM-deficient bacteria in 
trans is that WT and FIM-deficient bacteria localize differently in this model. 
FIM-deficient bacteria localize differently than WT and FHA-deficient bacteria in the 
lower respiratory tract 
To determine the location of WT and mutant bacteria in the lungs, we inoculated mice 
with 7.5x104 CFU of WT or mutant bacteria then sacrificed the mice three days p.i. and prepared 
the left lung lobe for sectioning. We then performed immunohistochemistry using serum from a 
rabbit chronically infected with WT B. bronchiseptica as the primary antibody, goat anti-rabbit 
conjugated to alkaline phosphatase (AP) as the secondary antibody, and Naphthol Red as the AP 
substrate. The lung sections were then counterstained with hematoxylin which stains nuclei dark 
purple. Lungs from mice inoculated with WT bacteria showed red staining around the ciliated 
epithelium of the major airways (black arrows) while control lungs, which were not incubated 
with rabbit serum, did not have any red staining (Fig 4A). This staining pattern indicates that WT 
bacteria localize to the major airways during infection.  
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Lungs from mice inoculated with FHA-deficient bacteria appeared similar to lungs of 
mice inoculated with WT bacteria, with noticeable red staining around the major airways, both 
on the ciliated epithelium as well as in the cellular infiltrate beneath the epithelial cells (black 
arrows), but very little red staining in the alveolar spaces, suggesting that FHA-deficient bacteria 
localize similarly to WT bacteria. By contrast, lungs from mice inoculated with FIM-deficient 
bacteria showed a dramatically different staining pattern. These lungs had red staining 
throughout the alveolar spaces (black arrow). Lungs from mice inoculated with ∆fimBCD∆fhaB 
double mutant bacteria appeared similar to lungs from mice inoculated with FIM-deficient 
bacteria. These results indicate that FIM-producing bacteria localize to major airways and 
bronchioles while FIM-deficient bacteria localize predominantly to alveoli, suggesting that FIM 
mediate attachment specifically to ciliated epithelia, which line bronchi and bronchioles. Without 
fimbria, many, if not most, bacterial bypass the ciliated epithelium and are deposited in alveoli. 
Lungs from mice co-inoculated with WT and FHA-deficient bacteria had red staining 
around the major airways (black arrows), but very little red staining in the alveolar spaces, 
similar to lungs from mice inoculated with WT or FHA-deficient bacteria alone. By contrast, 
lungs from mice co-inoculated with WT and either ∆fimBCD or ∆fimBCD∆fhaB bacteria had red 
staining in the major airways as well as distinct staining in the alveolar spaces (black arrows). 
These data suggest that even during co-inoculation, WT bacteria and FHA-deficient bacteria 
localize primarily to major airways, while FIM-deficient bacteria are delivered primarily to 
alveoli. Furthermore, these results provide a possible explanation for why co-inoculation with 
WT bacteria can rescue FHA-deficient bacteria but not FIM-deficient bacteria: the WT-mediated 
immune suppression occurs locally in the major airways and does not affect bacteria in the 
alveolar space because the WT bacteria do not gain access to this location. 
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We conducted an in vivo adherence assay using an equal mixture of WT and FIM-
deficient bacteria (Data not shown). The numbers of CFU recovered were similar to those from 
mice inoculated with WT or FIM-deficient bacteria alone. This result provides further evidence 
that WT and FIM-deficient bacteria function independently in the respiratory tract. 
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Discussion 
Bordetella fimbria are generally considered to function as adhesins despite there being no 
reports of adherence studies using B. pertussis strains defective only for production of fimbria. 
Studies with B. bronchiseptica also failed to provide convincing evidence that Bordetella fimbria 
function as adhesins as FIM-deficient bacteria showed no defect in adherence assays using a 
variety of non-ciliated cell lines (20) and this strain was only modestly defective in adherence to 
ciliated tracheal explants (22). Our results therefore provide the first demonstration that 
Bordetella fimbria are important adhesins and they indicate that fimbria mediate adherence 
specifically to airway epithelium. Our results also show that fimbria and FHA work together, 
playing equally important roles in allowing Bordetella to suppress inflammation, leading to 
prolonged colonization. 
A murine model in which large numbers of bacteria are delivered intranasally in a large 
volume has been used by our group and others to study respiratory infection by Bordetella (16, 
27–29, 31–34). It has been presumed that this inoculation method deposits bacteria evenly 
throughout the respiratory tract. Within the trachea, bronchi and bronchioles, bacteria must 
overcome mucociliary clearance through tight adherence. The bacteria also interact with or 
stimulate sentinel innate immune cells, such as alveolar macrophages and dendritic cells within 
the lower respiratory tract, which in turn stimulate the initial inflammatory response 
characterized by the recruitment of phagocytic cells, predominately neutrophils, to the site of 
infection. In this model both bacterial burden and cellular infiltrate peak at about seven days 
post-inoculation. Bacterial load then decreases, with clearance from the lungs occurring over the 
next two to three weeks and requiring adaptive immunity (16). For B. pertussis, the bacteria are 
cleared from the entire respiratory tract by about 30-40 days post-inoculation while for B. 
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bronchiseptica the bacteria are cleared from lower respiratory tract but persist in the nasal cavity 
indefinitely (16). 
Our newly-developed in vivo adherence assay and bacterial localization analyses showed 
that WT B. bronchiseptica are not distributed evenly throughout the lungs following high-dose, 
large volume inoculation. Instead they localize predominately to airway epithelium. This 
localization requires fimbria, as FIM-deficient mutants bypassed the ciliated epithelium and 
localized to the alveoli. In the alveoli, FIM-deficient bacteria did not adhere tightly enough to 
resist bronchoalveolar lavage, despite producing wild-type levels of FHA. It is possible that FHA 
receptors are not present on alveolar pneumocytes. Alternatively, tight adherence may require 
fimbria-mediated interactions that induce changes in either bacterial or host cells. FHA-deficient 
bacteria, by contrast, localized to the airways, presumably due to fimbrial attachment to ciliated 
epithelium, but these fimbria-mediated interactions alone were insufficient to resist 
bronchoalveolar lavage. Our data therefore suggest a model in which adherence of Bordetella is 
a two-step process requiring both fimbria and FHA.  In this model, fimbria mediate initial 
interactions to ciliated epithelia and this critical first step then allows FHA to mediate tighter 
adherence to these cells.  
Following adherence, the ability of Bordetella to influence the innate immune response is 
evident in the first three to four days post-inoculation.  We have previously shown a role for 
FHA in modulating the innate immune response as FHA-deficient B. bronchiseptica were hyper-
inflammatory compared to WT bacteria (27, 29). Here, we showed that FIM-deficient mutants 
were similar to FHA-deficient mutants in bacterial burden and in inducing high levels of pro-
inflammatory cytokines and chemokines during the first three days of infection, suggesting that 
fimbria also contribute to suppression of inflammation (Fig 2).  Lungs from mice inoculated with 
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FHA- or FIM-deficient bacteria, however, displayed strikingly different histopathology. Unlike 
FHA-deficient bacteria, which caused increased cellular infiltrate around the bronchioles, FIM-
deficient bacteria caused increased cellular infiltrate in the alveoli. This difference correlates 
with the different localization of these strains in the lungs. It also indicates that FHA alone is 
insufficient to modulate the inflammatory response in the alveoli, since FIM-deficient bacteria 
that localize to this site produce FHA. Furthermore, cytokine levels and histopathology from 
mice inoculated with ∆fimBCD∆fhaB bacteria were similar to those of mice inoculated with 
∆fimBCD bacteria. These data indicate that lack of fimbria is epistatic to lack of FHA; without 
fimbria, the presence or absence of FHA did not change the outcome of infection, underscoring 
the importance of fimbria for FHA-mediated interactions.  
In this murine model, bacterial burden and inflammatory infiltrate in the lungs both peak 
at about seven days post-inoculation. Subsequent to this time point, FHA- and FIM-deficient 
bacteria are cleared rapidly while WT bacteria persist for approximately three more weeks (16, 
29). Rapid clearance of the FIM- and FHA-mutant bacteria may reflect a decreased ability of 
these mutants to resist killing by inflammatory cells. However, because these mutants induce a 
hyper-inflammatory environment, it is also possible that their rapid clearance is due primarily, if 
not solely, to the increased numbers and/or activation of recruited inflammatory cells. Our lab 
has shown that mice co-inoculated with WT and FHA-deficient bacteria induce less 
inflammation compared to mice inoculated with FHA-deficient bacteria alone. Furthermore, in 
co-inoculated animals, there was increased persistence of FHA-deficient bacteria compared to 
animals inoculated with only the ∆fhaB mutant (29). We hypothesized that the increased 
persistence of ∆fhaB bacteria in co-inoculated animals resulted from FHA-producing WT 
bacteria suppressing inflammation. We also hypothesized that the decreased ability of FHA-
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deficient mutants, compared with WT bacteria, to persist in co-inoculated animals indicated a 
decreased ability of FHA-deficient bacteria to resist phagocytic cells. Our new results show that 
WT and FHA-deficient bacteria co-localize in the major airways, supporting the hypothesis that 
mutant bacteria benefit from local immune suppression mediated by WT bacteria and further 
supporting the hypothesis that FHA-deficient bacteria are unable to resist clearance by 
inflammatory cells, even if the activation state of these cells is suppressed by the presence of WT 
bacteria. 
By contrast, WT bacteria did not improve the survival of FIM-deficient bacteria, which 
were cleared as rapidly from mice co-inoculated with WT bacteria as from mice inoculated with 
FIM-deficient bacteria alone (Fig 3). The inability of WT bacteria to “trans complement” the 
∆fimBCD mutant (and the ∆fimBCD∆fhaB mutant) may be due simply to differences in 
localization, which would suggest that FHA-mediated suppression of inflammation occurs 
locally within the major airways. Rapid clearance of the ∆fimBCD and ∆fimBCD∆fhaB mutant 
bacteria likely reflects both an inability to suppress inflammation locally and an inability to resist 
the recruited phagocytic cells. Together, our data indicate that once FIM-mediated interactions 
localize WT bacteria to the ciliated epithelium, FHA-mediated interactions provide both 
localized immune suppression and protection against immune-mediated clearance.  
We have been using B. bronchiseptica and rabbits, rats, and mice to investigate how 
specific virulence factors and the regulation of virulence factor-encoding genes contribute to 
pathogenesis (20, 27, 29, 30). Because these animals are natural hosts for B. bronchiseptica, the 
results obtained from these studies are biologically relevant, i.e., we are confident in our 
conclusions that FHA and fimbria are required for lower respiratory tract colonization of these 
hosts by B. bronchiseptica. However, B. bronchiseptica infection of these rodents does not result 
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in the same course of infection or disease characteristics as B. pertussis infection of humans and 
therefore B. bronchiseptica infection of rabbits, rats, or mice should not be considered models of 
human pertussis. Nonetheless, we have demonstrated previously that the genes encoding FHA, 
adenylate cyclase, and BvgAS from B. pertussis can substitute for the corresponding genes in B. 
bronchiseptica during infection (15, 28, 30), suggesting that these virulence factors and 
regulatory system perform the same function for these two bacterial species during infection of 
their respective hosts. In our current study, we did not determine if the genes encoding fimbria 
from B. pertussis could substitute for their homologs in B. bronchiseptica. However, our results 
are consistent with those of a report showing that a B. pertussis strain defective for both FHA 
and fimbria was defective for persistence and caused increased cellular infiltrate in the alveoli of 
mice in which the authors concluded that fimbria were important for modulating the immune 
response (35). We hypothesize, therefore, that B. pertussis fimbria are required for adherence to 
airway epithelium and for FHA-mediated immunomodulation during human infection. Testing 
this hypothesis and determining if and how these factors contribute to disease characteristics 
unique to human pertussis may be achievable with the recently developed baboon model (36). 
Given the reemergence of pertussis and the increasing reports of shortcomings of the 
acellular vaccine (36–38), it is important to reevaluate vaccine design and immunization route. 
While FIM2 and FIM3 are components of the acellular vaccine and induce an antibody response, 
the contribution and method of action of this response to bacterial clearance is unclear. Our 
results suggest that antibodies that block FIM-mediated attachment may prevent bacterial 
attachment and colonization in the lower respiratory tract, but whether the current aP vaccine or 
natural immune response generates antibodies capable of performing this function is uncertain. 
As Bordetella is primarily an extracellular respiratory pathogen, generation of mucosal IgA 
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antibodies capable of blocking bacterial adherence could potentially prevent Bordetella 
colonization.  Most studies focus primarily on serum IgG responses following vaccination, so 
further characterization of the antibody response may be warranted.   
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Materials and Methods 
Ethics statement 
This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the Nation Institutes of Health. Our protocol was 
approved by the University of North Carolina IACUC (10-134, 12-307, 13-238). All animals 
were properly anesthetized for inoculations, monitored regularly, euthanized when moribund and 
efforts were made to minimize suffering 
Growth media and Bacterial Strains 
Escherichia coli were grown in lysogeny broth (LB) or on LB agar (1.5%) at 37°C. Wild-
type (WT) Bordetella bronchiseptica RB50 and mutant derivatives were grown at 37°C on 
Bordet-Gengou (BG) (Becton Dickinson Microbiology Systems) supplemented with 7.5% 
defibrinated sheep blood (Colorado Serum Co, Denver) or in Stainer-Scholte (SS) broth with 100 
mg/ml (2,6-O-dimethyl)-b-cyclodextrin. When necessary, media were supplemented with 
streptomycin (Sm, 20 µg/ml), gentamicin (Gm, 30 µg/ml),  Kanamycin (50 µg/ml or 
diaminopimelic acid (DAP; 300 µg/ml). 
Construction and cloning of plasmids was accomplished in E. coli DH5α. Plasmids were 
introduced into B. bronchiseptica via mating with E. coli RHO3. In-frame markerless deletion 
mutations were made using the pSS4245 allelic exchange system. pUC18-based plasmids were 
utilized to deliver genes encoding gentamicin resistance (aacC1) and kanamycin resistance 
(nptII) to the attTn7 site via transposase-mediated insertion. Detailed descriptions of each strain 
are given in Table 1. 
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Intranasal mouse inoculation 
Bacteria were grown overnight Stainer-Scholte (SS) broth with 100 mg/ml (2,6-O-
dimethyl)-b-cyclodextrin. When necessary, media were supplemented with streptomycin (Sm, 20 
µg/ml), gentamicin (Gm, 30 µg/ml) or Kanamycin (50 µg/ml). Six-week-old BALB/c mice from 
Jackson Laboratories (Bar Harbor, ME) were inoculated intranasally with 7.5 x 104 or 1.5 x 105 
CFU of B. bronchiseptica in 50 µl PBS. Mice were inoculated with strains RB50, RB63, 
RBX9F, RB54, SP5, AS16 or a mix of RB50/RB63 or RB50/AS16. Right lung lobes, trachea 
and nasal cavity were harvested from mice at specific time points post-inoculation (p.i.) in 1 ml 
PBS. Tissue was homogenized, serial dilutions were plated on BG agar, and CFU were 
determined.  
Cytokine and histological analysis 
Using lung homogenates, the cytokine and chemokine responses to infection were 
measured using ELISA kits (R&D Systems). Homogenates were diluted 1:10 and then cytokines 
and chemokines measured were IL-1β, KC, MCP-1 and IL-17 following manufacturer’s 
instructions, and concentrations were calculated using standard curve data for each cytokine. 
Absorbance was determined using a Molecular Devices plate reader and analyzed by Softmax 
Pro software (Molecular Devices). To prepare histology slides, left lung lobes were harvested at 
indicated time points and inflated with 10% formalin. The Animal Histopathology Core Lab then 
embedded the tissue in paraffin, sectioned the tissue at 5 µm, and then stained the tissue with 
hemotoxylin and eosin (H&E). Lung sections were examined at the Microscopy Services 
Laboratory using Brightfield imaging on an Olympus BX61 microscope at 10x and 40x 
magnification.  
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In vivo adherence 
Bacteria were grown as mentioned above, and 6 week old BALB/c mice were inoculated 
with 7.5 x 104 CFU of bacteria. 30 minutes p.i., mice were euthanized, the trachea was 
cannulated and bronchoalveolar lavage was performed with 1 ml PBS to determine adherence. 
The right and left lung lobes were then excised and homogenized in 1 ml PBS to determine CFU 
remaining post-BAL. Serial dilutions of both BAL and homogenate were plated on BG agar to 
determine CFU recovered. 
Bacterial Localization 
6 week old BALB/c mice were inoculated as described above. Lung tissue was harvested 
three days p.i. and the left lobe was inflated with 10% formalin. The Animal Histopathology 
Core Lab then embedded the tissue in paraffin and provided unstained 5 µm lung sections. 
Sections were incubated with serum from a rabbit chronically infected with RB50 bacteria, then 
incubated with goat anti-rabbit secondary antibody conjugated to alkaline phosphatase 
(Promega). Sections were then incubated with alkaline phosphatase substrate Naphthol Red 
(SIGMA), counterstained with hemotoxylin (SIGMA) and examined on an Olympus Bx61 
microscope at 10x and 40x magnification. 
Statistical Analysis 
Statistical analyses were performed using Prism 5.0 software from Graphpad Software, 
inc. Statistical significance was determined using unpaired Student’s T-test or analysis of 
variance (ANOVA). Figures were generated using Adobe Illustrator CS6 (Adobe Systems, Inc). 
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Supporting Information 
Figure 1. Fimbria are required for adherence in vivo 
 
Fig 1. (A) Mice were inoculated intranasally with approximately 7.5x104 CFU of WT or mutant 
bacteria. The numbers of CFU recovered from lungs for which bronchoalveolar lavage (BAL) 
was not performed, from BAL fluid (BALF), and from lungs post-BAL, are shown. (B) Data 
shown as the percent of the recoverable CFU, which is calculated as mean CFU recovered from 
either BALF or lungs post-BAL divided by mean CFU recovered from lungs for which BAL was 
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not performed for each strain, respectively. Data are mean for two independent experiments. 
Significance when comparing WT to mutant bacteria * = p<0.05, ** = p<0.01, *** = p<0.001  
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Figure 2. Fimbriae are required for persistence in the lower respiratory tract 
 
Fig 2. (A,B,C) Bacterial burden in respiratory tissues from mice inoculated with WT or mutant 
bacteria. Each symbol represents an individual animal, the horizontal dashed line represents the 
lower limit of detection and the black bar represents the mean. Data are mean (A,B,C) for at least 
two independent experiments. Significance when comparing WT to mutant bacteria * = p<0.05, 
** = p<0.01, *** = p<0.001 
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Figure 3. Fimbriae are required to modulate the innate immune response in mice 
 
 
Fig 3. (A) Hematoxylin and eosin stained 5 µm lung sections at 10x magnification and 40x 
magnification. Black arrows indicate areas of cellular infiltrate. (B) Cytokine and chemokine 
levels in lung homogenates of WT, ∆fimBCD or ∆fimBCD∆fhaB mutant-inoculated animals. 
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Data are mean ±SE (B) for at least two independent experiments. Significance when comparing 
WT to mutant bacteria * = p<0.05, ** = p<0.01, *** = p<0.001 
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Figure 4. Fimbriae do not complement “ in trans ” during coinoculation 
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Fig 4. (A) Bacterial burden in respiratory tissue from mice inoculated with WT or mutant 
bacteria alone, or co-inoculations of WT and mutant bacteria. Each symbol represents an 
individual animal, the horizontal dashed line represents the lower limit of detection and the black 
bar represents the mean. (B) Hematoxylin and eosin stained 5 µm lung sections at 10x 
magnification. Arrows indicate areas of cellular infiltration. (C) Cytokine and chemokine levels 
in lung homogenates of WT, ∆fimBCD or ∆fimBCD∆fhaB mutant-inoculated animals. Data are 
mean (A, B) or mean ±SE (C) for at least two independent experiments. Comparing single strain 
mutants to WT bacteria: * = p<0.05, ** = p<0.01, *** = p<0.001 Comparing WT and mutant 
bacteria within co-inoculations # = p<0.05, ## = p<0.01, ### = p<0.001 
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Figure 5. FIM-deficient bacteria localize differently than WT and FHA-deficient bacteria 
in the lower respiratory tract 
 
Fig 5. (A) Lung sections three days p.i. from mice inoculated with WT, mutant or co-inoculated 
with WT and mutant bacteria. Immunohistochemistry was performed using convalescent rabbit 
serum from a WT-infected rabbit, goat anti-rabbit secondary antibody conjugated to alkaline 
phosphatase, incubated with Naphthal Red substrate. Red staining (black arrows) indicate 
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alkaline phosphatase activity. Tissue was counterstained with hematoxylin.  Pictures were taken 
at 10x and 40x magnification.  
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CHAPTER 3. NEW INSIGHT INTO FILAMENTOUS HEMAGGLUTININ SECRETION 
REVEALS A ROLE FOR PRE-PROCESSED FHAB IN BORDETELLA VIRULENCE1 
Introduction 
Two-partner secretion (TPS) is a widespread protein secretion pathway for Gram-
negative bacteria in which a large exoprotein (generically called TpsA) is translocated through a 
cognate outer membrane β-barrel pore protein (TpsB) to the bacterial surface, where the 
exoprotein is then able to interact with its environment. The mechanism by which this occurs is 
complex, with fundamental aspects of the process, such as how unidirectional protein 
translocation across a membrane is achieved in the absence of chemical energy and how these 
massive proteins are able to fold correctly in the absence of typical quality control mechanisms, 
remaining unclear. Virulence functions have been attributed to most TPS systems and include 
adherence to host tissues1,2, iron acquisition3, cytotoxicity4,5, and immune evasion6, which 
contribute to bacterial colonization and persistence. 
Whooping cough, or pertussis, is a currently reemerging disease in the United States and 
other developed countries. Increased incidence in recent years has coincided with a switch from 
whole-cell pertussis (wP) vaccines to acellular pertussis (aP) vaccines that display reduced 
reactogenicity7. Pertussis is primarily caused by the human-restricted Gram-negative pathogen 
Bordetella pertussis, and aP vaccines typically consist of three to five proteins that it secretes: 
_______________________ 
1This chapter is currently in review to be published at mBio. 
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filamentous hemagglutinin (FHA), pertussis toxin (Ptx), pertactin (Prn), and often fimbrial 
subunits (Fim2 and Fim3). While the underlying reasons are not completely understood, the 
recent surge in pertussis incidence is likely largely due to deficiencies in aP vaccine efficacy, 
including induction of relatively short-lived immunity and inability to prevent colonization and 
transmission8-10. Despite decades of research, our understanding of the physiological properties 
of aP vaccine components remains incomplete, a critical shortfall in attempts to decide how best 
to prevent pertussis in the future. 
In accordance with its role as a virulence factor, in vivo studies have shown that FHA is 
required for colonization and persistence in the lower respiratory tracts of mice, rats, and pigs by 
Bordetella bronchiseptica2,6,11-14, a close relative of B. pertussis that naturally infects a broad 
range of mammalian hosts. Many Bordetella virulence factors, including FHA, are highly 
conserved and have been shown to be functionally interchangeable between B. pertussis and B. 
bronchiseptica in animal models of disease12,15,16. For these reasons, we use B. bronchiseptica 
infection of common laboratory animals to assess the contribution of Bordetella virulence factors 
to pathogenesis. In addition to its postulated role as an adhesin17, FHA appears to perform 
immunomodulatory functions that contribute to colonization and/or persistence6,11, though 
whether these effects are a direct result of some undefined FHA activity18-22 or an indirect result 
of FHA-mediated adherence to specific host cells6,23,24 is unclear. 
FHA serves as a paradigm for TPS. FHA (defined as the ~250 kDa protein that is both 
surface-associated and released from the bacterial surface) is initially translated as a 
preproprotein called FhaB (~370 kDa), which contains an N-terminal signal peptide and a large 
C-terminal ‘prodomain’ that are removed during the secretion process. As for most processed 
proteins, the ‘mature’ molecule (~250 kDa FHA, in this case) has been assumed to be the 
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functional form of the protein. According to the current model of FHA secretion25, the signal 
peptide directs FhaB across the inner membrane via the Sec translocation machinery26 and is 
then removed by leader peptidase. The ~250 aa region of FhaB immediately C-terminal to the 
signal peptide, referred to as the TPS domain and which is highly conserved among TpsA 
proteins, is bound by chaperones that maintain the protein in a non-folded state as it transits 
through the periplasm27,28. FhaB then transits through FhaC in an N- to C-terminal direction, 
with the N-terminus remaining anchored to FhaC at the cell membrane13,25. The TPS domain 
initiates folding of FhaB into a rigid β-helix on the surface of the bacterium29,30, and progressive 
folding results in formation of a ~50 nm long shaft. C-terminal to the β-helical shaft, a ~500 aa 
globular domain begins to fold into the mature C-terminal domain (MCD) at the distal end of the 
molecule13,31, which mediates adherence of the bacteria to host cells in vitro and to respiratory 
epithelium in vivo12,25. Upon translocation of the residues composing the MCD, the proximal 
region of the FhaB prodomain (called the prodomain N-terminus or PNT), which is conserved 
among FhaB-like TpsA proteins, prohibits further translocation and retains the prodomain in an 
intracellular compartment25. We hypothesize that anchoring of the C-terminus of the MCD near 
the membrane by the PNT acts as a sort of intramolecular chaperone that restricts the 
conformations that the MCD can sample during folding25. Deletion of the prodomain abrogates 
the ability of B. bronchiseptica to adhere to host cells in vitro and to colonize the lower 
respiratory tracts of mice and rats in vivo13,25, presumably due to misfolding of the MCD. 
Subsequent to translocation and folding of the MCD, proteolysis of the FhaB C-terminal 
prodomain occurs by an as yet unidentified protease(s)13,25. Degradation is rapid and 
complete13,25,32, making it unlikely that the prodomain performs an independent function. In 
∆PNT strains, in which the prodomain is aberrantly translocated to the surface, the prodomain is 
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readily detected25, indicating that the prodomain is not intrinsically unstable, but rather subject to 
regulated degradation inside the cell. Production of FhaB molecules lacking the C-terminal half 
of the MCD results in detectable, stable intracellular prodomain polypeptides25, further 
supporting the hypothesis of regulated degradation and indicating a role for the extracellular 
MCD in this regulation. Additional processing to form the C-terminus of ‘mature’ FHA occurs 
and is dependent on the surface-localized serine protease autotransporter SphB133. Although the 
primary function attributed to FHA is adherence to respiratory epithelium, FHA is ultimately 
released from the cell surface, liberating FhaC to secrete another FhaB molecule. 
Our previous observations suggest that portions of the FhaB prodomain contribute to 
virulence activities that FHA performs in addition to mediating adherence. For example, small 
deletions near the C-terminus of the prodomain abrogated persistent tracheal colonization of rats 
by B. bronchiseptica, though adherence capabilities in vitro were preserved13. Here, we set out to 
determine the contribution of two C-terminal FhaB subdomains, a proline-rich region and a 
conserved extreme C-terminus, to FhaB/FHA function. We also investigated how prodomain 
degradation is controlled and what role its regulation plays in the maturation and function of 
FHA.  
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Results 
The FhaB prodomain localizes to the periplasm 
Previous studies demonstrated that the PNT is necessary for retention of the FhaB 
prodomain in an intracellular compartment, which is essential for proper folding and function of 
FHA25. To determine if the C-terminus of the prodomain enters the periplasm or if it remains in 
the cytoplasm, we created a B. bronchiseptica strain containing a fusion of phoA (lacking the 
codons for its natural signal peptide) to the 3’ end of fhaB. (All mutations described in this study 
were made in a derivative of B. bronchiseptica strain RB50 lacking fhaS (RBX11) to facilitate 
genetic manipulation of fhaB and interpretation of FhaB maturation data34. Deletion of fhaS does 
not produce any detectable effects on B. bronchiseptica pathogenicity in animal models34, and 
we will henceforth refer to RBX11 as the wild-type (WT) strain used in this study.) PhoA 
activity, assayed by conversion of the chromogenic substrate 5-bromo-4-chloro-3-indolyl 
phosphate (X-P) to a blue product, is observed only when PhoA is present in the periplasm35. 
Western blot analysis of whole-cell lysates (WCL) and culture supernatants of the WT strain 
producing the fusion protein displayed no changes in the amount of FhaB/FHA produced, 
processed, or released (Fig. 1a), indicating that fusion of PhoA to the C-terminus of FhaB did not 
alter FhaB secretion. We also performed a dot blot on the strain producing FhaB with the C-
terminal PhoA fusion, probing the blots with an α-MCD antibody (and secondary antibody with 
‘green’ fluorescence) and an α-PhoA antibody (and secondary antibody with ‘red’ fluorescence). 
As seen previously25, the MCD was detected on the surface of intact bacteria and in disrupted 
cells (Fig. 1b). In contrast, PhoA was only detected in disrupted cells, indicating that the 
prodomain remained intracellular. Culture of this strain on plates containing X-P resulted in 
growth of blue colonies (Fig. 1c), which, combined with the fact that proteins are secreted 
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through the Sec translocon in an N- to C-terminal fashion36, indicates that the entire FhaB 
prodomain is transported to the periplasm during secretion and therefore that the periplasm is the 
compartment in which prodomain functions occur. 
 
The ECT of FhaB negatively regulates prodomain degradation, while the PRR plays no 
apparent role in FhaB/FHA processing 
Western blot analysis of WT B. bronchiseptica reveals the ~370 kDa FhaB preproprotein 
and multiple processed FHA proteins of ~250 kDa in whole-cell lysates (WCL) and only 
processed ~250 kDa FHA proteins in culture supernatants (Fig. 2). The largest processed 
polypeptide is referred to as FHA’ in B. bronchiseptica (FHA* in B. pertussis) and is produced 
via degradation of the prodomain by an unidentified protease(s)13,33. The most abundant 
processed polypeptide is referred to as FHA and is produced in an SphB1-dependent manner via 
cleavage of FhaB or FHA’13,33. Two smaller processed polypeptides, which are similar in size 
and often co-migrate on SDS-PAGE gels, are referred to as FHA1 and FHA2 and are also 
produced in an SphB1-dependent manner. The SphB1-dependent FHA, FHA1, and FHA2 
proteins are the predominant forms released from the bacterial surface, while FHA’/FHA* is 
primarily only released in strains lacking SphB1, although a slight amount can sometimes be 
detected in culture supernatants of WT cells13,33. 
The FhaB C-terminus includes a proline-rich region (PRR)25,37 that is composed of 27% 
proline residues (as opposed to 2% across the remainder of FhaB) and contains two conspicuous 
repeat motifs (Supplementary Fig. 1b). Excluding minor differences in the length/number of 
repeats, the predicted PRR is 87% identical and 92% similar among the strains of Bordetella spp. 
that cause disease in mammals for which genome sequence information is available. C-terminal 
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to the PRR are 98 aa (Supplementary Fig. 1c) that are 100% identical among all predicted FhaB 
proteins, which we will henceforth refer to as the FhaB extreme C-terminus (ECT). Western blot 
analysis of a strain producing FhaB that lacks both subdomains (∆PRR-ECT) revealed the 
absence of full-length FhaB in WCL (Fig. 2), but lack of these subdomains had no discernable 
effect on the amount of FHA produced or released into the culture medium. Deletion of sphB1 in 
the ∆PRR-ECT strain resulted in detection of a doublet including FHA’ and a slightly smaller 
polypeptide that we had not observed previously, but which was also present in culture 
supernatants of the WT strain (Fig. 2). 
To investigate the contribution of the individual C-terminal subdomains in FhaB 
processing, we constructed B. bronchiseptica strains that produced FhaB proteins lacking either 
the PRR or the ECT. Similar to the ∆PRR-ECT strain, no full-length FhaB was detected by 
western blot analysis of the ∆ECT strain (Fig. 2). Deletion of sphB1 in the strain lacking the ECT 
resulted in detection of only FHA’ and the slightly smaller polypeptide (Fig. 2). Western blot 
analysis of a strain containing an HA epitope insertion 7 aa N-terminal to the FhaB C-terminus 
also abolished detection of full-length FhaB (Supplementary Fig. 2)25, suggesting that the reason 
for the strict conservation of the ECT in Bordetella is that this functional element is unable to 
tolerate mutation. Additionally, SphB1-dependent processing still occurred in the ∆ECT strain 
(Fig. 2), indicating that FhaB reaches the surface during secretion. These results indicate that the 
ECT is a negative regulator of prodomain degradation; without it, the prodomain is degraded 
aberrantly quickly such that full-length FhaB cannot be detected. 
Western blot analysis of WCL and culture supernatants of the ∆PRR strain, by contrast, 
displayed no difference in the amount of FhaB/FHA produced, processed, or released compared 
with WT bacteria (Fig. 2). This finding suggests that the PRR does not play a role in FhaB 
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processing. Additionally, fusion of PhoA to the C-terminus of FhaB in the strain lacking the PRR 
resulted in blue colonies (Fig. 1c), while western blot analysis of WCL and culture supernatants 
of the ∆PRR strain producing the fusion protein displayed no changes in the amount of 
FhaB/FHA produced, processed, or released (Fig. 1a). These results indicate that the PRR does 
not influence prodomain transport to the periplasm. To test whether the PRR is involved in 
retention of the prodomain in the periplasm, we performed a dot blot. Similar to the WT strain, 
the MCD was detected on the surface of intact bacteria and in disrupted cells and PhoA was only 
detected in disrupted cells (Fig. 1b), indicating that the prodomain remained intracellular and that 
the PRR does not contribute to intracellular retention of the prodomain. Furthermore, deletion of 
the PRR did not result in increased proportions of full-length FhaB in WCL samples or release of 
full-length FhaB into culture supernatants in a ∆sphB1 strain (Fig. 2), as is seen with strains 
lacking the PNT25. SphB1-dependent processing still occurs in the ∆PRR strain (Fig. 2), 
suggesting that FhaB reaches the surface during secretion. Together, these results suggest that 
the PRR does not play a role in production of ‘mature’ FHA. 
 
‘Mature’ FHA is sufficient to mediate adherence to respiratory epithelium 
 Since the ∆ECT strain essentially produces only ‘mature’ FHA, this strain provided a tool 
to investigate whether ‘mature’ FHA is indeed the active form of the protein in vivo. Because in 
vitro adherence assays are typically performed with non-ciliated, non-polarized cell lines and 
Bordetella adhere primarily to ciliated respiratory epithelium in vivo38,39, we developed an in 
vivo assay to assess the contribution of FHA to adherence to the respiratory tract (Scheller). 
Using this protocol, ~1% of the inoculum of WT bacteria was recovered in bronchoalveolar 
lavage fluid (BALF), indicating that ~99% of the bacteria were retained in the respiratory tract. 
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In contrast, ~27% of the inoculum was recovered for an avirulent Bvg– phase-locked strain that 
is completely non-adherent in vitro (Fig. 3)40. Thus, ~30% recovery appears to be the upper limit 
of detection in this assay for non-adherent strains. Inoculation with a FHA-null strain resulted in 
recovery of ~30% of the inoculum in the BALF (Fig. 3), indicating that FHA is an essential 
adhesin for B. bronchiseptica in the murine respiratory tract. 
To determine whether the accelerated degradation of the prodomain in strains lacking the 
C-terminal subdomains of FhaB alters adherence of B. bronchiseptica in vivo, we inoculated 
mice with strains lacking the PRR, the ECT, or both. Approximately two percent of the inoculum 
of the ∆PRR-ECT strain was recovered in the BALF (Fig. 3), indicating that the C-terminal 
subdomains are not required for FHA-mediated adherence in vivo. Accordingly, ~2% of the 
inoculum of the ∆ECT strain and ~4% of the inoculum of the ∆PRR strain were recovered in the 
BALF (Fig. 3). These findings reveal that ‘mature’ FHA is sufficient to mediate adherence to the 
respiratory tract. Additionally, co-inoculation of WT B. bronchiseptica with the ∆PRR strain, the 
∆ECT strain, or the FHA-null strain did not alter recovery of either strain compared to 
inoculation with each strain alone (Fig. 3). These results indicate that in vivo adherence is 
determined on a per bacterium basis and that FHA proteins secreted by WT bacteria are unable 
to complement adherence defects. 
Deletion of a large portion of the FhaB prodomain (including most of the PNT) was 
previously demonstrated to abrogate B. bronchiseptica adherence to rat lung epithelial L2 cells 
and B. pertussis adherence to human lung epithelial A549 cells in vitro13,25. This mutation also 
resulted in aberrant folding of the FHA MCD25. Furthermore, α-MCD antibodies were able to 
abrogate adherence of B. pertussis and B. bronchiseptica to both rat lung epithelial L2 cells and 
mouse macrophage-like J774A.1 cells in vitro12. Together, these findings suggest that the MCD 
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facilitates FHA-mediated adherence and that the FhaB prodomain is required for correct folding 
of the MCD. In agreement with these findings, ~24% of the inoculum of a B. bronchiseptica 
∆Prodomain strain was recovered in the BALF (Fig. 3). When considered with the result that 
deletion of the C-terminal subdomains did not abrogate FHA-mediated adherence to the 
respiratory tract, these findings support the requirement of an intact PNT to mediate retention of 
the prodomain, which facilitates folding of the MCD, and to produce an FHA molecule capable 
of mediating adherence to the respiratory tract. Combined, these data further suggest that FHA is 
folded correctly and is able to confer adherence capabilities to B. bronchiseptica in strains 
lacking the ECT. Since the PRR does not influence FhaB/FHA processing (Fig. 2) or FhaB 
prodomain localization (Fig. 1), these data also strongly suggest that the PRR does not play a 
role in production of functional ‘mature’ FHA. The ‘mature’ FHA molecules produced in the 
∆PRR and ∆ECT strains are thus indistinguishable from those produced by WT bacteria, and 
therefore the only difference between the WT and mutant strains is the ‘premature’ FhaB 
molecules they produce. 
 
‘Mature’ FHA is not sufficient for B. bronchiseptica persistence in the lower respiratory tract 
 Deletion of both the PRR and ECT subdomains (∆PRR-ECT) was previously shown to 
reduce persistence in the tracheas of rats13, even though this strain is capable of adhering both in 
vivo (Fig. 3) and in vitro13. To determine which of the individual C-terminal subdomains is 
involved in FhaB/FHA-mediated virulence activities, we inoculated mice intranasally with 
various B. bronchiseptica strains and monitored bacterial burden in the respiratory tract over 
time. As has been observed previously6,11,12, WT bacteria persisted at high levels in the trachea 
and lungs beyond 11 days post-inoculation, and FHA-null bacteria were mostly cleared from the 
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trachea and lungs by 11 days post-inoculation (Fig. 4a). The FHA-null strain displayed an 
increase in burden at 1 day post-inoculation compared to WT bacteria, a bimodal distribution of 
burden at 3 days post-inoculation, and a dramatic reduction in burden by day 11 (Fig. 4a). 
Additionally, as has been previously shown2,11-13, the number of CFU recovered from the nasal 
cavity for the FHA-null strain was similar to that for WT bacteria (Supplementary Fig. 3), 
indicating that FHA is not required for colonization and persistence in the upper respiratory tract 
of rodents. 
 Similar to the FHA-null strain, the ∆ECT strain was unable to persist in the murine lower 
respiratory tract, as most mice had completely cleared this strain from their trachea and lungs by 
11 days post-inoculation (Fig. 4a). However, the course of infection of the ∆ECT strain differed 
from that of the FHA-null strain; there was no increase in burden at 1 day post-inoculation or 
bimodal burden distribution at 3 days post-inoculation in the lungs (Fig. 4a). The ∆PRR strain 
also displayed increased clearance from the mouse trachea and lungs compared to WT bacteria 
(Fig. 4a), while, similar to FHA-null bacteria, colonization and persistence in the nasal cavity 
were not compromised (Supplementary Fig. 3). We also created the identical ∆PRR mutation in 
WT strain RB50, which contains an intact fhaS gene, and deletion of the PRR in this background 
resulted in the same persistence defect in the lower respiratory tract (Supplementary Fig. 4), 
demonstrating that the decreased persistence in the lower respiratory tract is due to the lack of 
the FhaB PRR rather than lack of fhaS (in addition to the ∆PRR mutation) or an undetected 
additional mutation elsewhere on the chromosome.  Since the ‘mature’ FHA molecules produced 
by the ∆PRR strain and the ∆ECT strain are indistinguishable from those produced by WT 
bacteria, these results indicate that ‘mature’ FHA is not sufficient to mediate B. bronchiseptica 
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persistence, revealing an active role for the full-length FhaB polypeptide in vivo that is 
dependent on both the PRR and the ECT. 
 
‘Mature’ FHA is sufficient for immunomodulation 
 Previous studies have suggested that FHA contributes to Bordetella persistence in mice 
via suppression of inflammation6,11. To ascertain whether the increased clearance observed with 
our ∆PRR and ∆ECT strains is due to an increased induction of inflammation compared to WT 
bacteria, we measured global cytokine and chemokine levels in the mouse lung during infection. 
As previously reported 6, the FHA-null strain induced higher production of pro-inflammatory 
cytokines, such as interleukin (IL)-1β, and chemokines, such as the neutrophil chemoattractant 
KC and the monocyte chemoattractant MCP-1, than WT bacteria (Fig. 4b). There was no 
difference in global levels of gamma interferon (IFNγ), tumor necrosis factor α (TNFα), IL-10, 
IL-12p70, IL-17, IL-22, or IL-23 produced in the lungs of mice infected with WT or FHA-null 
bacteria (Supplementary Fig. 5), suggesting that the primary difference in the innate immune 
response to infection with WT or FHA-null bacteria is the intensity of the initial IL-1β-mediated 
inflammation. 
 In contrast to FHA-null bacteria, neither the ∆ECT strain nor the ∆PRR strain stimulated 
higher inflammatory cytokine or chemokine production than the WT strain during infection (Fig. 
4b). These data suggest that the increased clearance observed with these strains is not due to a 
lack of FHA-mediated immunosuppression and that ‘mature’ FHA is sufficient to suppress the 
initial inflammatory response. 
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‘Premature’ FhaB is required for resistance to innate immune response-mediated clearance 
We have previously demonstrated that co-inoculation of mice with WT and FHA-null 
bacteria partially ‘rescues’ persistence of FHA-null bacteria in the lungs compared to inoculation 
with only the FHA-null strain, while persistence of WT bacteria after co-inoculation was 
unaltered compared to inoculation with only the WT strain11.  Inflammation was suppressed after 
co-inoculation compared to inoculation with only FHA-null bacteria; however, FHA-null 
bacteria were still not able to persist as well as WT bacteria11, suggesting that FhaB/FHA may 
mediate resistance to clearance even under less inflammatory conditions. Similar to these 
previous findings, the number of CFU of WT bacteria recovered after co-inoculation with the 
FHA-null strain was unchanged compared to inoculation with only WT bacteria, while the 
number of CFU of the FHA-null bacteria was increased compared to inoculation with only FHA-
null bacteria at 11 days post-inoculation (Fig. 5a). Additionally, production of pro-inflammatory 
cytokines and chemokines after co-inoculation was identical to that seen in mice inoculated with 
only WT bacteria (Fig. 5b). However, the number of CFU of the FHA-null strain at 11 days post-
inoculation in the co-inoculation experiment was still lower than that of WT bacteria, supporting 
the hypothesis that FhaB/FHA plays another role in persistence that is distinct from its role in 
suppressing the intensity of the inflammatory response. 
In contrast to co-inoculation of mice with WT and FHA-null bacteria, co-inoculation of 
WT bacteria with either the ∆ECT or ∆PRR strain did not alter clearance of the mutant bacteria, 
they were cleared as rapidly as when inoculated in the absence of WT bacteria (Fig. 5a). 
Production of cytokines and chemokines was similarly unaltered during co-inoculation compared 
to inoculation with only WT bacteria (Fig. 5b). Since WT bacteria failed to ‘rescue’ either the 
∆ECT or ∆PRR strain in the presence of an unaltered inflammatory response, these results 
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support the hypothesis that the virulence defect of the ∆ECT and ∆PRR strains that leads to the 
decreased persistence is a lack of resistance to clearance by the innate immune response. 
Moreover, these results strongly argue that ‘mature’ FHA is not sufficient for this activity, 
revealing a functional role for ‘premature’ FhaB in resistance to innate immunity-mediated 
clearance and indicating that the PRR is essential for that activity.  
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Discussion 
Our previous studies revealed that FhaB secretion and maturation is a highly regulated 
activity. The conserved N-terminal region of the prodomain is required for proper MCD folding 
and subsequent adherence capabilities25. Additionally, we observed production of stable 
intracellular prodomain fragments in strains lacking the C-terminal portion of the MCD25, 
suggesting a role for the MCD in regulating prodomain degradation. Together, these findings 
indicated that information is relayed bidirectionally across the outer membrane via the FhaB 
primary sequence (i.e. regulation of MCD folding on the bacterial surface and initiation of 
prodomain degradation in the periplasm). Here, we determined that the prodomain resides in the 
periplasm during FhaB secretion (Fig. 1) and demonstrated that deletion of the FhaB ECT 
resulted in the inability to detect full-length FhaB molecules (Fig. 2), indicating that the ECT is a 
negative regulator of prodomain degradation in the periplasm. A model of FhaB secretion taking 
these findings into account is shown in Supplementary Fig. 6. 
Taking advantage of the fact that the ∆ECT strain essentially produces only ‘mature’ 
FHA, we examined whether FHA was in fact capable of performing all virulence functions that 
have been attributed to this molecule. Using our recently developed in vivo adherence assay, we 
found that FHA is both necessary and sufficient to mediate adherence to the murine respiratory 
tract (Fig. 3). Additionally, the ∆ECT strain was capable of suppressing the acute inflammatory 
response in the murine lower respiratory tract (Fig. 4b), indicating that ‘mature’ FHA is also both 
necessary and sufficient to perform this function. Surprisingly, however, the ∆ECT strain was 
unable to persist in the murine lower respiratory tract (Fig. 4a), and co-infection with WT 
bacteria did not rescue the persistence defect or alter the inflammatory response (Fig. 5). These 
data reveal three previously unappreciated aspects of FHA physiology: 1) the persistence defect 
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of FHA-mutant strains is not solely due to lack of adherence or suppression of inflammation, 2) 
‘mature’ FHA is not sufficient to facilitate all fhaB-mediated virulence activities, and 3) full-
length ‘premature’ FhaB is therefore required for resistance to innate immune effectors. In 
support of these conclusions, deletion of the FhaB PRR, which did not result in any FhaB 
processing abnormalities (Fig. 1, Fig. 2) or affect production of functional ‘mature’ FHA (Fig. 3, 
Fig. 4b), produced almost identical phenotypes as seen for the ∆ECT strain, indicating that the 
defect for both these strains is the lack of functional ‘premature’ FhaB molecules and that the 
PRR is essential for FhaB activity. 
We hypothesize that transmission of information is the basis for the activity of full-length 
FhaB, acting as a transmembrane sensor, and that the PRR is integral for relaying information in 
vivo. Due to the fact that it contains repeat motifs (Supplementary Fig. 1b) and the proclivity of 
polyproline peptides to adopt an extended conformation41, we postulate that the PRR acts as a 
docking site for protein interactions in the periplasm and that modulation of interactions are 
required for resisting the innate immune response. These interactions likely direct the action of a 
short-range effector(s), as the defects observed with the ∆PRR and ∆ECT strains appeared to 
operate on a per bacterium basis (Fig. 3, Fig. 5). Discriminating between potential mechanisms 
by which this occurs will be the subject of future investigations. We expect that the defect in B. 
bronchiseptica lower respiratory tract persistence observed for the ∆PRR strain is due to 
decreased resistance to clearance by phagocytes. While decreased resistance to other aspects of 
the innate immune response is possible, it is unlikely that full-length FhaB is necessary for 
resistance to mechanical clearance, as the ∆PRR and ∆ECT strains display normal adherence to 
the respiratory tract (Fig. 3), or to secreted molecular immune effectors. By contrast, FhaB/FHA 
has been reported to mediate interactions with phagocytes42-44. 
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Our results suggest that once FhaB is processed to ‘mature’ FHA, B. bronchiseptica is no 
longer able to resist clearance by the innate immune response. This finding perhaps elucidates a 
paradox in FHA physiology; namely, that FHA, a critical adhesin, is released from the bacterial 
surface in large quantities (Fig. 2). While our experiments are unable to determine whether 
released FHA plays a role in suppression of the immune response, as has been suggested18-22, this 
work provides an alternative role for release of FHA. FHA release may predominantly serve the 
purpose of liberating FhaC to secrete a new FhaB molecule, which can then mediate persistence 
in the lower respiratory tract. If true, this hypothesis suggests that the multiple processing events 
that FhaB undergoes serve several purposes. Initiation of prodomain degradation may serve as 
the periplasmic signal that FhaB has sensed environmental changes, while SphB1-dependent 
cleavage, which results in increased release of FHA from the surface (Fig. 2)13,33, may facilitate 
FhaB turnover. 
Integral to understanding the physiological function of proteins is elucidation of the 
means by which they achieve their functional forms. For processed proteins, it is typically 
assumed that the final polypeptide observed in vitro is the functional form of the protein. This 
work suggests that precursor molecules are important to the physiological function of some 
processed proteins. The results presented here demonstrate the presence of multiple 
intramolecular determinants of FhaB prodomain degradation, in addition to multiple known 
intermolecular determinants, indicating that ‘maturation’ of FhaB is a tightly regulated process. 
While dysregulation of prodomain degradation does not affect the ability of ‘mature’ FHA to 
mediate adherence or immunosuppression during infection (Fig. 3, Fig. 4b), these studies yielded 
the unexpected finding that ‘premature’ FhaB plays an active role in pathogenesis, specifically in 
resisting clearance by innate immune effectors. Our results highlight the advantage of studying 
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protein secretion and function simultaneously as a role for the FhaB PRR was only evident from 
in vivo infection studies and not from studies on the production or maturation of FHA or even 
from virulence-associated in vitro assays13. Our results also provide a reminder that while 
culturing bacteria in the laboratory is extremely useful and often essential for understanding 
molecular mechanisms underlying microbiological processes such as protein secretion, in vitro 
growth conditions may not accurately mimic the conditions under which the microbiological 
processes under study function in nature. 
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Materials and Methods 
Bioinformatics 
Protein sequences were obtained from the NCBI Protein Database. Sequence alignments 
were conducted using Clustal Omega45 and visualized using Jalview Version 246. Searches for 
similar sequences were conducted with blastp. 
 
Ethics statements 
This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the NIH. Our protocols were approved by the 
University of North Carolina IACUC (10-134, 12-307, and 13-238). All animals were properly 
anesthetized for inoculations, monitored regularly, and euthanized when moribund, and efforts 
were made to minimize suffering. 
 
Growth media and bacterial strains 
B. bronchiseptica strains were grown at 37°C in Stainer-Scholte (SS) broth or on Difco 
Bordet-Gengou (BG) agar (BD) supplemented with 5.5% defibrinated sheep blood (Colorado 
Serum Co., Denver, CO). Escherichia coli strains were grown at 37°C in Luria broth (LB) or on 
LB agar. A detailed description of bacterial strains, their construction, and the rationale for their 
use is included in Supplementary Methods. Where appropriate, media were supplemented with 
gentamicin (30 µg/mL), streptomycin (20 µg/mL), kanamycin (50 µg/mL), MgSO4 (50 mM), 
diaminopimelic acid (200 µg/mL), or 5-bromo-4-chloro-3-indolyl phosphate (XP, 40 µg/mL). 
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Immunoblotting 
To evaluate FHA production and processing, proteins were prepared from B. 
bronchiseptica cultures grown in SS broth and normalized based on optical density. For cell-
associated proteins, whole-cell lysates (WCL) of bacteria were prepared by boiling in sodium-
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer. For released 
proteins, culture supernatants precipitated with 10% trichloroacetic acid (TCA, Fisher Scientific) 
were mixed with SDS-PAGE sample buffer and boiled. Proteins were separated by SDS-PAGE 
on 5% polyacrylamide gels, transferred to nitrocellulose (GE Healthcare), and probed with a 
rabbit polyclonal antibody generated against the FHA mature C-terminal domain (MCD)12, a 
mouse monoclonal antibody generated against PhoA (Covance), or a mouse monoclonal 
antibody generated against an HA epitope (Covance). Corresponding α-rabbit and α-mouse 
IRDye secondary antibodies were used to detect proteins (Li-Cor Biosciences). Membranes were 
imaged on a Li-Cor Odyssey Classic Infrared Imager (Li-Cor Biosciences). 
To assess the surface accessibility of proteins, B. bronchiseptica grown in SS broth were 
washed and resuspended in phosphate-buffered saline (PBS, Life Technologies), and half of each 
sample was boiled to disrupt the cells. Intact and disrupted cells were then spotted on 
nitrocellulose and probed with a rabbit polyclonal α-MCD antibody and a mouse monoclonal α-
PhoA antibody. Corresponding α-rabbit and α-mouse IRDye secondary antibodies were used to 
detect proteins, and membranes were imaged on a Li-Cor Odyssey Classic Infrared Imager. 
 
Bacterial adherence to the respiratory tract 
Bacterial adherence was measured using a recently developed in vivo adherence assay 
(Scheller). Briefly, six-week old female BALB/cJ mice from Jackson Laboratories (Bar Harbor, 
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ME) were anesthetized with isofluorane and inoculated intranasally with 7.5×104 colony forming 
units (CFU) of B. bronchiseptica in 50 µL PBS. For co-inoculation experiments, WT and mutant 
strains were marked with different antibiotic resistance genes as described in Supplementary 
Methods. Mice were euthanized 30-60 minutes after inoculation. Bronchoalveolar lavage fluid 
(BALF) was collected by inserting a cannula into the trachea, ligating with suture, and injecting 
and retracting 1 mL PBS. Serial dilutions of BALF and the inoculum were plated on BG agar to 
quantitate recovery of bacterial CFU. 
 
Bacterial persistence and characterization of the immune response during infection of mice 
Six-week old female BALB/cJ mice were inoculated and euthanized as above. For co-
inoculation experiments, WT and mutant strains were marked with different antibiotic resistance 
genes as described in the Supplementary Methods. Lungs, tracheas, and nasal cavities were 
harvested and homogenized in PBS. Serial dilutions of homogenized tissues were plated on BG 
agar (with appropriate antibiotics) to quantitate recovery of bacterial CFU. Cytokine and 
chemokine production were analyzed by conducting enzyme-linked immunosorbent assays 
(ELISA) on lung homogenates diluted in PBS (R&D Systems). 
 
Statistical analysis 
Data were plotted and statistical analyses were performed using Prism, version 5.0 
software (GraphPad Software, Inc.). For all conditions analyzed, n≥6 (two or more separate 
experiments on different days with n≥3), and statistical significance was determined using 
analysis of variance (ANOVA). 
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Supporting Information 
Figure 1. The FhaB prodomain transits to the periplasm, where it is retained during secretion 
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Figure 1. The FhaB prodomain transits to the periplasm, where it is retained during 
secretion. (a) Culture of strains containing various phoA insertions on an agar plate containing a 
chromogenic PhoA substrate. Fusion of PhoA (lacking its native signal peptide) to the C-
terminus of FhaB (CT-PhoA strains) resulted in production of blue colonies similar to those 
produced by a strain constitutively producing PhoA (WT PhoA), while a strain constitutively 
producing PhoA lacking its native signal peptide (WT ∆SP-PhoA) or not producing PhoA (WT) 
did not produce blue colonies. (b) Dot blot analysis of intact (not boiled) and disrupted (boiled) 
bacteria for strains not producing PhoA (WT) or with PhoA fused to the C-terminus of FhaB 
(CT-PhoA strains). Membranes were probed with α-MCD (green) and α-PhoA (red) antibodies, 
and the green and red channels are overlaid. PhoA was only accessible to antibodies after lysis of 
the cells by boiling. (c) Western blot analysis of whole-cell lysates (WCL) and culture 
supernatants (Sup.) from strains containing 3’ fusions of phoA to fhaB. C-terminal PhoA fusion 
(CT-PhoA strains) did not alter production or processing of FhaB or release of FHA. Membranes 
were probed as in (b). 
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Figure 2. The extreme C-terminus (ECT) of the FhaB prodomain inhibits prodomain 
degradation. 
 
 
Figure 2. The extreme C-terminus (ECT) of the FhaB prodomain inhibits prodomain 
degradation. Western blot analysis of whole-cell lysates (WCL) and culture supernatants (Sup.) 
from strains lacking the FhaB PRR (∆PRR), the FhaB ECT (∆ECT), both (∆PRR-ECT), or 
neither (WT), as well as each strain lacking sphB1. Strains lacking the FhaB ECT do not contain 
any observable FhaB in WCL or Sup. fractions. Membranes were probed with α-MCD 
antibodies. The FhaB molecules translated by each strain are diagrammed above (dark blue – 
signal peptide, pink – TPS domain, purple – β-helical domain, green – MCD, brown – PNT, light 
blue – uncharacterized prodomain, red – PRR, yellow – ECT). 
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Figure 3. Properly folded FHA is necessary and sufficient for adherence of B. 
bronchiseptica to the respiratory tract. 
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Figure 3. Properly folded FHA is necessary and sufficient for adherence of B. 
bronchiseptica to the respiratory tract. (a) CFU recovered in BALF 30-60 min after intranasal 
inoculation of mice. Each point represents the number of CFU recovered from a single animal. 
(b) Recovery of bacteria in BALF represented as percent of inoculum for each strain. Only 
strains lacking a properly folded MCD displayed decreased retention in the murine respiratory 
tract. The FhaB molecules translated by each strain are diagrammed above (dark blue – signal 
peptide, pink – TPS domain, purple – β-helical domain, green – MCD, brown – PNT, light blue 
– uncharacterized prodomain, red – PRR, yellow – ECT). Data are pooled from 2 separate 
experiments conducted on different days. Percent of inoculum data are represented as mean ± 
SEM. *** = p<0.001 
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Figure 4. The FhaB proline-rich region and extreme C-terminus are necessary for B. 
bronchiseptica persistence in the lower respiratory tract in a manner that is distinct from 
suppression of inflammation 
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Figure 4. The FhaB proline-rich region and extreme C-terminus are necessary for B. 
bronchiseptica persistence in the lower respiratory tract in a manner that is distinct from 
suppression of inflammation. (a) Bacterial burden in the murine lower respiratory tract after 
intranasal inoculation. Each point represents the number of CFU recovered from a single animal. 
Open symbols represent the lower limit of detection for that particular experiment as no CFU 
were recovered. (b) Production of pro-inflammatory cytokines (IL-1β) and chemokines (KC, 
MCP-1) in the murine lung during infection. Cytokine and chemokine levels were determined 
from lung homogenates by ELISA. Data represent mean ± SEM for all samples, which were 
collected from all animals for which CFU are shown in Fig. 6a. Data are pooled from ≥2 separate 
experiments conducted on different days. * = p<0.05, ** = p<0.01, *** = p<0.001 
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Figure 5. The persistence defect of the ∆PRR and ∆ECT strains cannot be rescued by WT 
bacteria. 
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Figure 5. The persistence defect of the ∆PRR and ∆ECT strains cannot be rescued by WT 
bacteria. (a) Bacterial burden in the murine lower respiratory tract after co-inoculation with WT 
and FHA mutant strains marked with different antibiotic resistance genes. Each point represents 
the number of CFU recovered from a single animal. Open symbols represent the lower limit of 
detection for that particular experiment as no CFU were recovered. (b) Production of pro-
inflammatory cytokines (IL-1β) and chemokines (KC, MCP-1) in the murine lung during co-
infection. Cytokine and chemokine levels were determined from lung homogenates by ELISA. 
Data represent mean ± SEM for all samples, which were collected from all animals for which 
CFU are shown in Fig. 7a. Data are pooled from 2 separate experiments conducted on different 
days. Statistical significance is indicated for mutant bacteria compared to WT from the same co-
inoculation group. * = p<0.05, ** = p<0.01, *** = p<0.0011 
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CHAPTER 4. CLEARANCE OF FIM-DEFICIENT BACTERIA REQUIRES A 
COMPONENT OF THE ADAPTIVE IMMUNE RESPONSE 
Rationale 
 As we have demonstrated in Chapter 2, FIM-deficient bacteria are defective for 
persistence in the lower respiratory tract of mice, as FIM-deficient bacteria were unrecoverable 
from the lungs by 14 days post-inoculation (1) (Chapter 2). This persistence defect coincides 
with increased pro-inflammatory cytokines, such as IL-1β, and increased production of the 
chemokines KC and MCP-1 (1) (Chapter 2). KC is a chemokine involved in the recruitment of 
neutrophils (2), and MCP-1 is a chemokine involved in the recruitment and activation of 
macrophages (3). H&E stained lung sections from mice inoculated with FIM-deficient bacteria 
indicated increased cellular infiltrate in the lungs (1) (Chapter 2). Taken together, these data 
suggest that FIM-deficient bacteria cause a hyper-inflammatory environment in the lower 
respiratory tract, leading to increased recruitment and activation of macrophages and neutrophils. 
We hypothesized that the innate immune response, specifically neutrophils and macrophages, 
would be sufficient to clear FIM-deficient bacteria from the lower respiratory tract of mice. To 
test this hypothesis, we used severe combined immunodeficiency (SCID) mice. We have 
previously shown that SCID mice, which do not have functional T or B-cells but do have 
macrophages and neutrophils (4) will not clear B. bronchiseptica and will succumb to infection 
approximately 60 days post-inoculation (5), suggesting the adaptive immune response is required 
for clearing WT Bordetella infection. Additionally, we have shown that neutrophils are required 
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to control the initial Bordetella infection  (5). Given that SCID mice possess functional 
macrophages and neutrophils, that neutrophils are required to control the initial Bordetella 
infection, and that Chapter 2 suggests that neutrophils and macrophages are sufficient to clear 
FIM-deficient bacteria, we hypothesized that FIM-deficient bacteria would be defective for 
persistence in the lower respiratory tract of SCID mice. 
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Results 
B and/or T-cells are required for clearance of FIM-deficient bacteria. 
 BALB/c SCID mice were inoculated intranasally with 7.5 x 104 CFUs of either WT or 
∆fimBCD B. bronchiseptica. Mice were euthanized three, 14 and 45 days post-inoculation, and 
bacterial burdens were determined from the right lung lobes. SCID mice inoculated with WT 
bacteria had high bacterial burden at three, 14 and 45 days post-inoculation (Fig 1A), consistent 
with previous published data of high bacterial burden of WT bacteria in SCID mice (5). These 
data also differed, as expected, from results from immune-competent BALB/c mice inoculated 
with WT bacteria, where the bacteria are cleared from the lower respiratory tract approximately 
30 days post-inoculation (5). Surprisingly, there was no significant difference between SCID 
mice inoculated with FIM-deficient bacteria and SCID mice inoculated with WT bacteria at any 
time point observed, indicating that the FIM-deficient bacteria were not defective for persistence 
in the SCID mice. These data suggest that SCID mice lack a cellular component that contributes 
to the early clearance of FIM-deficient bacteria that we had previously observed in immune-
competent BALB/c mice. 
 In Chapter 2, we observed that H&E stained lung sections from mice inoculated with 
FIM-deficient bacteria had increased cellular infiltrate, presumably neutrophils and 
macrophages. To determine if SCID mice inoculated with WT or FIM-deficient bacteria had 
increased cellular infiltrate in the lungs, the left lung lobes were prepared for histology, stained 
with hemotoxylin and eosin and observed by microscopy. Despite high bacterial burdens in the 
lungs of mice at 14 and 45 days post-inoculation, we observed very little cellular infiltrate in 
lungs from mice inoculated with either WT or FIM-deficient bacteria (Fig 1B). The absence of 
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cellular infiltrate was startling; we have previously shown that mice with high bacterial burden 
have robust cellular infiltrate around the major airways (1) (Chapter 2). The lung sections from 
the SCID mice inoculated with WT or FIM-deficient bacteria appeared similar to H&E stained 
lung sections of PBS mock inoculated mice. These data suggested that cellular components 
absent in SCID mice were critical in recruiting phagocytes to the lungs during Bordetella 
infection. We hypothesized that adoptive transfer of bulk splenocytes from immune-competent 
mice, which would contain B and T-cells absent in SCID mice, would provide immune 
components necessary for clearance of the FIM-deficient bacteria and recruitment of cellular 
infiltrate to the lungs. 
 To test this hypothesis, bulk splenocytes were purified from the spleens of immune-
competent BALB/c mice, and were adoptively transferred intravenously to SCID mice one day 
prior to inoculation. Mice were then inoculated intranasally with 7.5 x 104 CFU of either WT or 
∆fimBCD bacteria, and lungs were harvested to determine CFUs. At seven days post-inoculation, 
there was no significant difference in bacterial burden in the lungs from mice inoculated with 
WT or FIM-deficient bacteria (Fig 2A). At 14 days post-inoculation, however, we recovered 
significantly fewer bacteria from the mice inoculated with FIM-deficient bacteria compared to 
those inoculated with WT bacteria. At 21 days post-inoculation there was no significant 
difference in the number of CFUs recovered from of mice inoculated with either strain. These 
data indicate that adoptive transfers of bulk splenocytes can partially restore the persistence 
defect of the FIM-deficient bacteria. 
 To determine if adoptive transfer of bulk splenocytes restored cellular infiltrate to the 
lungs during infection, the left lung lobe was sectioned and stained with hemotoxylin and eosin. 
Seven and 14 days post-inoculation, lung sections from mice inoculated with WT bacteria had 
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cellular infiltrate around the major airways (Fig 2B). The amount of cellular infiltrate, 
qualitatively, appeared similar to the cellular infiltrate observed from H&E stained lung sections 
from immune-competent mice inoculated with WT bacteria at similar time points. When mice 
were inoculated with FIM-deficient bacteria, we observed cellular infiltrate around the major 
airways, as well as in the alveolar spaces. The amount of cellular infiltrate did not appear as 
robust, however, as we had previously observed in lung sections from immune competent mice 
inoculated with FIM-deficient bacteria. Together, these data indicate that bulk splenocytes are 
capable of restoring innate immune cell recruitment in SCID mice. The qualitative differences in 
the amount of cellular infiltrate observed from H&E stained lung sections, and the partial 
restoration of FIM-deficient bacterial clearance, suggests that adoptive transfer of bulk 
splenocytes does not completely reconstitute the immune environment of an immune-competent 
mouse. 
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Discussion 
Given that FIM-deficient bacteria are cleared from the lungs of mice by 14 days post-
inoculation (1) (Chapter 2), that there is an increased influx of cellular infiltrate to the lungs of 
mice inoculated with FIM-deficient bacteria (1) (Chapter 2), and that neutrophils have been 
shown necessary to control Bordetella infection (5, 6), we hypothesized that the innate immune 
response alone would be sufficient to clear FIM-deficient bacteria. Hence, we tested this 
hypothesis using SCID mice that lack B and T cells and therefore rely on innate immunity for 
protection. Surprisingly, SCID mice were unable to clear FIM-deficient bacteria from the lungs, 
and H&E stained lung sections indicated very little cellular recruitment to the lungs of mice 
inoculated with either WT or FIM-deficient bacteria. Adoptive transfer of bulk splenocytes 
partially restored clearance of FIM-deficient bacteria, and restored recruitment of immune cells 
to the lungs. The histology pattern and timing of bacterial clearance, however, were not identical 
to previously published data in immune-competent mice inoculated with FIM-deficient bacteria 
(1) (Chapter 2). Together, these data suggest B and/or T-cells, which are absent in SCID mice, 
are required for the early immune response to Bordetella infection. 
SCID mice have a defect in the enzyme Prkdc, an enzyme responsible for DNA repair 
and one that is integral for V(D)J recombination (4). V(D)J recombination is an important step in 
developing the broad diversity seen in the antigen binding regions of B and T-cell receptors (7, 
8). In the absence of V(D)J recombination, B-cells and T-cells will not fully mature and will not 
recognize antigens (7, 8). SCID mice, then, do not have functional components of adaptive 
immunity, and we have shown that the adaptive immune response is necessary for clearance of 
Bordetella in mice (5). However, we did not expect SCID mice to be unable to clear FIM-
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deficient bacteria, as our data suggested that the innate immune response, not a B or T-cell 
response, was responsible for clearing FIM-deficient bacteria. 
There are many cells types beyond the traditional B and T-helper cells that require V(D)J 
recombination to function (9, 10). For example, γδT cells are cells with a TCR. These cells, 
which undergo maturation in the thymus similar to traditional T-cells, will migrate and reside in 
the mucosal epithelium of the stomach and lungs (11, 12). Within the epithelium, γδT cells will 
respond to pathogen associate molecular patterns (PAMPs) and respond to cytokines from 
dendritic cells (9). Following stimulation, γδT cells can kill infected cells directly, secrete 
defensins to kill bacteria, or indirectly activate macrophages and neutrophils by secreting 
cytokines (9). γδT cells have been shown necessary for promoting innate immune responses to 
clear E. coli from the mucosal gut epithelium of mice (13) and innate immune responses to clear 
RSV from the lungs of mice (14). However, a role for γδT cells has not yet been shown for 
clearance of Bordetella. We hypothesize, given the observations from this chapter, that γδT cells 
may play a role in promoting innate cell recruitment to the lungs of mice in response to 
Bordetella infection. Additionally, since γδT cells reside primarily at mucosal surfaces (15), it is 
unsurprising that bulk splenocytes would not contain many, if any, γδT cells, explaining why 
bulk splenocytes did not fully restore clearance of the FIM-deficient bacteria. By exploring this 
question further, we may gain insight in to the host immune mechanisms necessary to control 
Bordetella early during infection. 
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Supporting Information 
Figure 4.1 SCID mice cannot clear FIM-deficient bacteria from the lungs  
 
  
Figure 4.1 SCID mice cannot clear FIM-deficient bacteria (A) Bacterial burden in lung tissue 
from SCID mice inoculated with WT or FIM-deficient bacteria. Each symbol represents a value 
for an individual animal, and the black bar represents the mean for the group. Values are means 
from at least two independent experiments. (B) Hematoxylin-and-eosin stained 5 µm lungs 
sections at 10x magnification.   
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Figure 4.2 Adoptive transfer of bulk splenocytes restored partial clearence of FIM-deficient 
bacteria 
 
Figure 4.2. Adoptive transfer of bulk splenocytes restored partial clearance of FIM-
deficient bacteria. (A) Bacterial burden in lung tissue from SCID mice that received adoptive 
transfer of bulk splenocytes inoculated with WT or FIM-deficient bacteria. Each symbol 
represents a value for an individual animal, and the black bar represents the mean for the group. 
Values are means from at least two independent experiments. Mean values for mutant bacteria 
that are significantly different from the mean value for WT bacteria are indicated by asterisks as 
follows: **, P<0.01.  (B) Hematoxylin-and-eosin stained 5 µm lungs sections at 10x 
magnification. 
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Materials and Methods 
Animal model 
 5-6 week old BALB/c SCID (Severe Combined Immunodeficiency) mice were 
inoculated with 7.5 x 104 CFUs of either WT or ∆fimBCD B. bronchiseptica. The right lobes of 
the lungs were harvested, homogenized in 1 ml PBS and plated on BG agar to enumerate CFUs. 
The left lobe of the lungs was inflated with formalin, embedded in paraffin, cut to 5 µm 
thickness and stained with hemotoxylin and eosin (H&E).  
Adoptive transfer 
 Donor BALB/c mice were euthanized and the spleens were removed and placed in a tube 
of PBS. Lymphocytes were prepared as a cell suspension by pressing the spleen through a plastic 
strainer; then, 10 ml of PBS was added to pass cells through the strainer. The spleen cell 
suspension was then depleted of red blood cells (RBCs) using RBCs lysis buffer. The suspension 
was then washed three times in 0.1% BSA in PBS and centrifuged at 1600 RPM at 4° C for 5 
minutes. The cells were counted and divided in to 2 parts, one for injection and the second for 
flow cytometry analysis. The cells to be injected were resuspended and injected intravenously 
one day prior to inoculation. 
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CHAPTER 5. CONCLUSIONS 
Summary of research accomplishments 
Prior to this research project, evidence suggested that fimbria were not required for 
Bordetella adherence. Furthermore, while fimbria had been shown necessary for Bordetella 
colonization, it was unclear how fimbria contributed to Bordetella colonization and persistence. 
The original goals of this project were to: 1) Develop an in vivo adherence assay to determine if 
fimbria contribute to bacterial adherence, as we hypothesize that fimbria mediate adherence 
specifically to ciliated epithelium, 2) Characterize the persistence defect of FIM-deficient 
bacteria and the host response of mice to FIM-deficient bacteria, as we hypothesize fimbria may 
also contribute to immune modulation. 
From this work, we successfully developed a novel in vivo adherence assay capable of 
determining the contribution of virulence factors to adherence. We showed that both fimbria and 
FHA are necessary for bacterial adherence to mouse epithelium in the lower respiratory tract, 
contrasting the existing in vitro data suggesting that fimbria are not required for adherence.  
Additionally, this work was the first to show that fimbria are necessary for B. 
bronchiseptica to persist in the lungs of mice, and that inoculation with FIM-deficient Bordetella 
causes increased pro-inflammatory cytokine production and distinct histological patterns of 
cellular infiltrate. This distinctive histological pattern, in which cellular infiltrate appeared in the 
alveolar spaces of mice inoculated with FIM-deficient bacteria, led us to develop a bacterial 
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localization assay, as we hypothesized that fimbria were required to localize the bacteria to the 
ciliated epithelium of the major airways.  
Results from the localization assay indicated that Bordetella containing fimbria localize 
to the ciliated epithelium of the major airways, and FIM-deficient bacteria localize to the alveoli. 
FHA was shown to be unnecessary for initial localization to the ciliated epithelium of the major 
airways, though our data suggest that FHA mediates tight adherence to the epithelium. Together, 
this work provides a model for the initial colonization of the respiratory epithelium by 
Bordetella. Upon inoculation, fimbria mediate initial attachment of the bacteria to the ciliated 
epithelium of the major airways in the respiratory system. Once this interaction occurs, FHA will 
then mediate tight interactions to the epithelium. This FHA-mediated interaction is important as 
it allows the bacteria to persist and suppress the innate immune response. We hypothesize that 
FHA may directly affect host cells by altering signal transduction or by facilitating the delivery 
of other virulence factors, such as adenylate cyclase toxin. 
Future Directions 
1. Modulation of the Immune System 
 B. pertussis and B. bronchiseptica are highly contagious respiratory pathogens that can 
successfully colonize their hosts (1). The Bordetella genome encodes a variety of virulence 
factors that allow the bacteria to subvert the host immune response (2–5), and we have shown 
that both fimbria and filamentous hemagglutinin are necessary factors to suppress pro-
inflammatory cytokine production and recruitment of innate immune cells. In experiments 
described in Chapters 2 and 3, we showed that FIM-mediated localization of the bacteria to the 
major airways is the first key step in colonization.  FHA-mediated interactions following this 
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initial adherence then likely contribute to immune suppression. However, there are many 
questions that still remain regarding the mechanism of immune suppression. 
 The first question, with regards to fimbria, is whether fimbria directly modulate the 
immune system through specific receptor interactions, or if FIM-mediated adherence is required 
for other virulence factors to modulate the immune system. FimH of UPEC has been shown to 
bind to mannose-containing receptors (6) and influence cell signaling pathways (7), and these 
data would suggest that the adhesive tip of Bordetella fimbria may also affect cell signaling. 
Purified FimD has been shown to adhere to monocytes (8) and possibly VLA-5 (9) and purified 
Fim2 and Fim3 have been shown to adhere to sulfated sugars (10), however because these 
experiments used purified protein, the binding partner of full length, native fimbria is still 
unclear. Because the binding partners of native fimbria have not been identified, a strain 
containing mutations in the putative ligand binding region of FimD can be tested to determine 
the effects on host response and bacterial persistence. Alternatively, laser capture 
microdissection can be used to isolate epithelial cells colonized with Bordetella producing 
fimbria but lacking other virulence factors, such as FHA. We could then perform qRT-PCR to 
investigate changes in cell signaling to determine if FIM-mediated adherence can directly 
modulate the immune response.  
 A second question pertaining to FIM and FHA is the respective contribution of these 
factors to avoiding phagocytosis by macrophages and neutrophils. Co-inoculation assays with a 
mix of WT and FHA-deficient bacteria indicated that WT bacteria can partially improve the 
persistence defect of FHA-deficient bacteria (11), presumably by suppressing the local immune 
environment. However, the persistence defect of the FHA-deficient bacteria was only partially 
improved, indicating that FHA may be required for another facet of immune evasion. H&E 
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stained lung sections indicated recruitment of immune cells seven days post-inoculation in mice 
are inoculated with WT (2, 12), yet the bacterial burden of WT bacteria does not decrease until 
14 days post-inoculation and this decrease requires the adaptive immune system (13). Together, 
these data suggest that FHA, and possibly fimbria, may contribute to avoidance of phagocytic 
killing. One possibility would be that FIM and FHA allow the bacteria to actively kill the 
phagocytic cells. Alternatively, these structures may contribute to inactivation of these cell types 
to prevent phagocytosis. To address this question, we can perform gentamycin protection assays 
using neutrophils or macrophages inoculated with FIM-deficient or FHA-deficient bacteria to 
determine if FIM or FHA can prevent phagocytic uptake. Additionally, we can perform LDH 
(lactate dehydrogenase) assays to determine eukaryotic cell death in the presence of bacteria with 
or without FIM or FHA. Together, these experiments would begin to answer the question as to 
how Bordetella avoids the innate immune response.  
2. Immune effectors necessary for Bordetella clearance 
 While Chapters 2 and 3 addressed how Bordetella modulates and avoids the host immune 
response, Chapter 4 raised the question of what components of the host immune response are 
important for clearance of Bordetella. We have previously shown that SCID mice inoculated 
with WT B. bronchiseptica will die 60 days post-inoculate, suggesting that B-cells and/or T-cells 
are necessary for bacterial clearance (13). We have also shown that neutropenic mice inoculated 
with B. bronchiseptica will die three days post-inoculation, suggesting that neutrophils are 
required to control early Bordetella infection (13). Given these previous data and the data from 
Chapter 2 suggesting that the innate immune response was responsible for clearing FIM-deficient 
bacteria, we hypothesized that SCID mice, which do not contain cell types with B or T-cell 
receptors, but do contain macrophages and neutrophils, would be capable of clearing FIM-
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deficient B. bronchiseptica. Surprisingly, SCID mice were unable to clear FIM-deficient 
bacteria, suggesting that the neutrophils and macrophages of SCID mice are insufficient to clear 
FIM-deficient bacteria. Interestingly, H&E stained lung sections indicated that, despite high 
bacterial numbers, there was very little cellular infiltrate in the lungs of SCID animals inoculated 
with either strain. SCID animals that received adoptive transfer of bulk splenocytes and were 
then inoculated with WT or FIM-deficient bacteria were partially able to clear the FIM-deficient 
bacteria. Together, these data suggest that cell types with a B or T-cell receptor, which are absent 
in SCID mice, are required for recruitment of macrophages and neutrophils to the lungs early 
during Bordetella infection. 
 To determine what components of the immune system are required for the early response 
to Bordetella infection, we could first perform adoptive transfer of specific components of the 
adaptive immune response. To do this, we could isolate T and B cells from bulk splenocytes, and 
adoptively transfer those to SCID mice to be inoculated with WT or FIM-deficient bacteria. We 
could then determine the contribution of only cells possessing B or T-cell receptors to controlling 
bacterial burden and cellular infiltrate to the lungs. Given that T-cells can contribute to innate 
immunity, we would expect T-cells to contribute to the early immune response to Bordetella. 
The T-cell populations are broad, however, as there are many T-cell subsets: T-helper cells, T-
regulator cells as well as NKT and γδT cells (14). γδT cells are particularly interesting, as these 
cells are primarily located in the epithelium, can response to pathogen associated molecular 
patterns (PAMPs) and can activate macrophages and neutrophils  (15, 16). Given these cells are 
located in the epithelium, the role of γδT cells clearing gut pathogens (16) and promoting 
inflammation in the lungs (17), one hypothesis would be that γδT cells are responsible for 
activation and recruitment of macrophages and neutrophils to the lung during early time points 
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following Bordetella inoculation. One study has indicated that γδT cells may play a regulatory 
role in the lungs of mice inoculated with B. pertussis (18). We could more rigorously test this 
hypothesis in a natural host model by isolating and adoptively transferring γδT cells to SCID 
mice, or alternatively depleting γδT cells in immune-competent mice, and then determine if γδT 
cells contribute to control of B. bronchiseptica infection and recruitment of phagocytic cells 
early in infection. Together, these experiments would further the understanding of what host cell 
components are necessary for the control of early Bordetella infection. Knowledge gained from 
these experiments may contribute to developing better therapeutics and vaccines. 
3. Vaccine Implications 
Bordetella pertussis is a reemerging pathogen: The CDC and others report that the cases 
of pertussis are reaching numbers that have not been seen since the 1950s  (19). This 
reemergence coincides with the change from a whole cell vaccine (wP) to an acellular 
component vaccine (20, 21). Data from the baboon model indicate that the aP vaccine, while 
protective against pertussis disease, does not protect from colonization (22). Furthermore, studies 
indicate that the wP and aP vaccine elicit different immune responses, with the aP vaccine 
causing a more Th2 driven immune response, and the wP vaccine driving a Th1/Th17 immune 
response (23), suggesting that the type of immune response is important for protective immunity. 
This different T-cell response is believed to be due to the alum adjuvant in the aP vaccine (24, 
25).  
The evidence is compelling that the vaccine strategy against pertussis needs to change: 
the aP vaccine is not sufficient to protect against colonization in those that have been vaccinated 
or prevent transmission of bacteria to those that cannot be vaccinated. The best form of 
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protection against colonization, at least in the baboon model, has been shown to be natural 
infection (22). One possibility to explore, then, is that the aP components themselves may not 
elicit the optimal immune response, either because the antibody response against those specific 
virulence factor cannot prevent colonization or due to the antigens in the vaccine themselves. As 
we have shown, adherence early during colonization is critical for Bordetella to establish 
infection (12) (Chapter 2). One hypothesis would be that antibodies capable of blocking 
adherence would prevent Bordetella from successfully colonizing. To test this, we could pre-
incubate WT Bordetella with anti-FIM or anti-FHA antibodies and determine if antibody-antigen 
interactions are capable of blocking bacterial adherence. Additionally, it would be interesting to 
investigate the different antibody types for the ability to protect against colonization. Current 
vaccine administration is intramuscular and leads to anti-Bordetella IgG antibodies (23, 26). 
Within the mucosa, however, IgA has been shown to be critical for mucosal immunity (27).  It is 
possible that anti-Bordetella IgA, not IgG, would be a crucial in preventing Bordetella 
colonization, and focusing vaccine development efforts to explore this possibility may lead to 
improved vaccine efficacy. 
 Another possibility is that the current aP vaccine components are not optimal for 
generating an antibody response capable of preventing Bordetella colonization. For example, 
Fim2 and Fim3, the major fimbrial subunits, are included in the aP vaccine. For most Type I pili, 
however, the adhesive tip is the important end of the molecule, responsible for mediating ligand 
binding (28, 29). Additionally, other major fimbrial subunits are encoded within the Bordetella 
genome, so it is unclear whether antibodies against Fim2 and Fim3 would be protective against 
colonization and the addition of FimD as a vaccine component could be considered. Another 
antigen of interest would be FHA. To prepare FHA in the acellular vaccine, the secreted form is 
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processed and prepared to remain stable within the vaccine formulation. Chapter 3, however, 
indicated that surface bound, pre-mature FhaB is an important contributor to virulence. It is 
possible that the antibodies formed against the FHA found in acellular vaccine would not protect 
against the physiological relevant FHA utilized by the bacteria. Beyond considering FIM and 
FHA, there are a variety of other surface and secreted factors that would be present in the wP 
vaccine that would be absent from the aP vaccine, and should be considered as viable vaccine 
components.  
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APPENDIX A. BORDETELLA PERTUSSIS PATHOGENESIS: CURRENT AND 
FUTURE CHALLENGES1 
Introduction 
Pertussis is a highly contagious respiratory disease that is transmitted directly from 
human to human1, most likely via aerosolized respiratory droplets. The primary causative agent, 
Bordetella pertussis, is a Gram-negative bacterium that was first described by Bordet and 
Gengou in 1906 2. The closely related bacterium Bordetella parapertussisHu is responsible for a 
minority of cases (approximately 14%) and is less capable of causing severe disease3. Both B. 
pertussis and B. parapertussisHu are human-specific, and phylogenetic analyses indicate that they 
evolved from Bordetella bronchiseptica or a B. bronchiseptica-like ancestor4, 5 (Box 1). B. 
bronchiseptica infects a broad range of mammals, including humans, and although it can cause 
overt disease such as kennel cough in dogs and atrophic rhinitis in pigs, it typically colonizes its 
hosts chronically and asymptomatically6. Despite differences in host range and disease-causing 
propensity, B. pertussis, B. parapertussisHu and B. bronchiseptica are so closely related that they 
are now considered subspecies. Together, these organisms provide a paradigm for understanding  
bacterial adaptation to humans and the dichotomy between acute disease and chronic 
asymptomatic infection4, 5. Although other Bordetella species have been isolated from humans, 
they seem to be primarily opportunistic human pathogens. 
_____________________________________________________ 
1This chapter was previously appeared as an article in Nature Reviews Microbiology. The original citation is as follows: Melvin JA, Scheller EV, 
Miller JF, Cotter PA. “Bordetella pertussis pathogenesis: Current and future challenges” Nat Rev Microbiol. 2014 Apr;12(4):274-88. doi: 
10.1038/nrmicro3235. Epub 2014 Mar 10. 
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In the pre-vaccine era, pertussis was widespread and mainly affected young children (1-9 
years old)7. The classical manifestation of the disease, which typically occurs in this age group, 
is characterized by three phases: catarrhal, paroxysmal, and convalescent8. Clinical observations 
combined with results from studies using animal models (Box 2) suggest that classical pertussis 
is initiated by adherence of bacteria to ciliated respiratory epithelium in the nasopharynx and 
trachea9, 10. Adherent bacteria survive innate host defences, such as mucociliary clearance and 
the action of antimicrobial peptides, multiply locally and resist elimination by inflammatory 
cells. Symptoms during this catarrhal phase are similar to those of many upper respiratory 
infections, including the common cold. After one to two weeks, the disease progresses to the 
paroxysmal phase, which can persist from one to ten weeks and is characterized by periods of 
normal airway function interspersed with multiple severe spasmodic coughing fits, followed by 
characteristic inspiratory whoops and often emesis. The onset of adaptive immunity correlates 
with bacterial clearance but not with the cessation of symptoms, which typically decline 
gradually over another month but can persist for much longer (the convalescent phase)8. In 
infants (< 1 year old), pertussis can take a more serious course with bacteria disseminating into 
the lungs causing necrotizing bronchiolitis, intra-alveolar hemorrhage and fibrinous edema10. In 
severe cases, extreme lymphocytosis occurs, which is positively correlated with intractable 
pulmonary hypertension, respiratory failure and death10. 
Introduction of whole-cell pertussis (wP) vaccines in the late 1940s resulted in a rapid 
reduction in both the incidence of pertussis and death caused by the infection. However, the 
success of these vaccines was undermined by concerns over their safety (Box 3); thus, they were 
replaced with acellular pertussis (aP) vaccines in the late 1990s in many developed countries11. 
Since then, pertussis cases have increased and dramatic epidemic cycles have returned. In 2012, 
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48,277 cases of pertussis and 18 deaths were reported to the Centers for Disease Control and 
Prevention (CDC), which represents the greatest burden of pertussis in the United States in 60 
years and similar outbreaks are occurring in other countries12-14. However, the epidemiology of 
contemporary pertussis does not replicate that of the pre-vaccine era. Disease is now more 
common in infants and older children (ages 9-19) and, strikingly, older children who develop 
pertussis are often fully vaccinated according to current recommendations15, 16. Ominously, 
studies that have analyzed pertussis incidence among children that were born and vaccinated 
during the transition to aP vaccines have found that the rate of infection is significantly higher 
among children vaccinated with only aP vaccines compared to those vaccinated with even a 
single dose of wP vaccine17. To combat the rise of infections in this group, regulatory agencies 
have called for boosters to be administered earlier18. However, the benefit of boosting with aP 
vaccines is unclear because it is unknown whether the re-emergence of pertussis is due simply to 
waning immunity or to fundamental differences in the nature of the immune response induced by 
aP vaccines compared with wP vaccines or with natural infection. 
 The increased incidence of disease among older children and adults is especially 
worrisome because of the corresponding risk of transmission to non- or incompletely-immunized 
infants1. Compounding the problem, antibiotic treatment has minimal efficacy by the time most 
diagnoses are made and severe cases can be unresponsive to standard therapies for respiratory 
distress (such as mechanical ventilation)10. Therefore, the re-emergence of pertussis as a global 
public health problem presents two challenges: first, the development of vaccines that have an 
acceptable safety profile, provide long-lasting immunity, reduce infection burden and prevent 
transmission; and second, the development of therapeutic agents and treatment strategies that 
reduce morbidity and mortality in vulnerable populations. Both goals require a better 
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understanding of the etiological agents of pertussis and the mechanisms by which they cause 
disease. 
In this Review, we discuss our current understanding of the mechanisms used by 
Bordetella spp. to cause respiratory disease, focusing on the roles and functions of virulence 
factors in pathogenesis. For the interested reader, more specialized recent reviews on pertussis 
toxin biology19, 20, virulence gene regulation21, immunity22, 23 and vaccines24 are available, as 
well as an earlier comprehensive review on Bordetella spp. pathogenesis25. 
Bordetella spp. virulence regulation 
Several Bordetella spp. virulence factors were identified and characterized biochemically 
before genetic tools became available, including pertussis toxin (PT), adenylate cyclase toxin 
(ACT), dermonecrotic toxin (DNT), filamentous hemagglutinin (FHA) and fimbriae (Fim). The 
first transposon mutagenesis screen of B. pertussis identified the genes encoding these factors as 
well as a locus, now known as bvgAS, encoding a two-component regulatory system required for 
their expression26. Reasoning that BvgAS also activates expression of genes encoding additional 
unknown Bordetella spp. virulence factors, mutagenesis screens using Tn5lac and Tn5phoA 
were conducted27, 28. These, together with subsequent genome-wide analyses, revealed that 
BvgAS controls hundreds of genes in response to changing environmental conditions, including 
those encoding surface structures and secreted proteins involved in pathogenesis, factors required 
for survival outside the mammalian host, enzymes involved in cellular metabolism and 
physiology and additional regulatory systems29, 30.  
The BvgAS phosphorelay 
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BvgA is a typical response regulator protein with a receiver domain at its N-terminus and 
a DNA-binding helix-turn-helix domain at its C-terminus21 (Fig. 1A). BvgS is a polydomain 
sensor kinase containing two N-terminal venus flytrap (VFT) domains, which are located in the 
periplasm31. C-terminal to the VFT domains is a membrane-spanning region, followed by a 
cytoplasmically-located PAS domain, a histidine kinase (HK) domain, a receiver domain and a 
histidine phosphotransferase (Hpt) domain. During growth in standard medium at 37°C, BvgAS 
is active and uses ATP to phosphorylate a conserved histidine within the HK domain32. The 
phosphoryl group is subsequently relayed to an aspartate in the receiver domain, then to a 
histidine in the Hpt domain and finally to an aspartate in the receiver domain of the response 
regulator BvgA32. Phosphorylated BvgA is competent for dimerization and binds to specific 
DNA sequences to either activate or repress transcription33, 34. Although the signal(s) to which 
BvgS responds in nature are unknown, growth at low temperature (~25°C) or in the presence of 
MgSO4 or nicotinic acid (so-called“chemical modulators” of BvgS) inactivates BvgS; thus, 
BvgA remains unphosphorylated and is unable to regulate transcription. 
BvgAS controls multiple phenotypic phases 
The genes regulated by the BvgAS phosphorelay fall into four classes and their 
differential regulation results in at least three distinct phenotypic phases (Fig. 1B). Class 1 genes 
include the ptx-ptl operon (which encodes PT and its transport system), cyaA-E (which encodes 
ACT) and the bsc operon (which encodes a Type III Secretion System (T3SS)). These genes are 
maximally expressed when BvgAS is fully active (the so-called Bvg+ phase). Class 2 genes are 
expressed maximally in both the Bvg-intermediate (Bvgi) and Bvg+ phase. The Bvgi phase 
occurs when bacteria are grown in the presence of low concentrations of chemical modulators or 
within the first few hours following a switch from Bvg– phase conditions to Bvg+ phase 
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conditions. Class 2 genes include fhaB (encoding filamentous hemagglutinin (FHA)), fim 
(encoding fimbriae) and bvgAS itself; thus bvgAS is positively autoregulated. Class 3 genes, of 
which only one (bipA, encoding an outer membrane protein of unknown function) has been 
characterized so far35, 36, are expressed maximally in the Bvgi phase. Class 4 genes, which are 
also known as vrgs (virulence repressed genes), are expressed maximally in the Bvg– phase and 
include genes required for flagella synthesis and motility in B. bronchiseptica. 
 
Role of BvgAS-mediated gene regulation  
The conservation of BvgAS among Bordetella spp. and its ability to control multiple 
phenotypic phases in response to environmental cues suggests that it has an important and 
conserved role in the infectious cycle. Because B. pertussis and B. parapertussisHu strains are 
unable to survive extended periods of time outside of the human host (unpublished observations 
from various research groups), it was hypothesized that BvgAS-mediated gene regulation must 
occur within the mammalian respiratory tract. However, experiments with mutants that were 
locked in either the Bvg+ or Bvg– phase, or that expressed Bvg– phase factors ectopically in the 
Bvg+ phase, showed that the Bvg+ phase is necessary and sufficient for respiratory infection; that 
the Bvg– phase is unable to survive in vivo; and that failure to repress Bvg– phase factors (such as 
flagella) is detrimental to the development of infection37-40. Moreover, recent studies with 
sensitive reporter systems have provided strong evidence that switching to the Bvg– phase does 
not occur in vivo41, 42. In B. bronchiseptica, the Bvg– phase is required for survival under 
nutrient-limiting conditions, such as those that might be encountered in an external 
environment43. It has been hypothesized that the Bvgi phase is important for transmission, and 
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with the development of the baboon model (Box 2), this hypothesis is now testable. Although 
additional regulatory systems are undoubtedly important during the Bordetella spp. infectious 
cycle, their precise roles have not yet been determined. 
Toxins 
Pertussis toxin 
One of the first identified and most extensively characterized B. pertussis virulence 
factors, pertussis toxin (PT), sometimes referred to as lymphocytosis-promoting factor for its 
ability to induce lymphocytosis in mammals44. The presumed requirement of PT for the 
development of infection and the observed positive correlation between PT-specific immunity 
and bacterial clearance led to the hypothesis that pertussis, like cholera and diphtheria, is a toxin-
mediated disease45. However, although PT is important for pathogenesis, it is now clear that 
pertussis results from the coordinated function of many different bacterial factors46. 
PT is an ADP-ribosylating AB5-type toxin47 (Fig. 2a). The holotoxin is composed of one 
catalytic subunit (A) and five membrane-binding/transport subunits (B), which are assembled in 
the periplasm and then exported by the type IV secretion system encoded by the ptl locus48. PT 
holotoxin can bind nearly any sialic acid-containing glycoprotein49 and thus multiple receptors 
have been identified and characterized in a broad range of cell types in vitro20; however, the 
specific cell types targeted by PT in vivo are unknown. After binding, PT enters the host cell by 
receptor-mediated endocytosis and follows a retrograde transport pathway to the Golgi apparatus 
and then the endoplasmic reticulum (ER) (Fig. 2b)50. The A subunit exits the ER, possibly by 
hijacking the ER-associated degradation pathway that normally expels misfolded proteins51. In 
the cytoplasm, the A subunit catalyzes the transfer of ADP-ribose from NAD+ to a cysteine 
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residue near the C-terminus of the alpha subunit of heterotrimeric G-proteins, some of which are 
inhibitory G -proteins. Amongst other downstream effects, this modification eliminates the 
ability of these inhibitory G proteins to inhibit adenylate cyclase activity and blocks other G 
protein regulated enzymes and pathways20, 52, leading to dysregulation of the immune response. 
PT has an extraordinarily broad range of pharmacological effects in cell culture and 
animal models, which has confounded efforts aimed at identifying its precise role(s) during 
human infection. PT inhibits the migration of cells that express G-protein coupled chemokine 
receptors in vitro, such as neutrophils, monocytes and lymphocytes53. In mouse models, 
production of PT by B. pertussis correlates with decreased proinflammatory chemokine and 
cytokine production, decreased recruitment of neutrophils to the lungs and increased bacterial 
burdens early in infection54, 55. Experiments in which alveolar macrophages are depleted with 
clodronate suggest that PT initially targets these cells56. PT production at the peak of infection 
correlates with exacerbated inflammation and pathology in the airways57. While these and other 
observations in animal models suggest that PT contributes to the establishment of infection by 
suppressing early inflammation and inhibiting the microbicidal action of inflammatory cells, in 
addition to contributing to inflammatory pathology at the peak of infection, it is unknown 
whether PT produces these effects during human infection. However, it has been shown that PT 
production positively correlates with the extreme lymphocytosis that occurs in primary human 
pertussis cases58, and antibodies against PT protect against severe disease59. 
 
Adenylate cyclase toxin  
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Adenylate cyclase toxin (ACT, Fig. 2c, d), which is a member of the RTX (repeats in toxin) 
toxin family, is encoded by cyaA and produced by all Bordetella subspecies that infect 
mammals19. ACT is secreted by the cyaBDE-encoded Type I secretion system and is 
palmitoylated by the product of cyaC60, 61. The toxin contains two distinct functional modules: 
the C-terminal domain, which contains the RTX repeats, mediates binding to target cells and 
forms cation-selective pores in plasma membranes62, 63; and the N-terminal domain is a 
calmodulin-dependent adenylate cyclase that converts ATP to cyclic AMP (cAMP)64, 65. Recent 
studies indicate that ACT can adopt multiple conformations and that these forms are distinct in 
their ability to effect pore formation or adenylate cyclase translocation into the host cell66. Thus, 
the observed effects of ACT on different cell types are the result of a combination of ion 
permeability, increased levels of cAMP (leading to perturbation of downstream signalling 
events) and possibly the depletion of intracellular ATP. 
Although ACT can intoxicate many cell types, it binds with high affinity to CR3 
(CD11b/CD18, Mac-1), which is present on neutrophils, macrophages and dendritic cells67, and 
early work correlated ACT-dependent cAMP production in human neutrophils with inhibition of 
phagocytosis and oxidative burst68. More recent studies have shown that ACT blocks 
complement-dependent phagocytosis by macrophages69. In addition, this toxin also suppresses 
activation and chemotaxis of T-cells70. The significance of these in vitro observations is unclear; 
however, a recent study using the baboon model and clinical samples from humans showed that 
the concentrations of ACT in B. pertussis-infected respiratory tissues are significantly lower than 
the amount of purified protein used in most in vitro studies71. In mouse models, ACT-deficient 
bacteria are cleared faster than wild-type bacteria, and studies with immunodeficient and 
neutropenic mice suggest that ACT has a crucial role in enabling bacteria to resist neutrophil-
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mediated clearance72, 73. These data, in addition to the fact that ACT is one of the few virulence 
factors that is conserved and produced by all pathogenic Bordetella species5, suggest that ACT 
has the potential to be an effective antigen in future vaccine formulations74. 
 
Type III Secretion 
For reasons of experimental tractability, the Bordetella spp. Bsc type III secretion system 
(T3SS) is most extensively studied in B. bronchiseptica and induces caspase-independent 
necrotic death in a diverse array of cell types in vitro75. Mutations that eliminate T3SS activity 
decrease bacterial persistence in the lower respiratory tract following intranasal inoculation of 
rats and mice76, 77. Infection of mice with T3SS-defective B. bronchiseptica mutants also results 
in a more robust antibody response and re-stimulated splenocytes from animals infected with 
these mutants show increased production of pro-inflammatory IFN-γ and decreased production 
of anti-inflammatory IL-1078. Consistently, IFN-γ facilitates clearance of B. bronchiseptica from 
the lower respiratory tract, whereas IL-10 delays it 78. Together, these observations suggest that 
the Bsc T3SS has an immunomodulatory role that promotes persistence in the lower respiratory 
tract but the mechanistic basis of this phenomenon remains to be determined.  
 Remarkably, and despite concerted efforts by several research teams, only a single 
effector protein, BteA, has been definitively identified as a translocated substrate of the Bsc 
T3SS79, 80. BopN, a homolog of YopN (which regulates type III secretion in pathogenic Yersinia 
spp.) has been proposed as a second effector81 but thus far, evidence that BopN is translocated by 
the Bsc system is lacking. BteA is both necessary and sufficient for cytotoxicity in vitro, and 
mutations in bteA recapitulate the phenotypes associated with eliminating T3SS activity in vitro 
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and in vivo77, 79. Following translocation into host cells, the N-terminal targeting domain results 
in BteA localization to ezrin-rich lipid rafts that underlie sites of bacterial attachment82. 
However, the mechanisms responsible for the potent cytotoxicity of BteA remain unclear.  
Type III secretion is tightly regulated in Bordetella spp. The bteA and bsc genes are 
transcriptionally activated by the alternative sigma factor BtrS, which is activated by BvgAS83. 
Expression of the bcs genes is also up-regulated by iron starvation84.  In addition to these 
regulatory mechanisms, the partner-switching proteins BtrU, BtrV and BtrW mediate a cycle of 
serine phosphorylation and dephosphorylation events that regulate secretion activity83, 85. 
 Perhaps the most pressing question regarding the Bsc T3SS relates to its potential role 
during human infection. A requirement of T3SS activity for B. pertussis cytotoxicity has not 
been documented, despite the fact that T3SS genes are intact, highly conserved, transcribed and 
regulated, in addition to the observation that bteA alleles are functionally interchangeable 
between subspecies82, 83. Fortunately, recent studies are beginning to shed light on this paradox. 
Although Bsc activity is not generally observed with laboratory-adapted B. pertussis strains, the 
tip complex of the T3SS, Bsp22, is secreted by clinical isolates in vitro, and mutations in the 
ATPase gene, bscN, result in elevated production of pro-inflammatory cytokines and accelerated 
clearance of B. pertussis from the lungs of aerosol-infected mice86. Furthermore, T3SS activity 
seems to be lost following laboratory passage of B. pertussis and regained after passage in 
mice86, 87.  
  
Tracheal cytotoxin 
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Tracheal cytotoxin (TCT) is a disaccharide-tetrapeptide monomer of peptidoglycan that is 
produced during cell wall remodelling88. Although most Gram-negative bacteria recycle this 
molecule89, 90, B. pertussis does so inefficiently and releases a large amount of TCT into the 
extracellular environment. TCT is the only known B. pertussis virulence factor that is not 
regulated by BvgAS. In hamster tracheal rings, TCT functions synergistically with 
lipooligosaccharide to stimulate the production of pro-inflammatory cytokines (TNF-α, IL-1α, 
IL-1β, and IL-6) and iNOS, resulting in destruction and extrusion of ciliated cells from the 
epithelial surface91, 92. The biological activity of TCT depends on NOD1, a cytosolic pattern 
recognition receptor that senses bacterial peptidoglycan and induces the production of pro-
inflammatory mediators93. NOD1-dependent detection of TCT seems to be host specific, as 
human NOD1 poorly detects TCT whereas mouse NOD1 does so efficiently93. Although it has 
been postulated that TCT-mediated cytopathology contributes to the characteristic cough in 
pertussis, the lack of relevant animal models has prevented testing of this hypothesis. Thus, the 
contribution of TCT to pertussis pathogenesis in humans remains unclear. 
Dermonecrotic toxin 
Subcutaneous injection of B. pertussis or B. bronchiseptica cells into mice results in the 
formation of necrotic lesions due to the activity of dermonecrotic toxin (DNT)94. Consistent with 
a role in infection, DNT production is positively regulated by BvgAS 26, 29 and there is evidence 
that DNT contributes to the ability of B. bronchiseptica to induce turbinate atrophy and lung 
pathology in swine95. DNT has transglutaminase activity, can activate Rho GTPases96, 97 and 
inhibits osteogenic cell differentiation in vitro, suggesting that the toxin acts directly on host 
cells98, 99. However, as DNT lacks a signal sequence for export and is not secreted from bacterial 
cells grown in culture94, 100 ,it may actually function within the bacterial cytoplasm during 
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infection, possibly by facilitating bacterial survival within a specific host niche and hence 
functioning indirectly in pathogenesis. 
Surface Structures 
Filamentous hemagglutinin 
Filamentous hemagglutinin (FHA, Fig. 3a) is a large rod-shaped protein and, together 
with FhaC, serves as a prototypical member of the Two-Partner Secretion (TPS) pathway 101. It 
is initially synthesized as an ~370 kDa preproprotein (FhaB) that undergoes processing to 
produce the mature ~250 kDa FHA as it is translocated across the cytoplasmic membrane by the 
Sec translocation system and across the outer membrane by FhaC102. The N-terminal signal 
peptide is likely removed by leader peptidase and the C-terminal prodomain is processed by 
SphB1 and other as yet unidentified factors103, 104. Mature FHA is oriented with its mature C-
terminus (the MCD) distal to the bacterial surface, and a substantial amount of FHA is also 
released into culture supernatants when the bacteria are grown in vitro104. 
FHA is both necessary and sufficient to mediate bacterial adherence to several eukaryotic 
cell types in vitro105, 106. However, FHA is only one of several factors contributing to bacterial 
adherence to tracheal explants9, 107, suggesting that additional adhesins are important for 
adherence in vivo. Studies using cultured, non-ciliated cells have reported that FHA binds to 
CR3, Very Late Antigen V (VLA-5) and Leukocyte Response Integrin/Integrin Associated 
Protein (LRI/IAP) complexes, and an RGD motif located in the centre of the FHA molecule is 
implicated in this process108-110. More recent studies that have examined B. bronchiseptica 
infection of animal and cell culture models have shown that the FHA molecules produced by B. 
pertussis and B. bronchiseptica are functionally interchangeable. These studies have also 
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demonstrated that production of an FHA protein containing an RAE motif instead of RGD 
results in no observable differences and that the MCD is required for function111. Whether FHA 
interacts with CR3, VLA-5, LRI/IAP or other mammalian receptors during infection has yet to 
be determined. 
Experiments in which B. bronchiseptica is delivered in a small volume to the nasal 
cavities of rats and pigs have revealed FHA is essential for progression of the infection from the 
upper to the lower respiratory tract111, 112. In mouse models, in which large numbers of bacteria 
are delivered directly into the lungs, FHA-deficient B. bronchiseptica strains induce a more 
robust inflammatory response than wild-type bacteria73, 111. This response is characterized by 
increased production of proinflammatory cytokines and chemokines in lung tissue (such as TNF-
α, KC, MCP-1 and IL-17) and increased recruitment of neutrophils to the lungs during the first 
four days post-inoculation73. Animals that do not succumb to inflammation-mediated pulmonary 
damage clear the FHA-deficient bacteria from their lungs much faster than animals inoculated 
with wild-type bacteria73, 111. These data suggest that FHA enables B. bronchiseptica to modulate 
inflammation during the establishment of infection, thereby facilitating bacterial persistence. It is 
currently unknown whether FHA exerts these effects by binding directly to host receptors while 
attached to the bacterial cell surface or after release from the bacterial cell. Furthermore, it has 
been suggested that FHA serves as a scaffold to direct the delivery of other virulence factors 
(such as ACT113); however, the in vivo relevance of this activity has not been determined. 
 
Fimbriae 
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Bordetella spp. produce type 1 pili, which are also known as fimbriae (Fig. 3b). The 
putative chaperone (FimB), usher (FimC) and tip adhesin (FimD) proteins are encoded by the 
fimBCD operon, which is located between the fhaB and fhaC genes114. The genes encoding the 
two primary major fimbrial subunits, fim2 and fim3, are located elsewhere on the chromosome 
and can undergo phase variation115. Alternative major fimbrial subunit genes (fimA, fimN and 
fimX) have also been identified116-118. Although in vitro adherence assays using cultured cells 
have yielded variable results119, 120, studies with tracheal explants indicate a role for fimbriae in 
mediating adherence to ciliated respiratory epithelium9, 107. Studies with both B. pertussis and B. 
bronchiseptica have demonstrated a requirement for fimbriae during colonization of the lower 
respiratory tract in rodents120, 121, and mice inoculated with Fim-deficient B. pertussis display a 
more robust inflammatory response than mice inoculated with wild-type bacteria122. Similarly to 
FHA, fimbriae seem to be involved in adherence and/or suppression of the initial inflammatory 
response to infection, potentially contributing to persistence. 
Pertactin 
Pertactin (PRN) is a member of the classical autotransporter family of outer membrane 
proteins (Fig. 3c)123. The surface-localized ‘passenger’ domain forms a β-helix with β-strands 
connected by short turns or, in a few cases, large extrahelical loops124. Similarly to fimbriae, 
studies using non-ciliated mammalian cells to investigate a role for PRN in adherence or 
invasion have yielded equivocal results112, 125. Studies using ciliated rabbit tracheal explant 
cultures suggest that PRN contributes to B. pertussis adherence to ciliated respiratory 
epithelium9, although experiments with mice failed to identify a role for PRN in vivo126. 
However, in the case of B. bronchiseptica, studies indicate that PRN is involved in mediating 
resistance to neutrophil-mediated clearance and promoting persistence in the lower respiratory 
127 
 
tract112, 125. In recent years, B. pertussis strains that do not produce PRN have been isolated from 
pertussis patients127, raising the concern that such strains have been selected due to the presence 
of anti-PRN antibodies generated in response to immunization with PRN-containing aP vaccines. 
Whether vaccine driven evolution of B. pertussis strains is actually occurring is currently under 
investigation, as it has decisive implications for the development of new and improved vaccines. 
Lipopolysaccharide 
B. pertussis, B. parapertussisHu and B. bronchiseptica produce different forms of 
lipopolysaccharide (LPS). B. pertussis produces a penta-acylated lipid A linked to a complex 
core trisaccharide, B. bronchiseptica produces hexa-acylated lipid A linked to a similar, if not 
identical, complex core trisaccharide and O-antigen repeats and B. parapertussisHu produces a 
hexa-acylated lipid A linked to an altered core structure and O-antigen repeats128-130. Because it 
lacks O-antigen, B. pertussis LPS is often referred to as lipooligosaccharide (LOS)131. The genes 
required for synthesis of O-antigen in B. bronchiseptica and B. parapertussisHu are repressed by 
BvgAS132; however, some O-antigen is produced under Bvg+ phase conditions and mutants 
unable to produce O-antigen display defective virulence in mouse models132, 133.     
In mice, B. bronchiseptica LPS is sensed by TLR4, resulting in an early TNF-α response 
and recruitment of neutrophils to the lungs134, 135. Although B. parapertussisHu LPS and B. 
pertussis LOS can stimulate murine TLR4, they do so less efficiently and TLR4–/– mice are only 
modestly impaired in their ability to control infection by these organisms136-138. In addition, it has 
been reported that B. pertussis LOS stimulation of murine dendritic cells results in the 
development of anti-inflammatory regulatory T cells136.  On the basis of these observations it has 
been suggested that B. pertussis and B. parapertussisHu have evolved to be less inflammatory 
128 
 
than B. bronchiseptica and that diminished inflammation might facilitate persistence during 
human infection136, 137. However, subsequent studies have demonstrated that human and murine 
TLR4-MD-2-CD14 complexes differ in their ability to recognize different forms of lipid A. 
Although murine TLR4-MD-2-CD14 responds similarly to both penta- and hexa-acylated lipid 
A, human TLR4-MD-2-CD14 responds robustly to hexa-acylated lipid A but only weakly to 
penta-acylated lipid A139. Furthermore, as opposed to murine TLR4-MD-2-CD14, which 
responds to B. pertussis lipid A regardless of whether the phosphate groups are modified or not, 
human TLR4-MD-2-CD14 responds more robustly to lipid A containing glucosamine (GlcN)-
modified phosphate groups than to lipid A with unmodified phosphates140. Although it seems 
that the majority of B. pertussis LOS contains GlcN-modified phosphate groups141, the fact that it 
is penta-acylated suggests that its ability to stimulate TLR4 in humans is even weaker than its 
ability to stimulate TLR4 in mice. These data provide additional support for the hypothesis that 
B. pertussis and B. parapertussisHu strains have evolved to be relatively non-inflammatory in 
humans. However, they also raise concerns about extrapolating conclusions drawn from murine 
studies to humans, as the TLR4-MD-2-CD14-dependent immune responses clearly differ in these 
hosts. 
 
Additional surface proteins 
Many additional BvgAS-activated genes encode known or predicted surface-localized or 
secreted proteins and are suspected to have roles in pathogenesis29, 142. BrkA, TcfA, BapC, BatB, 
Vag8, SphB1 and Phg are BvgAS-activated classical autotransporter proteins, and their putative 
roles in pathogenesis include mediating adherence, serum resistance, evasion of antibody-
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mediated clearance and proteolytic processing of other surface proteins103, 143-148. BipA and BcfA 
are BvgAS-regulated members of the intimin/invasin family, and although their roles in 
pathogenesis are unknown35, 149, immunization of mice with BcfA can accelerate clearance of B. 
bronchiseptica following intranasal challenge150, suggesting that these poorly characterized 
surface molecules should be considered for the development of new vaccines containing 
different or additional antigens. 
Metabolic proteins 
Many BvgAS-regulated genes encode proteins that are probably involved in metabolism, 
respiration and other physiological processes29, 142, presumably reflecting the diversity of 
environmental conditions encountered by Bordetella spp. as they travel within and outside the 
mammalian respiratory tract. Among these factors, those involved in the acquisition and use of 
iron have been the focus of most studies. In addition to producing and using the siderophore 
alcaligin151, B. pertussis and B. bronchiseptica can use a variety of xenosiderophores (including 
enterobactin152) and haem iron sources such as hemoglobin153. Most, if not all, of these iron 
acquisition mechanisms are required during murine respiratory infection154, 155, demonstrating the 
necessity of iron for bacterial survival, the variety of mechanisms used by the host to sequester 
iron and the reciprocal array of mechanisms used by the bacteria to acquire this essential 
element. 
In addition, accumulating evidence suggests that biofilm production by pathogenic 
Bordetella spp. in vitro and during infection may contribute to colonization of the respiratory 
tract. This process is regulated by a complex program of both Bvg-dependent and Bvg-
independent gene expression156-159, with genes that promote biofilm formation being maximally 
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expressed in the Bvgi phase156. Bvg-independent production of an exopolysaccharide via 
expression of the bps locus and the presence of extracellular DNA are also required for biofilm 
production157, 160, 161. Recent evidence suggests that the second messenger cyclic-di-GMP is also 
crucial for the regulation of biofilm formation162. 
 
Current and future challenges 
Despite high rates of immunization with aP vaccines, epidemics of pertussis have 
recently occurred in the US, Europe, Australia and Japan (CDC, Australian Government 
Department of Health and Aging, Japanese National Institute of Infectious Diseases)163, 164 and 
similar outbreaks seem imminent in developed countries throughout the world. Moreover, 
irrespective of socioeconomic status, the highest rates of mortality are in infants, who are also 
the most difficult population to treat and protect. In considering these challenges and looking 
ahead, we suggest three priorities for future studies. 
 The first priority is to improve the robustness and duration of protection conferred by 
vaccination, which will require further study of the immunological responses to infection and 
vaccination (Box 4). The deficiencies of current aP vaccines are well documented, including the 
striking observation that aP vaccination of baboons only protects against disease symptoms but 
not colonization or transmission165. Numerous efforts are in progress to overcome these 
deficiencies24, such as the inclusion of additional antigens in aP vaccines, reformulation with 
adjuvants that favour Th1/Th17 responses as opposed to the Th2-type immunity generated by 
alum-adjuvanted vaccines as well as the development of live, attenuated B. pertussis vaccines166. 
The latter approach has significant advantages, including the ability to generate mucosal 
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immunity, but the issue of public acceptance looms large. In a similar vein, it is interesting to 
note that outside of North America, Europe and parts of Asia, wP vaccines remain in widespread 
use and approaches to decrease their reactogenicity while retaining immunogenicity should be 
considered167. The known efficacy of these vaccines combined with the cost effectiveness of this 
approach might be of more benefit to people than the development of improved but more costly 
vaccines composed of purified proteins. It is important to remember that the development and 
approval of novel vaccines will be a prolonged process. In light of recent findings concerning the 
lack of protection against colonization or transmission by aP vaccination165, maximizing the 
efficacy of current vaccines through prenatal vaccination, additional boosting and additional 
strategies is imperative. 
 A second priority is to mitigate infant mortality. Nearly 90% of all deaths due to pertussis 
occur in infants that are less than four months of age168, and the most frequent cause is 
intractable pulmonary hypertension associated with marked lymphocytosis and 
bronchopneumonia. Currently, the only efficacious therapy for severe cases is rapid 
leukodepletion, which is only available at advanced critical care centres169, 170. Respiratory 
samples obtained during autopsies show luminal aggregates of leukocytes occluding small 
pulmonary arteries, along with an abundance of B. pertussis10, 171. The pathology of fatal 
pertussis pneumonia appears to be largely caused by pertussis toxin. Thus, in addition to 
protecting susceptible infants by maternal vaccination or by vaccination at birth, it is also 
imperative to pursue approaches for limiting PT activity during infection. Potential therapeutic 
modalities include humanized monoclonal antibodies and small molecules to target PT 
interactions with host cell receptors or the enzymatic activity of PT, as well as regulatory factors 
such as the BvgAS system. 
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 Finally, although animal models have proven useful, we need to enhance our 
understanding of human disease. Decades of research on B. pertussis virulence determinants 
have primarily been based on tissue culture models and murine infections. These studies have 
shown what adhesins, toxins and other virulence factors can do under laboratory conditions, but 
very little, if anything, is known about what they really do during human disease. Specificity is 
the rule for human adapted pathogens and it can manifest at several levels including gene 
expression, virulence factor delivery, binding specificity and activity. Perhaps the most vivid 
illustration of our lack of understanding of B. pertussis is that we still don't know why infection 
makes people cough! 
 
Box 1- Bordetella phylogenomics  
The Bordetella genus includes nine species and the "classical" or "mammalian" 
bordetellae (B. pertussis, B. parapertussisHu and B. bronchiseptica) are the most important 
species in the context of mammalian infection. Comparative analyses of their genomes have been 
informative on at least two levels. The first involves comparisons between subspecies, which has 
revealed intriguing clues regarding mechanisms of host adaptation and virulence evolution; and 
the second involves studies of the population dynamics of B. pertussis in the context of recent 
outbreaks and the possibility of vaccine-driven evolution. 
 Early studies revealed limited genetic diversity between isolates, arguing that the 
classical bordetellae should be regarded as closely related subspecies and that B. pertussis and B. 
parapertussisHu evolved independently from different B. bronchiseptica-like ancestors172, 173. 
This hypothesis suggested that B. bronchiseptica, a zoonotic generalist, has the propensity to 
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give rise to host-restricted specialists that cause acute disease. Whole genome sequence 
comparisons support this idea and show that the transition by B. pertussis and B. parapertussisHu 
to the human-restricted niche was accompanied by large-scale gene loss, an accumulation of 
pseudogenes and an expansion of IS elements174, 175. Based on this framework, a seminal study 
characterized a set of 132 Bordetella isolates from diverse mammalian hosts using a combination 
of multilocus sequence typing, comparative whole-genome microarray analysis and IS typing4. 
Four distinct complexes comprised of related strains were resolved, representing B. pertussis 
(complex II), B. parapertussisHu (complex III) and two distinct B. bronchiseptica complexes (I, 
IV) (see the figure). Surprisingly, although B. bronchiseptica complex I isolates were primarily 
of animal origin (68%), 80% of B. bronchiseptica complex IV strains were from humans that had 
whooping cough-like symptoms. Notwithstanding the fact that human isolates were 
overrepresented in the collection, the clustering of B. bronchiseptica strains isolated from 
humans into a genetically related group was intriguing. A follow-up study based on whole-
genome sequencing suggested that B. pertussis evolved from a B. bronchiseptica complex IV-
like ancestor5.  These observations illustrate the evolutionary dynamics of Bordetella subspecies 
and raise the question of whether complex IV B. bronchiseptica are on a path towards human 
adaptation. 
 At the other end of the evolutionary spectrum, the resurgence of pertussis has prompted 
numerous efforts to characterize polymorphisms in B. pertussis populations in a search for 
correlations with the introduction of aP vaccines. Although numerous shifts in allelic frequencies 
have been documented in different countries since the vaccines were introduced176, 177, a 
comprehensive analysis of isolates from the United States shows that the majority of these 
polymorphisms predate the wP to aP transition and are not the result of aP-driven selection178. 
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Nonetheless, currently circulating strains in the Americas, Asia, Australia and Europe carry a 
single nucleotide substitution in the PT promoter (the ptxP3 allele) that confers a slight (ca. 1.6 
fold) increase in PT production compared to the previously dominant allele179.  ptxP3 strains 
were present before aP vaccines, but given the roles of PT in immunosuppression it has been 
suggested that their expansion and apparent fixation reflects a selective advantage for 
establishing infection in partially immune hosts, regardless of the source of immunity180. Cause 
and effect is unclear, as is the likelihood that such a small difference in PT expression could have 
such a major effect. One of the difficulties in interpreting these studies is their reliance on allelic 
variability in small subsets of genes, raising the possibility that "hitchhiker" mutations located 
elsewhere in the genome are responsible for apparent clonal shifts177. It is essential that these 
analyses continue, but they need to be based on whole genome sequences and appropriate 
sampling of circulating and reference strains. 
 
Box 2: Animal models 
One of the greatest challenges in studying the pathogenesis of pertussis has been the 
development of animal models that accurately reflect human disease as the most commonly used 
laboratory animals do not cough and none of them are natural hosts for B. pertussis. Nonetheless, 
the availability of wild-type, knock-out and transgenic mouse strains, as well as a plethora of 
murine-specific reagents, have made mice attractive and commonly used model organisms. To 
establish infection in mice, high numbers of B. pertussis must be delivered directly to the lungs, 
where they multiply for the first week or so post-inoculation and are eventually cleared. 
Although murine models do not mimic classical whooping cough, they have provided insight 
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into the importance of several virulence factors, the roles of various host immune responses in 
controlling infection and the potential efficacy of vaccines (as outlined in the main text). 
 Suckling pigs have been used to model infant pertussis and intrapulmonary inoculation 
with B. pertussis results in low-grade fever, mild cough, hypoglycemia, lymphocytosis, weight 
loss and pneumonia181. In this model, passively transferred immunity provides protection for 
newborn piglets upon challenge182, supporting the recently instituted policy of maternal 
immunization during pregnancy183, 184. Studies with infant and adult pigs have also revealed that 
B. pertussis is susceptible to host antimicrobial peptides, whereas B. bronchiseptica and B. 
parapertussisHu are resistant 185. 
 The most recent and exciting advance in modelling human pertussis is the development 
of a baboon (Papio anubis) model186. Delivery of B. pertussis to the nasopharynx of weanling 
baboons results in low-grade fever, paroxysmal coughing, lymphocytosis, robust production of 
anti-PT antibodies and protection from subsequent challenge, all of which are manifestations of 
pertussis in humans186. A unique advantage of this model is the ability to study transmission, 
which was demonstrated to occur by contact and via aerosols187. Importantly, a recent study 
showed that aP vaccination provided protection against the  development of disease symptoms 
but not against colonization or transmission165, which suggests that nonsymptomatic individuals 
might be capable of transmitting the infection to unprotected infants. Use of this model to 
investigate mechanisms of transmission and disease will be crucial for the development of new 
vaccines and therapeutics. 
Rodents, rabbits, and swine are not natural hosts for B. pertussis or B. parapertussisHu; 
however, they are commonly infected with B. bronchiseptica in nature. This fact, in combination 
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with the close phylogenetic relationships between these subspecies (Box 1) and the conservation 
of many known virulence factors among them, has prompted several groups to use B. 
bronchiseptica infection of natural hosts to study features of pathogenesis that are common to B. 
pertussis and B. parapertussisHu. Studying B. bronchiseptica pathogenesis is also of veterinary 
and clinical importance, as B. bronchiseptica is a common pathogen of domestic animals188, 189 
and occasionally causes disease in humans190. These models have revealed roles for several 
conserved virulence determinants and regulatory factors (see main text), and have also shown 
that several factors are functionally interchangeable between B. pertussis and B. 
bronchiseptica111, 125, 191, thereby validating the use of B. bronchiseptica as model for studying B. 
pertussis virulence and regulatory function. Thus far, the results of these studies suggest that host 
specificity is determined by differences other than sequence polymorphisms in highly conserved 
virulence genes. 
 
Box 3: Vaccination against pertussis 
The introduction of whole cell vaccines (wP) in the 1940s resulted in dramatic decreases 
in morbidity and mortality caused by pertussis, and by the early 1970s pertussis was nearly 
eradicated in the developed world7. Attention then turned to the side-effects associated with 
immunization. The National Childhood Encephalopathy Study (NCES), a prospective case-
controlled study that was carried out in the U.K. in the late-1970s to evaluate acute neurological 
illnesses in children aged between 2 and 26 months, concluded that pertussis vaccination was 
associated with brain damage192 – although this correlation was later demonstrated to be 
unfounded. Lack of circulating disease was misinterpreted as being equivalent to a lack of risk in 
137 
 
contracting the disease, and the NCES report (among others) led to a precipitous decline in 
vaccine coverage in many countries worldwide. The reported association with brain damage also 
effected a change in manufacturing policies; decreased vaccination compliance combined with a 
rise in legal action associated with previous vaccinations led many pharmaceutical companies to 
abandon the production of wP vaccines. However, the decrease in vaccine coverage almost 
immediately sparked the largest pertussis epidemics since the pre-vaccine era in many countries, 
which resulted in a substantial rise in infant mortality, a much more severe outcome than the 
alleged dangers caused by the wP vaccine. Eventually, public concern over the increase in 
pertussis disease and the number of infant deaths rose and vaccine coverage returned to high 
levels. Efforts to develop improved pertussis vaccines were rekindled, with the subsequent 
development, testing and deployment of aP vaccines. Although supposedly safer and 
undoubtedly less reactogenic than the wP vaccine, we now know that aP vaccines are also less 
effective. The experience with vaccination against pertussis clearly highlights the effect that 
public perception and misperception can have on the implementation of public vaccination 
programs. 
 
Box 4: Immunity to pertussis 
Clinical studies suggest that both humoral and cell-mediated immunity are important for 
controlling human pertussis. Measurements of B. pertussis-specific T cell proliferation, cytokine 
production and titers of different IgG subclasses from human samples suggest that naive 
infection causes primarily a Th1 response, resulting in pro-inflammatory cytokine and 
opsonizing antibody production, combined with the stimulation of antigen presenting cells193, 194. 
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wP vaccines also stimulate a Th1 response195, 196, whereas aP vaccines seem to produce a mixed 
Th1/Th2 response196-198. Many studies have demonstrated that vaccination with aP vaccines 
produces antibody responses that are equal to or exceed those produced by vaccination with wP 
vaccines194, 196, 198, yet the immunity induced by aP vaccines is inefficient, which underscores the 
importance of investigating and evaluating cell-mediated immune responses induced by 
vaccination and infection. Studies that have evaluated human infection or vaccination have not 
comprehensively addressed the role of Th17 responses, which result in pro-inflammatory 
cytokine production and stimulation of professional phagocytes. However, studies with the 
baboon infection model show that infection causes a mixed Th1/Th17 response that is long-lived 
and protective against colonization following subsequent challenge186, 199. Immunological data 
from animal models mostly agree with these findings23, 165, 199. Regardless of the natural immune 
response to infection, efficacious vaccines need to be long lasting, prevent transmission and 
reduce disease burden. As B. pertussis is primarily an extracellular respiratory pathogen, it is 
likely that an effective immune response will require the induction of a mixed Th1/Th17 
response that stimulates the production of opsonizing, toxin-neutralizing and mucosal antibodies, 
along with memory T cells that produce cytokines to recruit and activate professional phagocytes 
at the site of infection. As such, there is a pressing need to re-evaluate antigens, adjuvants and 
immunization routes to achieve these goals. 
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Figure 1. The BvgAS master regulatory system. 
 
Figure 1. The BvgAS master regulatory system. (a) BvgS is a polydomain histidine sensor 
kinase containing (from the N- to the C-terminus) two periplasmically-located venus flytrap 
domains (VFT1 & VFT2), a transmembrane domain, a PAS domain (PAS), a histidine kinase 
domain (HK), a receiver domain (Rec) and a histidine phosphoryl transfer domain (Hpt). BvgA 
is a response regulator protein with an N-terminal receiver domain (Rec) and a C-terminal helix-
turn-helix domain (HTH). BvgS is activate at 37°C, autophosphorylates at a conserved histidine 
in the HK domain, and transfers the phosphoryl group to the Rec, the Hpt and then to the Rec 
domain of BvgA. Phosphorylated BvgA (BvgA-P) activates expression of virulence-associated 
genes (vags; which are subdivided into class 1 and 2 genes) and represses expression of 
virulence-repressed genes (vrgs; known as class 4 genes). BvgS is inactive and remains 
unphosphorylated when bacteria are grown at a low temperature (∼25°C) or at 37°C in the 
presence of chemical modulators (such as MgSO4 or nicotinic acid). (OM-outer membrane, CM-
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cytoplasmic membrane) (b) BvgAS controls four classes of genes and three distinct phenotypic 
phases. The Bvg+ phase occurs when BvgAS is fully active and is characterized by maximal 
expression of genes encoding adhesins (class 2 genes, such as fhaB, fim2 and fim3, expression 
levels indicated by an orange line) and toxins (class 1 genes, such as cyaA-E, ptx-ptl and bsc 
genes, expression levels indicated by a red line), and minimal expression of class 3 and class 4 
genes (expression levels indicated by purple and blue lines, respectively). The Bvg+ phase is 
necessary and sufficient to cause respiratory infection (i.e., in vivo). The Bvg– phase occurs when 
BvgAS is inactive and is characterized by maximal expression of class 4 genes and minimal 
expression of class 1, 2, and 3 genes. (Note that regulation of some vrgs is indirect; when BvgAS 
is inactive, it does not repress frlAB, a positive regulator at the top of the motility regulon, and it 
does not activate bvgR, a negative regulator of vrg loci.) The Bvg– phase is required for growth 
under nutrient limiting conditions, such as may be encountered in the environment (i.e., ex vivo). 
The Bvgi phase occurs when BvgAS is partially active and is characterized by maximal 
expression of class 3 genes and minimal expression of class 1, 2, and 4 genes. The only class 3 
gene characterized so far is bipA, which is activated by BvgA under Bvgi phase conditions and 
repressed by BvgA under Bvg+ phase conditions. The Bvgi phase may be important for 
transmission between hosts, but this has not been fully elucidated. 
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Figure 2. Toxin-mediated virulence of Bordetella spp. 
 
Figure 2. Toxin-mediated virulence of Bordetella spp.  
(a) Pertussis toxin (PT, PDB ID 1PRT), is an AB5-type toxin composed of one catalytic subunit 
(A subunit) and five membrane-binding/transport subunits (B subunits)47. PT is assembled in the 
bacterial periplasm and exported by a type IV secretion system. (b) On binding to a 
sialoglycoprotein host cell receptor, PT is endocytosed and trafficked through the Golgi to the 
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endoplasmic reticulum. In the endoplasmic reticulum, the B5 complex binds to ATP and 
dissociates from the A subunit. The A subunit is then transported into the cytoplasm and traffics 
on exosomes to the cytoplasmic membrane, where it ADP-ribosylates the α subunit of 
heterotrimeric G proteins. This modification alters the ability of G proteins to regulate multiple 
enzymes and pathways, including their ability to inhibit cyclic AMP (cAMP) formation. The 
overall result of these modifications is an initial suppression of inflammatory cytokine 
production and inhibition of immune cell recruitment to the site of infection. (c) Bordetella spp. 
adenylate cyclase toxin (ACT) is composed of two primary domains, a calmodulin-responsive 
adenylate cyclase enzymatic domain (yellow) and an RTX domain (black), which are connected 
by hydrophobic segments (green).  (d) The RTX domain of ACT interacts with CR3 receptors 
that are expressed on host cell membranes from a wide range of cell types. The hydrophobic 
segments of the linker region (green) form pores in the membrane that enable the passage of ions 
and translocation of the adenylate cyclase domain into the cytoplasm. Adenylate cyclase activity 
is stimulated by binding to calmodulin in the host cell. The combined effects of ACT 
intoxication and pore formation result in inhibition of complement-dependent phagocytosis, 
induction of anti-inflammatory cytokines, suppression of pro-inflammatory cytokines and 
inhibition of immune cell recruitment. 
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Figure 3. Presentation of filamentous hemagglutinin, fimbriae and pertactin on the 
Bordetella cell surface. 
 
 
Figure 3. Presentation of filamentous hemagglutinin, fimbriae and pertactin on the 
Bordetella cell surface. (a) Filamentous hemagglutinin (FHA) is a TpsA exoprotein (blue) that 
is translocated across the outer membrane through its cognate TpsB pore protein (red), FhaC. 
This translocation occurs via the two-partner secretion pathway. Processing during translocation 
removes the C-terminal prodomain (yellow) from the full-length FhaB protein to produce the 
mature ~250 kDa FHA protein. FHA is required for adherence to ciliated epithelial cells and for 
persistence during infection, possibly by directly or indirectly modulating the host immune 
system. (b) Bordetella spp. fimbriae are type 1 pili. FimB is similar to chaperone proteins that 
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traffic major fimbrial subunits (Fim2 and Fim3, in this case) to the membrane usher FimC. FimB 
and FimC are necessary for fimbrial secretion and FimD (the tip subunit) is necessary for 
fimbrial assembly. Fimbriae are required for persistence during infection, possibly by 
functioning similarly to FHA by directly or indirectly modulating the immune system. 
Furthermore, studies have suggested that fimbriae are necessary for adherence to ciliated 
epithelial cells. (c) Pertactin is a classical autotransporter. The C-terminal ~30 kDa region (red) 
forms a channel in the outer membrane (om) that is required for translocation of the ~70 kDa β-
helical passenger domain (blue) to the cell surface. Although the precise role of pertactin is 
unclear, data suggests that pertactin may contribute to virulence by resisting neutrophil-mediated 
clearance. 
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APPENDIX B. EVIDENCE FOR PHENOTYPIC BISTABILITY RESULTING FROM 
TRANSCRIPTIONAL INTERFERENCE OF BVGAS IN BORDETELLA 
BRONCHISEPTICA1 
Summary: 
Members of the Bordetella genus cause respiratory infections in mammals. The 
Bordetella master regulatory system BvgAS controls expression of at least three distinct 
phenotypic phases in response to environmental cues. Studies with BvgAS phase-locked and 
ectopic expression mutants have shown that the Bvg+ phase is necessary and sufficient for 
respiratory infection, the Bvg– phase is required for survival ex vivo, and that alterations in 
BvgAS-dependent gene regulation can be detrimental to the infectious process. We obtained 
large colony variants (LCVs) from the lungs of mice infected with B. bronchiseptica strain 
RBX9, which contains a large in-frame deletion mutation in the gene encoding filamentous 
hemagglutinin. RBX9 also yielded LCVs when switched from Bvg– phase conditions to Bvg+ 
phase conditions in vitro. We determined that LCVs are composed of both Bvg+ and Bvg– phase 
bacteria and that they result from defective bvgAS positive autoregulation that “traps” a small 
proportion of bacteria in the Bvg– phase. The LCV phenotype was linked to the presence of a 
divergent promoter 5´ to bvgAS, suggesting a previously undescribed mechanism of  
transcriptional interference that, in this case, leads to feedback-based bistability (FBM) 
_______________________ 
1This chapter was previously appeared as an article in Moleculuar Microbiology. The original citation is as follows: Mason E, Henderson MW, 
Scheller EV, Byrd MS, Cotter PA. “Evidence for phenotypic bistability resulting from transcriptional interference of BvgAS in Bordetella 
bronchiseptica” Mol Microbiol. 2013 Nov;90(4):716-33. doi: 10.1111/mmi.12394. Epub 2013 Sep 30. 
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by decreasing bvgAS expression in the Bvg– phase. Our results also indicate that a small 
proportion of RBX9 bacteria modulates to the Bvg– phase in vivo, but this level of modulation 
had no impact on the overall outcome of infection. In addition to providing insight into 
transcriptional interference and FBM, our data provide an example of an in-frame deletion 
mutation exerting a ‘polar’ effect on nearby genes.  
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Introduction 
The genus Bordetella includes Gram-negative bacteria that cause respiratory infections. 
Bordetella pertussis and Bordetella parapertussishu are strictly human-specific pathogens that 
cause whooping cough, an acute disease that has experienced a recent resurgence despite 
widespread vaccination (1–3). Phylogenetic analyses indicate that B. pertussis and B. 
parapertussishu have recently evolved from Bordetella bronchiseptica, which infects a wide 
range of mammals and can also survive naturally for long periods of time outside the host (4–6). 
Although the factors that determine host specificity remain unknown, the presence and 
regulation of virulence factor-encoding genes is highly conserved between these three sub-
species (7, 8). 
Filamentous hemagglutinin (FHA), encoded by the fhaB gene, is a well-characterized 
virulence factor of Bordetella and is a primary component of acellular pertussis vaccines (1, 9, 
10). A prototypical member of the Two Partner Secretion family of proteins, FHA is a large, 
surface-exposed protein that is produced and secreted at a high levels during growth in vitro (10–
12). In B. bronchiseptica, FHA mediates adherence to a wide range of cell lines and is required 
for colonization of the lower respiratory tract in both rats and mice (13–15). Although FHA was 
first characterized as an adhesin, it has subsequently been reported to perform several other 
important functions. For example, exposure of lipopolysaccharide and IFN-γ-stimulated 
macrophages to purified B. pertussis FHA suppresses interleukin-12 (IL-12) production, and 
macrophages treated with FHA exhibit higher rates of apoptosis compared to untreated controls 
(16, 17). FHA-deficient B. bronchiseptica causes an infection that is hyperinflammatory 
compared to infection caused by wild-type bacteria and is characterized by increased influx of 
interleukin-17 (IL-17)-positive neutrophils, macrophages, and CD4+ Tcells, suggesting that FHA 
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plays an immunomodulatory role in vivo (15, 18). Additionally, there is strong evidence that 
FHA interacts with another important virulence factor, adenylate cyclase toxin ACT (19, 20).  
In Bordetella, the master regulator that controls the expression of all known virulence 
factor-encoding genes is called BvgAS (21). A two-component sensory transduction system, 
BvgAS controls at least three distinct phenotypic phases (Bvg+, Bvgi, and Bvg–) by altering gene 
expression patterns in response to environmental stimuli (Figure 1A) (22). The Bvg+ phase is 
induced during standard laboratory growth conditions at 37ºC on Bordet Gengou (BG) blood 
agar or in Stainer-Scholte broth. Bvg+ phase bacteria are non-motile and form small, dome-
shaped, hemolytic colonies on BG blood agar. Bacteria can be induced (or modulated) to the 
Bvg– phase in the laboratory by growth at room temperature or by supplementing media with 
millimolar concentrations of chemical modulators such as MgSO4 or nicotinic acid. Bacteria in 
the Bvg– phase are motile (B. bronchiseptica only) and form large, flat, non-hemolytic colonies. 
The Bvgi phase can be induced in the laboratory with intermediate concentrations of chemical 
modulators and these bacteria form colonies that appear phenotypically intermediate compared 
to Bvg– and Bvg+ phase colonies. Each phenotypic phase is defined by a unique pattern of gene 
expression (Figure 1B) (7, 22, 23). For example, bacteria in the Bvg+ phase are characterized by 
maximal expression of virulence-activated genes (vags) such as fhaB, cyaA-E (encoding 
adenylate cyclase toxin ACT), ptxA-E (encoding pertussis toxin in B. pertussis), and bvgAS itself 
(which is positively autoregulated). In contrast, Bvg– phase bacteria maximally express 
virulence-repressed genes (vrgs) including those required for motility (i.e., flaA, encoding 
flagellin and frlAB, the Bordetella flhDC homolog) and chemotaxis (B. bronchiseptica only) but 
do not express vags. The vags fall into two classes: those expressed in the Bvgi phase and the 
Bvg+ phase, and those expressed maximally only in the Bvg+ phase. Additionally, some genes, 
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such as bipA, (encoding Bvg-intermediate phase protein A) are expressed maximally only in the 
Bvgi phase (24, 25). Thus, Bvgi phase bacteria are characterized by maximal expression of bipA, 
bvgAS, and fhaB, and minimal expression of vrgs, cyaA, and ptxA (B. pertussis only) (Figure 1B) 
(7, 23–26).  
Upon activation of the BvgAS phosphorelay in response to environmental signals, BvgS 
(the sensor kinase) autophosphorylates, becoming the substrate for BvgA (the response 
regulator). BvgA-phosphate (BvgA~P) binds DNA and activates or represses transcription (22, 
25, 27–30). In vitro transcription and DNA binding experiments have identified both high and 
low affinity BvgA binding sites located at various positions relative to the transcription start sites 
of BvgAS-regulated genes (22, 25, 27, 30, 31). These data, together with a recent report 
describing a direct assessment of BvgA~P levels in B. pertussis cultures (32), support a model in 
which BvgA~P levels are extremely low under Bvg– phase conditions, moderate under Bvgi 
phase conditions, and high under Bvg+ phase conditions (22, 32). In addition to controlling 
distinct phenotypic phases in response to steady-state conditions, BvgAS can regulate gene 
expression in a temporal manner (27, 33–35). Because bvgAS is positively autoregulated, both 
the concentration of BvgA and the proportion that is phosphorylated increase when bacteria 
sense activating signals. Therefore, gene expression patterns change temporally as the total 
concentration of BvgA~P gradually increases when bacteria are switched from Bvg– to Bvg+ 
phase conditions (27, 33–35).  
The bvgAS and fhaB genes are adjacent and transcribed divergently. Experiments with B. 
pertussis indicate that the 426 bp intergenic region contains at least three promoters (with at least 
two that control bvgAS, called P2 and P1) and multiple high-affinity BvgA binding sites (29, 30, 
36, 37) (Figure 1C). In the Bvg– phase, bvgAS transcription is driven by the BvgAS-independent 
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promoter P2 that is responsible for basal levels of BvgA (which likely remain unphosphorylated) 
(36, 37). When switched to the Bvg+ phase, BvgA becomes phosphorylated and activates fhaB 
and bvgAS via binding to high-affinity sites near PfhaB and P1 (36, 38). Once a relatively high 
concentration of BvgA~P is achieved, genes with low-affinity BvgA binding sites at their 
promoters, such as cyaA and ptxA in B. pertussis, are activated and the bacteria transition into the 
Bvg+ phase (27, 35, 39). The Bvg+ phase, and therefore high levels of BvgA~P, is maintained as 
long as bacteria sense a Bvg+ phase environment. Without bvgAS positive autoregulation, the 
ability of B. bronchiseptica to transition between and maintain each phenotypic phase is 
compromised (35).  
Data obtained thus far indicate that the Bvg+ phase is necessary and sufficient to cause 
respiratory infection, the Bvg– phase facilitates survival outside of the host, and BvgAS 
modulation to the Bvgi or Bvg– phase does not occur during infection (40–45). For example, 
several groups have shown that Bvg+ phase-locked bacteria behave identically to wild-type 
bacteria in colonization, persistence, and contribution to lung pathology (40, 42–44). In contrast, 
Bvg– phase-locked bacteria cannot establish an infection and Bvgi phase-locked bacteria are 
severely limited in colonization and persistence (23, 40–43). Additionally, we recently 
demonstrated that flaA is not expressed at a detectable level when mice are infected with the B. 
bronchiseptica wild-type strain RB50 (46) and Akerley et. al. showed that production of flagella 
in the Bvg+ phase is detrimental to infection (44). Although the natural signals that affect BvgAS 
activity and the role of modulation in nature remain unknown, all of these data suggest that wild-
type Bordetella do not modulate to the Bvg– phase within the mammalian host. 
B. bronchiseptica strain RBX9, which contains an in-frame deletion mutation of fhaB 
(Figure 1C), has been used extensively to characterize the function of FHA in vitro and in vivo 
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(11, 13, 15, 18, 47, 48). RBX9 is defective in adherence to multiple cell lines, is unable to 
autoaggregate in liquid culture, and causes hyperinflammation in the murine lung infection 
model (13–15, 18, 48). We isolated large colony variants (LCVs) from mice infected with RBX9 
and also by modulating RBX9 to the Bvg– phase in vitro. We determined that the LCVs were a 
product of transcriptional interference that influenced bvgAS and produced an unusual bistable 
phenotype. Despite evidence suggesting that Bordetella do not modulate during infection, the 
discovery of LCVs indicates that a subpopulation of RBX9 bacteria modulates in vivo. 
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Results 
Isolation and characterization of LCVs 
While comparing wild-type B. bronchiseptica strain RB50 with its ∆fhaB derivative 
RBX9 in a murine lung infection model, we noticed that at early time points post-inoculation (12 
and 24 h), a small proportion (~1%) of cfus recovered from the lungs of RBX9-inoculated mice 
formed colonies on BG blood agar (Bvg+ phase conditions) that were larger, flatter, and less 
hemolytic than colonies typically formed by RBX9 and RB50 (Table 1) (Figure 2D). These 
Large Colony Variants (LCVs) were not recovered from RB50-infected mice. When LCVs were 
picked, diluted, and replated on BG blood agar, approximately 95% of the resulting colonies 
were phenotypically Bvg+ phase, and approximately 5% were LCVs (Table 1) (Figure 2H). 
When replated again, LCVs continued to yield 95% Bvg+ phase colonies and 5% LCVs. All 
phenotypically Bvg+ phase colonies yielded only phenotypically Bvg+ phase colonies after 
replating onto BG agar.  
We found serendipitously that LCVs were also induced in vitro under certain conditions. 
Specifically, when RBX9 was grown on BG blood agar + 50mM MgSO4 (Bvg– phase 
conditions) and then replated onto BG blood agar—effectively switching the bacteria from Bvg– 
to Bvg+ phase conditions—approximately 95% of the colonies were phenotypically Bvg+ phase 
and 5% were LCVs (Table 1) (Figure 2C). When these LCVs were picked, diluted, and replated 
onto BG blood agar, approximately 95% of colonies displayed the Bvg+ phase morphology and 
approximately 5% of colonies were LCVs (Table 1) (Figure 2G). Again, all phenotypically Bvg+ 
phase colonies yielded only phenotypically Bvg+ phase colonies after replating onto BG agar. 
When RBX9 was streaked onto BG agar supplemented with 50mM MgSO4, or passaged 
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continuously under Bvg– phase conditions, all colonies displayed typical Bvg– phase 
morphology.  
To determine if the generation of LCVs in RBX9 was due to the ∆fhaB mutation and not 
an unknown secondary mutation, we reconstructed strain RBX9 by allelic exchange. The newly 
constructed strain behaved identically to RBX9, producing LCVs following BvgAS modulation 
and generating a similar proportion of LCVs upon restreaking an LCV onto BG blood agar. 
Although LCVs appear morphologically similar to Bvgi phase colonies (Figure 2), the fact that 
restreaking LCVs yielded a heterogeneous population of morphologically different colonies 
indicates that the ∆fhaB mutation does not lock bacteria into one particular phenotypic phase 
(such as the Bvgi phase.)  
 
LCVs are composed of both Bvg– and Bvg+ phase bacteria 
To better understand the properties of LCVs, we investigated specific gene expression 
patterns within the bacteria that composed them. The fact that LCVs are hemolytic suggests that 
cyaA, a Bvg+ phase gene, is expressed because ACT is responsible for hemolysis on BG blood 
agar (49). Additionally, electron micrographs of negatively stained LCVs revealed the presence 
of numerous flagella, which are only produced in the Bvg– phase (data not shown). To determine 
if bacteria within LCVs were motile, we grew bacteria on Stainer-Scholte plates with 0.3% agar 
(Bvg+ phase conditions). LCVs stab-inoculated into this agar produced a zone of migration that 
was smaller than that produced by Bvg– phase-locked bacteria, but larger than Bvg+ and Bvgi 
phase bacteria, which do not produce a zone of migration (data not shown), suggesting that at 
least some bacteria within LCVs are motile. Together, our observations indicate that both cyaA 
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and flaA are expressed within each LCV. However, previous studies have shown that expression 
of vags, such as cya, and vrgs, such as flaA, is mutually exclusive (7). Therefore, we 
hypothesized that LCVs are composed of at least two phenotypically distinct populations of 
bacteria: a population in the Bvg+ phase and a population in the Bvg– phase. 
 To determine the phenotypes of individual bacteria present in each LCV, we created 
RBX9BatB-HAfla-gfp, a strain that contains two unique tags that permit the distinction between 
Bvg+ and Bvg– phase bacteria. RBX9BatB-HAflaA-gfp contains an HA epitope-encoding 
sequence in batB (encoding the Bvg+ phase surface-exposed protein BatB) as well as gfp driven 
by the flaA promoter at a neutral site in the chromosome. The batB gene is expressed maximally 
in the Bvg+ phase and minimally in the Bvgi and Bvg– phases (50). The flaA gene, as described 
previously, is a typical vrg and contains a strong promoter that is active only in the Bvg– phase 
(22, 51). Therefore, Bvg+ phase bacteria should produce a surface-exposed HA-tagged BatB 
protein and be GFP– and Bvg– phase bacteria should be GFP+ and lack a surface-exposed HA 
epitope.  
We used Alexa-Fluor 594-conjugated antibodies to indirectly recognize HA epitopes so 
that BatB-producing bacteria displayed red fluorescence. Bacteria expressing fla-gfp produced 
GFP and displayed green fluorescence. When Bvg+ phase colonies of RBX9BatB-HAfla-gfp 
were stained with anti-HA and an Alexa-Fluor 594-conjugated secondary antibody, only red-
fluorescing bacteria were observed and no green fluorescence was detected (Figure 3). When 
Bvg– phase colonies were stained, only green-fluorescing bacteria were observed and no red 
fluorescence was detected. When Bvgi phase colonies were stained, a small proportion of cells 
displayed red or green fluorescence, but the majority of cells were not fluorescent and no 
bacteria displayed both red and green fluorescence (Figure 3). In contrast, when LCVs from 
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RBX9BatB-HAfla-gfp were stained, approximately half of the bacteria fluoresced red and 
approximately half fluoresced green (Figure 3). No co-localization of red and green fluorescence 
from either LCVs or Bvgi phase colonies was observed, confirming that the expression of vags 
and vrgs is mutually exclusive under these conditions. These data demonstrate that LCVs are 
composed of both Bvg+ and Bvg– phase bacteria and are not a homogeneous population of Bvgi 
phase bacteria. 
The ∆fhaB mutation in RBX9, but not lack of FHA protein, is responsible for the LCV phenotype 
To determine if the generation of LCVs was due to lack of FHA protein production or the 
specific genetic architecture created by the ∆fhaB mutation in RBX9, we first determined if other 
fhaB mutants yielded LCVs. Strain RB50∆PfhaB contains a deletion mutation of the fhaB 
promoter, strain RB50∆SPfhaB contains a deletion mutation in fhaB such that the extended signal 
peptide of FHA is missing, and strain RB50∆βhelixfhaB contains a large deletion mutation in the 
region of fhaB encoding the β-helix structure (Figure S1). These strains were analyzed for FHA 
production by western blot, and either produced no FHA protein (RB50∆PfhaB and RB50∆SPfhaB) 
or a severely truncated FHA protein (RB50∆β-helix) (data not shown). We grew these strains 
under Bvg– phase conditions and plated single colonies onto Bvg+ phase conditions to determine 
if they would produce LCVs similar to RBX9. No LCVs were observed, suggesting that a lack of 
wild-type FHA protein is not sufficient to produce the LCV phenotype.  
To investigate the contribution of the genetic architecture created by the fhaB deletion to 
the LCV phenotype, we created RB50::pBam, a strain that produces FHA and contains an altered 
fhaB-bvgAS locus (Figure S1). RB50::pBam was created by integrating pBam, a suicide plasmid 
containing the fhaB-bvgAS intergenic region, into the RB50 chromosome. When integrated in the 
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chromosome, the genetic architecture 5’ to bvgAS is similar in that fhaB coding sequences are 
replaced with non-native sequences (those from the suicide plasmid, in this case). By contrast 
with RBX9, however, the complete, intact fhaB gene, including its promoter region, is present in 
RB50::pBam – it is located 5’ (relative to bvgAS) to the integrated plasmid sequences. After 
modulation, RB50::pBam produced LCVs similar to RBX9. These data suggest that the LCV 
phenotype can be produced by altering the genetic architecture 5´ to the fhaB-bvgAS intergenic 
region and is independent of FHA production.  
 
The LCV phenotype results from a defect in bvgAS positive autoregulation 
In addition to activating all of the known virulence factor-encoding genes in Bordetella, 
BvgAS activates bvgAS expression through positive autoregulation. Williams et al. demonstrated 
that positive autoregulation is required for the precise transition between and maintenance of the 
Bvg+, Bvgi, and Bvg– phases (35). Three observations suggested that LCVs resulted from 
defective bvgAS autoregulation in RBX9. First, the mutations that cause LCVs are genetically 
linked (immediately 5´) to bvgAS; second, LCVs consist of bacteria in least two separate BvgAS-
controlled phenotypic phases; and third, LCVs were induced in vitro following a switch from 
Bvg– to Bvg+ phase growth conditions.  
We hypothesized that when RBX9 (or RB50::pBam) bacteria are switched from Bvg– 
phase conditions to Bvg+ phase conditions, most, like all wild-type bacteria, are able to activate 
transcription at the bvgAS P1 promoter, leading to increased BvgAS levels and resulting in the 
transition to and maintenance of the Bvg+ phase. According to our hypothesis, however, a small 
subset of RBX9 and RB50::pBam bacteria are unable to activate bvgAS transcription, possibly 
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due to insufficient levels of BvgA and/or BvgS, and these bacteria are therefore “trapped” in the 
Bvg– phase. We hypothesized further that although some descendants of these “Bvg– phase-
trapped” bacteria will be able to activate bvgAS transcription and hence “escape” to the Bvg+ 
phase, many will remain Bvg– phase-trapped and thus a substantial Bvg– phase population will 
be maintained in the LCV. An alternate hypothesis is that LCVs arise from spontaneous or 
transient shifting of bacteria between the Bvg+ and Bvg– phases, which would also result in a 
mixture of Bvg+ and Bvg– phase bacteria within a single colony. 
To determine if LCVs contain Bvg– phase-trapped bacteria, we used the recombinase-
based reporter system pGFLIP, which creates a permanent genetic change in response to gene 
activation (46). In this system, a promoter of interest drives expression of the site-specific 
recombinase-encoding gene flp, which when activated, results in recombination between Flp 
recombinase target (FRT) sites that flank gfp and the kanamycin (Km) resistance gene nptII. 
Therefore, any activation (even transient, low-level expression) of flp results in a permanent loss 
of Km resistance and GFP fluorescence. This system targets the reporter construct to the neutral 
attTn7 site 3’ to glmS. We created strain RBX9cyaAFLP by mating the plasmid pGFLIP-PcyaA, in 
which the B. bronchiseptica cyaA promoter drives flp expression, into RBX9. The cyaA gene is 
exclusively controlled by BvgAS, is highly expressed in the Bvg+ phase, and is expressed 
minimally in the Bvg– phase (22). In RBX9cyaAFLP, bacteria that have never expressed cyaA 
should remain GFP+ and Kmr, whereas bacteria that have expressed cyaA should convert to GFP– 
and Kms. If gfp is lost due to PcyaA activation, all descendent cells will also be GFP– and Kms.  
Previously, we demonstrated that RB50cyaAFLP bacteria remain GFP+ under Bvg– phase 
conditions with Km selection and that they reach 100% resolution (GFP– cfu/total cfu) when 
grown under Bvg+ phase conditions (46). When RBX9cyaAFLP was plated under Bvg– phase 
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conditions with Km selection, each colony was morphologically identical and fluorescent, 
indicating that cyaA had not been activated to a level required for sufficient flp expression to lead 
to recombination between FRT sites (Figure 4A). In contrast, when a colony of RBX9cyaAFLP 
that was grown under Bvg– phase conditions was plated and grown under Bvg+ phase conditions, 
approximately 15% of the colonies were LCVs and approximately 80% of those LCVs were 
GFP+ (Figure 4B). None of the Bvg+ phase colonies were GFP+. When a GFP+ LCV was replated 
and grown under Bvg+ phase conditions, approximately 5% of the colonies were LCVs and 
approximately 80% of those were GFP+ (Figure 4C). We serially replated GFP+ LCVs eight 
times and in all cases, additional GFP+ LCVs were generated (data not shown). These data 
indicate that a significant proportion of bacteria within a GFP+ LCV had never activated cyaA 
and had therefore failed to switch to Bvg+ phase in response to a change in conditions; i.e., they 
were Bvg– phase-trapped. Moreover, our data suggest that all LCVs arise from a Bvg– phase-
trapped bacterium and that upon subsequent multiplication, most descendants have “escaped” to 
the Bvg+ phase but a small proportion remain trapped in the Bvg– phase. These data do not 
support a model in which LCVs consist of bacteria that transiently fluctuate between Bvg+ and 
Bvg– phase, because if this was true, LCVs would not be GFP+. 
Approximately 20% of the LCV colonies were GFP–, indicating that PcyaA-flp expression 
was sufficient to mediate recombination in the bacterium that founded the LCV or in its early 
descendants. Although this result appears inconsistent with our model, we have observed 
previously that when RB50cyaAFLP is grown under Bvg– phase conditions (when cyaA 
expression is minimal) and without Km selection, PcyaA-flp is expressed sufficiently in 
approximately 15% of bacteria such that they convert to GFP– and KmS (46). These data indicate 
that the cyaA promoter activity under Bvg– phase conditions is near the threshold level required 
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for flp expression and subsequent recombination. Therefore, GFP– LCVs are most likely due to 
the activity level of the cyaA promoter under Bvg– phase conditions and not due to bacteria 
switching to the Bvg+ phase and then back to the Bvg– phase. Nonetheless, our data indicate that 
in approximately 80% of LCVs, there are a substantial number of bacteria that appear to have a 
defect in bvgAS positive autoregulation, leading to the observed Bvg– phase-trapped population. 
Sequences upstream of the fhaB-bvgAS intergenic region affect the efficiency of bvgAS activation 
in the Bvg– phase. 
Our data indicate that bvgAS autoregulation is defective in RBX9 and specifically, that 
LCVs are composed of a subpopulation of Bvg– phase-trapped bacteria. As stated in the 
introduction, bvgAS expression is controlled primarily by two promoters. Studies with B. 
pertussis have shown that under Bvg– phase conditions, P2 is transcribed at a low basal level (36, 
37). This level of transcription results in BvgS levels that are sufficient to respond to Bvg+ phase 
conditions by autophosphorylating and mediating phosphorylation of BvgA. The resulting 
BvgA~P levels are sufficient to bind at the bvgAS P1 promoter, recruit RNAP, and activate 
transcription (38). (Although similar transcriptional analyses have not been conducted with B. 
bronchiseptica, the nucleotide sequence of the fhaB-bvgAS intergenic region in B. bronchiseptica 
is %91.1% identical and most of those differences are located in regions that, based on B. 
pertussis studies, are not bound by either BvgAS or RNAP.) We considered two hypotheses: 1) 
the level of transcription from P2 in RBX9 is lower than in RB50 such that in some bacteria the 
levels of BvgAS are too low to activate transcription at P1 in response to Bvg+ phase conditions, 
and 2) transcription activation at P1 by BvgA~P is somehow defective in RBX9 compared to 
RB50. Our data suggest that defective autoregulation in RBX9 is due to the lack of native 
sequences or presence of non-native sequences 5´ to the fhaB-bvgAS intergenic region.  
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To test our hypotheses, we constructed RB50PshortbvgAFLP and RB50PlongbvgAFLP, 
where RB50PshortbvgAFLP contains only the fhaB-bvgAS intergenic region driving flp and 
RB50PlongbvgAFLP contains this region plus an additional 1200 bp of fhaB sequences driving flp 
(Figure 5A). These strains were constructed under Bvg– phase conditions in the presence of Km. 
To investigate P2 expression, we determined the percent resolution (the percentage of cfu that 
had activated flp) of each strain grown under Bvg– phase conditions by counting the ratio of 
GFP– cfu to total cfu when one colony was plated from Bvg– phase conditions with Km selection 
to Bvg– phase conditions without Km selection. The average resolution under Bvg– phase 
conditions in RB50PshortbvgAFLP was 68% whereas the average resolution in 
RB50PlongbvgAFLP was 97%. Plates are shown from one representative experiment (Figure 5B, 
C). Our data indicate that the per-cell activation of RB50PshortbvgAFLP is lower than the per-cell 
activation of RB50PlongbvgAFLP under Bvg– phase conditions, and demonstrate that either a lack 
of native fhaB sequences or the presence of non-native sequences has a direct effect on the 
efficiency of bvgAS transcription from the P2 promoter in the Bvg– phase.  
When a colony from each strain was grown on Bvg– phase conditions with Km selection 
and then plated onto Bvg+ phase conditions without Km selection, maximum resolution was 
achieved and there were no GFP+ colonies in either strain (Figure 5D, E). These data suggest that 
RBX9 does not have a defect in transcription activation at P1. 
The LCV phenotype is caused by a (divergent) promoter in proximity to bvgAS 
Based on our results, we hypothesized that sequences within fhaB (1-1200 nucleotides of 
the coding region) 5´ to the fhaB-bvgAS intergenic region effect the low level of transcription 
from P2 that occurs under Bvg– phase conditions. To test this hypothesis, we constructed a strain 
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containing a deletion mutation from nt 8 to 1256 of fhaB (Figure S1, C). This mutant did not 
produce LCVs when switched from the Bvg– to the Bvg+ phase. We conclude that the lack of 
specific sequences within the first 1200bp of fhaB does not cause the LCV phenotype.  
These data led us to closely reexamine the genetic architecture of each strain that 
produced LCVs (RBX9 and RB50::pBam) as well as the strains that showed a difference in 
bvgAS-flp reporter activation (RB50PshortbvgAFLP and RB50PlongbvgAFLP). A comparison of 
these strains revealed the presence of a divergent promoter 5´ to the fhaB-bvgAS intergenic 
region in RBX9, RB50::pBam, and RB50PshortbvgAFLP (Figure 6). In RBX9, the fimA promoter 
is very close to the fhaB-bvgAS intergenic region, in contrast to RB50 in which it is separated by 
the entire (>12kb) fhaB gene. In RB50::pBam, the bla promoter (driving expression of the 
ampicillin resistance gene on the plasmid) is adjacent to the fhaB-bvgAS intergenic region. In the 
strain RB50PbvgAshortFLP, the npt promoter (driving expression of the kanamycin resistance 
gene on the plasmid) is proximal to PbvgA-flp, whereas the RB50PbvgAlongFLP reporter is 
“buffered” from the same npt promoter by an additional 1200bp of fhaB (Figure 6). We 
hypothesized that the presence of a promoter 5´ to the bvgAS-fhaB intergenic region was 
interfering with bvgAS P2 transcription, possibly by sequestering RNA polymerase away from P2. 
To test the hypothesis that a nearby promoter could affect P2 transcription, we reversed the 
orientation of the insert in the plasmid pBam. In the resulting plasmid, pBamR, the bla promoter 
is no longer proximal to the bvgAS homology region. Instead, the closest promoter 5’ to bvgAS 
on the plasmid is the aaC1 promoter (driving expression of the gentamicin resistance gene), 
which is more than 1.5kb away (Figure 6). We created RB50::pBamR by integrating the pBamR 
plasmid into the RB50 chromosome. Modulating RB50::pBamR and plating bacteria onto Bvg+ 
phase conditions resulted in all colonies having the typical Bvg+ phase morphology, and no 
178 
 
LCVs were observed. The LCV phenotype was therefore abolished by changing the sequences 
upstream of the bvgAS-fhaB region, presumably by increasing the distance between a promoter 
and bvgAS. Additionally, we deleted the intergenic region between fhaB and fimA (which 
includes the fimA promoter) in RBX9. The resulting strain RBX9F did not produce LCVs after 
modulation. These data strongly support a model in which a promoter upstream of bvgAS 
interferes with normal P2 transcription efficiency, resulting in some cells having an insufficient 
quantity of BvgAS to activate transcription at P1. 
 
Each Bvg– phase-trapped bacterium within an LCV initiates the formation of a new LCV and the 
proportion of Bvg– phase-trapped bacteria within an LCV decreases over time 
 Our data indicate that LCVs are founded by a single Bvg– phase-trapped bacterium and 
that each LCV harbors Bvg– phase-trapped bacteria that can propagate additional LCVs. 
However, it is unclear whether all Bvg– phase-trapped bacteria, or only a subset of these cells, 
yield LCVs upon replating. To address this question, we needed two pieces of information: the 
proportion of Bvg– phase-trapped bacteria within one LCV and the frequency of new LCV 
formation from the same parent colony when replated. We used RBX9cyaAFLP to evaluate the 
composition and LCV-forming capacity of single LCVs. 
Plating a GFP+ LCV onto Bvg– phase conditions, in which cyaA expression is minimal, will 
minimize further Flp-mediated recombination due to cyaA activation during colony formation, 
permitting us to determine the proportion of GFP+ bacteria (and hence Bvg– phase-trapped) that 
existed within the original LCV at that time. Plating the same GFP+ LCV onto Bvg+ phase 
conditions allows us to determine the number of new LCVs generated from the subpopulation of 
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Bvg– phase-trapped bacteria in the parent LCV. Comparing the frequency of newly generated 
LCVs under Bvg+ phase conditions to the frequency of GFP+ cfu under Bvg– phase conditions 
will reveal the proportion of Bvg– phase bacteria that form LCVs when replated. 
We first grew RBX9cyaAFLP on Bvg– phase conditions with Km selection to maintain 
the gfp and Kmr markers (Figure 7A I). Then we took single GFP+ (Bvg– phase) colonies and 
plated them onto Bvg+ and Bvg– phase conditions (Figure 7A II). GFP+ LCVs that were 
recovered from Bvg+ phase plates were then plated again onto Bvg+ and Bvg– phase conditions 
(Figure 7A III). The frequencies of GFP+ cfu, LCVs, and Bvg+ phase colonies from each plate 
were recorded, and the results from one representative experiment are shown in Figure 7A. 
When the GFP+ LCVs were plated onto Bvg+ and Bvg– phase conditions, there was no 
significant difference in the average number of GFP+ cfu under Bvg– phase conditions compared 
to the average number of GFP+ LCVs on the corresponding Bvg+ phase BG blood agar plate 
(Figure 7B). These data suggest that each Bvg– phase bacterium within an LCV is Bvg– phase-
trapped and forms an LCV when replated onto Bvg+ phase conditions.  
Additionally, we asked if the composition of LCVs (i.e., the ratio of Bvg– to Bvg+ phase 
bacteria) changed over time. We hypothesized that this ratio would change due to bacterial 
division as well as the rate of conversion of Bvg– phase-trapped bacteria to Bvg+ phase bacteria. 
Because we expected a unidirectional conversion of phenotypes (Bvg– to Bvg+ phase only) under 
Bvg+ phase conditions, we predicted that the ratio of Bvg– to Bvg+ phase bacteria would decrease 
as the bacterial population increased. To determine if the compositions changed after an 
additional day of growth, we compared GFP+ LCVs plated after our standard incubation time 
(48h) (Figure 7A III) to GFP+ LCVs plated after 72 h (Figure 7A IV). When GFP+ LCVs were 
plated after 48h of incubation, we obtained an average of 12 ± 1.2% GFP+ cfu under Bvg– phase 
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conditions, whereas after 72h, we obtained an average of 5.75 ± 1% GFP+ cfu under the same 
conditions (P=0.005) (Figure 7C). These data indicate that the frequency of GFP+ (and therefore 
Bvg– phase-trapped) bacteria in an LCV decreases over time.  
These data also strongly suggest (as discussed in a previous result) that GFP– LCVs are a 
result of the background activation of cyaA in RBX9PcyaAflp, as the background cyaA-flp 
activation under conditions of inactivity (Bvg– phase conditions) was the same as the frequency 
of GFP– LCVs (to total LCVs) under Bvg+ phase conditions (Figure 7A II).  
 
Modulation of RBX9 in vivo occurs at a very low frequency 
All data published thus far strongly suggest that wild-type Bordetella do not modulate to 
the Bvgi or Bvg– phase in vivo and that the Bvg+ phase is necessary and sufficient for infection 
(40–45). The recovery of LCVs from mouse lung homogenates and the fact that LCVs were 
recovered in vitro only following modulation, however, supports the hypothesis that RBX9 
modulates during infection. To test this hypothesis, we constructed strain RBX9flaAFLP, a strain 
containing the pGFLIP cassette in which the flaA promoter drives expression of flp (46). 
Previously, using the same PflaA-flp-containing cassette in wild-type RB50, we showed that flaA 
was not activated to a detectable level in RB50 during murine infection (46). RB50flaAFLP and 
RBX9flaAFLP bacteria were grown under Bvg+ phase conditions with Km selection to minimize 
background resolution prior to inoculation. Mice were inoculated intranasally with 7.5x104 – 
1x105 cfu and lungs were harvested at 3, 24, 30 and 72 hours post-inoculation. We conducted 
this experiment several times. In all experiments, a low proportion (≤1%) of GFP– bacteria was 
recovered from the lungs of both RB50flaAFLP- and RBX9flaAFLP-inoculated animals (data not 
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shown). This low proportion was not significantly different, however, from the proportion of 
GFP– bacteria present in the samples used for inoculation (plated after inoculating the animals). 
Data from previous work with RB50flaAFLP (46) and our experiments with RBX9flaAFLP 
indicate that resolution of the PflaA-flp cassette is BvgAS-dependent, and GFP– bacteria were not 
recovered from strains containing the bvgS-C3 mutation, which locks the bacteria in the Bvg+ 
phase (data not shown). For the RBX9flaAFLP-inoculated animals, most of the GFP– colonies 
recovered from the mouse lungs were LCVs and no GFP+ LCVs were recovered, indicating that 
formation of LCVs in vivo correlates with, and is most likely caused by, BvgAS modulation. 
Together, these data suggest that a very small proportion of RBX9 modulates to the Bvg– phase 
during infection. However, our data neither support nor refute the possibility that a small number 
of RB50 bacteria modulates as well. 
To determine if bacteria modulate to the Bvgi phase during infection, we attempted to 
construct strains with Bvgi phase promoters, including the bipA promoter, driving flp. However, 
we were unable to construct these strains, presumably because the level of expression of these 
genes in Bvg+ phase conditions was above the threshold of flp activation required for 
recombination and loss of GFP and KmR. 
 
If BvgAS modulation occurs in vivo, it does not alter the outcome of infection 
Our data suggest that a small proportion RBX9 (and possibly RB50) bacteria may 
modulate to the Bvg– phase during infection. Although several previous experiments have shown 
that wild-type and Bvg+ phase-locked B. bronchiseptica strains are indistinguishable in animal 
models (40–43, 45), we considered the possibility that the proportion of RBX9 bacteria that 
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modulate in vivo could actually be greater than that of RB50, but not apparent from the PflaA-flp 
data because modulated RBX9 bacteria are killed in the host (i.e., that modulated bacteria, and 
perhaps specifically modulated RBX9 bacteria, are more susceptible to host-mediated clearance 
than modulated RB50 bacteria). To test this hypothesis, we compared RBX9, RBX9c (the Bvg+ 
phase-locked derivative of RBX9), RBX9F (the ∆PfimA derivative of RBX9 which is not 
defective for bvgAS autoregulation), and RBX9cF (a Bvg+ phase-locked derivative of RBX9F) in 
mice. The results of three independent experiments are shown in Figure 8. In no case did a 
statistically significant difference in bacterial burden occur amongst the various strains. These 
data negate our hypothesis and provide strong evidence that the low level of BvgAS modulation 
that occurs in vivo (based on the recovery of LCVs) does not impact the outcome of infection. 
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Discussion 
The discovery and characterization of LCVs in B. bronchiseptica yielded several 
interesting findings, the most significant being evidence that transcriptional interference can 
result from activity at a promoter located several hundred nucleotides 5´ to the affected 
promoter. Given this relatively large distance between promoters, the mechanism of interference 
likely does not involve direct blocking of transcription; therefore, we suggest the name “passive 
transcriptional interference” for this phenomenon. Our data indicate that the bvgAS P2 promoter 
is sensitive to passive transcriptional interference and that it results in the emergence of a 
bistable phenotype, apparent as LCVs, when bacteria are switched from Bvg– phase conditions to 
Bvg+ phase conditions. The fact that LCVs, which contain Bvg– phase-trapped bacteria, were 
recovered from the lungs of infected mice, provided evidence that BvgAS modulation occurs in 
vivo. Our experiments indicate, however, that although a small proportion of bacteria apparently 
do modulate during infection, this level of modulation does not alter the outcome of infection. 
Bacterial populations often exhibit phenotypic heterogeneity. A common mechanism by 
which bacteria can generate this heterogeneity is phase variation, a reversible and heritable 
change in phenotype (due to either genetic or epigenetic modifications) often manifested as 
different colony morphologies (52, 53). Phase variation frequently alters the production of 
surface-exposed epitopes such as pili, capsule, flagella, lipopolysaccharide (LPS), and adhesins 
(52). Coincidently, phase variation is often associated with virulence and is an important strategy 
used by pathogens to avoid immune selection. Some well-characterized examples of phase 
variation include the opa operon encoding adhesin proteins in Neisseria species, the pap operon 
encoding fimbrae in E. coli, and the flagella subunits encoded by fljBA and fliC in Salmonella 
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enterica serotype Typhimurium (54–56). In Bordetella, phase variation in both fim3 and bvgAS 
has been described (57, 58).  
More recently, a phenomenon that generates bistable populations at the single-cell level 
has been discovered, called feedback-based multistability (FBM) (59). FBM is distinct from 
phase variation in that it is not based on genetic mutations but is instead based on feedback loops 
of regulatory networks (59). In isogenic populations, these feedback networks can result in 
bistability, which occurs when individuals in a population exhibit either one of two alternative 
stable steady-states (but not intermediate states) (60). A well-characterized example of FBM is in 
Bacillius subtilis, in the regulation of competence orchestrated by the transcription factor ComK 
(61). Competence is a cellular state induced by nutrient depletion, but only occurs in a fraction of 
the B. subtilis population due to oscillating levels of ComK at the single-cell level (62, 63). In 
one study, Smits et al. removed the external regulation of comK, leaving only positive 
autoregulation, and showed that ComK levels continued to exhibit bistability. Therefore, the 
authors argue that ComK bistability can be reduced to a positive autoregulatory loop in concert 
with random transcriptional and translational fluctuations or “noise” (64). This claim is 
supported by other examples, in which feedback regulation and a non-linear input are the only 
required components for a bistable system (60, 65).  
We discovered LCVs of B. bronchiseptica after plating lung homogenates of mice 
infected with strain RBX9 and found that they yielded a heterogeneous population upon 
restreaking onto BG blood agar. We did not find evidence of classical phase variation in RBX9. 
Instead, the mechanism by which LCVs are generated appears more similar to FBM, in which 
the concentration of BvgA under Bvg– phase conditions varies in the population and results in 
some, but not all, bacteria committing to a positive feedback loop when switched to Bvg+ phase 
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conditions. In support of this hypothesis, we were able to label bacteria within LCVs with tags 
unique to the Bvg+ and Bvg– phases and demonstrate the existence of two phenotypically distinct 
populations within LCVs (Figure 3). The dual-tagged RBX9 strain also provided the first direct 
evidence that Bvgi phase cultures are not simply a mixture of Bvg+ and Bvg– phase bacteria. 
Use of the recombinase-based reporter system pGFLIP (46) showed that the ∆fhaB 
mutation in RBX9 causes a decrease in the efficiency of bvgAS positive autoregulation and 
results in Bvg– phase-trapped bacteria that decline in proportion over time and can initiate the 
formation of new LCVs (Figures 4, 5, and 7). Based on these results and previous data, we 
postulate a model of LCV formation and propagation (Figure 9). According to this model, the 
concentration of BvgA varies in a population and also in individual cells as they grow and 
divide. In RB50, the average concentration of BvgA under Bvg– phase conditions is such that 
100% of the bacteria are able to respond to Bvg+ phase conditions and transition to the Bvg+ 
phase phenotype (Figure 9A, B). In RBX9 however, the average concentration of BvgA is 
decreased under Bvg– phase conditions compared to wild-type bacteria (curve shifted to the left 
in Figure 9A), such that a subpopulation is below the threshold level required to respond to Bvg+ 
phase conditions (Figure 9B). These bacteria are thus Bvg– phase trapped and remain 
phenotypically Bvg– phase even under Bvg+ phase conditions. Under Bvg+ phase conditions, 
these bacteria form LCVs, which continue to harbor Bvg– phase-trapped bacteria. The Bvg– 
phase-trapped bacteria within LCVs occasionally escape to become Bvg+ phase descendants, 
possibly through unequal distribution of BvgA upon cell division or by stochastic accumulation 
of BvgA (Figure 9C). Therefore, in this system, a mutation that decreases the basal concentration 
of the positively autoregulated factor (BvgA) results in an FBM-like phenotype, whereas in other 
systems, FBM is the natural mechanism by which bacteria reach a bistable state.  
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Our pGFLIP data indicated that the bvgAS positive autoregulation defect is due to 
decreased activity of P2. This result explains why RBX9 has lower levels of BvgA: it has 
decreased transcription of bvgAS. Our data suggest that the reason for decreased transcription is 
the presence of a promoter located 5´ to the P2 promoter. This upstream divergent promoter 
exerts its negative effects on bvgAS from relatively far away (~800 bp) and this phenomenon 
appears to represent a previously undescribed form of transcriptional interference (the 
suppressive influence of one transcriptional process on another) (66). It is unclear whether this 
promoter must be highly active or divergently transcribed. However, as with other examples of 
transcription interference, we predict that increasing this promoter’s strength would also increase 
the degree of interference (67). Additionally, we predict that the orientation of the promoter may 
not be important and that reversing its orientation would not abolish interference if transcription 
read through was prevented. We do not understand mechanistically how this “passive” 
transcriptional interference occurs. One possibility is that the divergent promoter sequesters 
RNA polymerase away from the sensitive promoter (P2) or that transcription at this site 
influences DNA topology in a way that is prohibitive to P2 activation. These data suggest that the 
level of expression from the bvgAS P2 promoter is poised at the threshold of that required for all 
cells in the population to respond to Bvg+ phase conditions when they are encountered. Although 
the LCV phenotype appeared as an artifact of genetic manipulation, our results are important as 
they demonstrate a form of transcriptional interference that, to our knowledge, has not been 
described previously, and also because they reveal a mechanism by which in-frame deletion 
mutations can have unanticipated polar effects on neighboring genes. Furthermore, RBX9 and its 
derivatives constitute a genetically tractable system for studying additional mechanisms of 
transcriptional interference and details of FBM. 
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The LCVs also provided insight into the behavior of BvgAS during infection. The role of 
BvgAS-dependent modulation in the Bordetella life cycle is not completely understood and 
remains an important area of investigation. Several studies have attempted to determine if Bvgi 
or Bvg– phase bacteria exist at any point during Bordetella infection, and so far none have 
yielded positive results (40–43, 45). These data, together with those demonstrating that Bvg– 
phase bacteria transition rapidly to the Bvg+ phase following intranasal inoculation (46, 68), have 
led to the conclusion that not only is the Bvg+ phase necessary and sufficient for infection, but 
that bacteria switch to and remain in the Bvg+ phase in vivo. The Bvgi and Bvg– phases are 
hypothesized to be important for transmission and survival ex vivo, however, no role for these 
phenotypic phases in a natural setting has been demonstrated. For B. pertussis particularly, which 
appears to survive outside the host only briefly during transmission to a new host, the role of 
BvgAS modulation remains mysterious. The isolation of LCVs from mouse lungs provides 
strong evidence that at least some RBX9 bacteria modulate during infection. However, the 
proportion of bacteria that modulated and that could be recovered from the animals was very 
low. Because the PflaA-flp system was unable to reliably distinguish this low proportion of 
modulated bacteria from background resolution, we could not determine if wild type bacteria 
modulate in vivo. If they do not, our data would suggest that only FHA-deficient bacteria 
modulate in vivo, which would suggest that FHA functions to prevent the bacteria from 
experiencing a Bvg– phase environment during infection. In pilot experiments, we also recovered 
LCVs from mice infected with ∆fhaB, ∆cyaA double mutants – in higher proportions, in some 
cases, than in mice infected with RBX9. These preliminary data suggest the intriguing possibility 
that FHA and ACT function together to prevent Bordetella from creating or entering a 
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modulating environment in the host. Our future experiments will be aimed at testing this 
hypothesis. 
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Experimental Procedures 
Strains and growth conditions 
Escherichia coli were grown in lysogeny broth (LB; 10 g l-1 tryptone, 5 g l-1 yeast extract, 
2.5 g l-1 NaCl) or on LB with agar (1.5%) at 37°C. Bordetella were grown in Stainer-Scholte 
(SS) broth (25) or on Bordet-Gengou (BG) agar (1.5%) (BD Biosciences, San Jose, CA) 
supplemented with 7.5% defibrinated sheep’s blood (Colorado Serum Company, Denver, CO) at 
37°C (16). As required, culture media were supplemented with kanamycin (Km; 50 µg ml-1), 
ampicillin (Ap; 100 µg ml-1), streptomycin (Sm; 25 µg ml-1), magnesium sulfate (MgSO4; 50 
mM in plates and 20 mM in liquid), and diaminopimelic acid (DAP; 400 µg ml-1) for the E. coli 
mobilizer strain RHO3 (∆asd ∆aphA) (19). Unless otherwise noted, all restriction enzymes and 
T4 DNA ligase was purchased from New England Biolabs. 
 
Construction of bacterial strains 
Allelic exchange and Campbell-type integrations were done by matings using parental 
Bordetella and E. coli strain RHO3 harboring the appropriate suicide plasmid. The pGFLIP 
plasmid was delivered to the attTn7 site using tri-parental mating with the above strains and with 
RHO3 cells harboring pTNS3, which encodes the transposase genes tnsABCD. Integration at the 
attTn7 locus was confirmed via PCR. For details on specific strain constructions see the 
Supplemental text. 
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Immunofluorescence 
HA epitopes on the surface of RBX9BatB-HAflaA-gfp bacteria were stained and 
visualized using indirect immunofluorescence. After 72h of growth at 37˚C, five to twenty 
colonies of each morphology including Bvg+, Bvg–, Bvgi, and LCV, were scraped off of BG 
blood agar plates and resuspended into 1ml of 4% paraformaldehyde and were allowed to fix on 
ice for 30 min. Cells were pelleted and washed with 1% BSA in PBS in a microcentrifuge tube. 
Primary antibody (mouse monoclonal anti-HA IgG diluted 1:2000 in 1% BSA in PBS) was used 
to resuspend the pellet and this mixture was incubated for 1h at room temperature (RT). The 
pellets were washed twice in 1% BSA for 5 min. Secondary antibody (Alexa Fluor 594-
conjugated goat anti-mouse IgG, diluted 1:250 in 1% BSA in PBS; Invitrogen) was used to 
resuspend the pellet and this mixture was then incubated for 30 min at RT in the dark. The 
pellets were washed twice with 1% BSA for 5 min. Four microliters of the leftover pellet and 
liquid was pipetted onto a slide for visualization. 
 
Confocal Microscopy 
Immunofluorescent RBX9BatB-HAflaA-gfp bacteria were visualized using a Zeiss LSM 
710 confocal microscope. Secondary antibody (Alexa Fluor 594-conjugated goat anti-mouse 
IgG) was detected using a 594 nm laser and GFP was detected at 488 nm. We used the 63× oil 
objective with 3× digital zoom. Images were viewed and saved with the Zen software from Carl 
Zeiss Microscopy. 
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pGFLIP assays 
For RBX9cyaAFLP, RB50PbvgAshortFLP and RB50PbvgAlongFLP, strains were grown on 
BG blood agar plates under promoter-inactive conditions (Bvg– phase) with Km for 48h at 37°C 
and were determined to be GFP positive (GFP+) using a G:BOX Chemi imaging system with an 
UltraBright-LED blue transilluminator and an SW06 short-pass filter (495 to 600 nm; Syngene, 
Frederick, MD). Single GFP+ colonies were then resuspended in PBS, diluted, and plated onto 
Bvg+ or Bvg– phase conditions (promoter-active and promoter-inactive conditions, respectively) 
in the absence of Km selection. For RBX9cyaAFLP, GFP+ LCVs were picked, diluted, and 
plated onto Bvg+ and Bvg– phase conditions in the absence of Km selection. Percent resolution 
was determined by averaging the ratio of GFP– cfu/total cfu for at least three plates.  
 
Intranasal inoculation of mice 
Four- to eight-week-old BALB/c mice (Jackson Laboratories, Bar Harbor, ME) were 
inoculated intranasally with 1×105 cfu of B. bronchiseptica in 50 µl of PBS. For all infections, 
bacteria were grown overnight in SS medium. Lungs were harvested at 1h and 72h p.i. Right 
lungs were homogenized in 1 ml of PBS, diluted in PBS, and plated in at least duplicate on BG 
agar. Figure 8 represents data from three independent experiments performed with at least two 
mice per strain per time point.  
 
This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health. Our protocol 
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was approved by the University of North Carolina IACUC (10-134, 12-307). All animals were 
properly anesthetized for inoculations, monitored regularly, euthanized when moribund, and 
efforts were made to minimize suffering. 
 
Statistical analyses 
 
Statistical analyses were performed using Prism 5.0 (GraphPad Software, Inc.). Statistical 
significance was determined using the unpaired Student’s t-test or analysis of variance 
(ANOVA) followed by Tukey’s multiple comparison test. Images were formatted using Adobe 
Photoshop CS5 and figures were generated using Adobe Illustrator CS5 (Adobe Systems, Inc.). 
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Figures 
Figure 1. The Bordetella BvgAS system controls at least four different classes of genes and 
three different phenotypic phases in response to environmental stimuli 
 
Figure 1: The Bordetella BvgAS system controls at least four different classes of genes and 
three different phenotypic phases in response to environmental stimuli. A,  BvgAS is responsible 
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for the Bvg+, Bvgi, and Bvg– phases and is repressed by chemical modulators or low temperature. 
B, The three phenotypic phases are defined by unique patterns of gene expression as indicated, 
and rely on the intracellular concentration of BvgA~P. C, The chromosomal organization of the 
fhaB and bvgAS loci in RB50 (top) and RBX9 (∆fhaB, bottom). 
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Figure 2: RB50 and RBX9 colony morphology. 
 
Figure 2: RB50 and RBX9 colony morphology. Bacteria were plated on either BG agar or BG 
agar + 50mM MgSO4 and were imaged after 48h. A, RB50; B, RBX9; C, RBX9 LCV produced 
after in vitro modulation: D, RBX9 LCV recovered from mouse lung homogenate; E, RB50i (a 
Bvg-intermediate phase-locked strain in the RB50 background); F, RBX9i (a Bvg-intermediate 
phase-locked strain in the RBX9 background); G, RBX9 restreak of an LCV produced after 
modulation; H, RBX9 restreak of an LCV recovered from the mouse lung; I, RB50; J, RBX9; K, 
RBX9 restreak of an LCV produced after modulation; L, RBX9 restreak of an LCV recovered 
from the mouse lung.  
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Figure 3. Detection of Bvg+ and Bvg– phase bacteria in typical RBX9 colonies and LCVs. 
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Figure 3: Detection of Bvg+ (α-HA, red) and Bvg– phase (flaA-gfp, green) bacteria in typical 
RBX9 colonies and LCVs. RBX9BatBN-HAflaA-gfp was grown on BG blood agar (Bvg+ phase 
conditions), BG blood agar + 50 mM MgSO4 (Bvg– phase conditions), or BG blood agar + 6 mM 
MgSO4 (Bvgi phase conditions). Several colonies of each phenotype were combined and stained 
with mouse monoclonal α-HA IgG followed by an Alexa Fluor 594-conjugated goat anti-mouse 
IgG secondary antibody. Fluorescence was detected using a Zeiss LSM 710 confocal 
microscope. 
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Figure 4. LCVs from the strain RBX9PcyaAFLP are GFP+, indicating that cyaA has not 
been activated in a substantial proportion of these colonies 
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Figure 4: LCVs from the strain RBX9PcyaAFLP are GFP+, indicating that cyaA has not been 
activated in a substantial proportion of these colonies. A, RBX9PcyaAFLP on BG blood agar + 
50mM MgsO4 (Bvg– phase conditions); B, a GFP+ colony from A plated onto BG blood agar 
(Bvg+ phase conditions); C, a GFP+ LCV from B plated onto BG blood agar (Bvg+ phase 
conditions). Colonies were visualized after 48h of growth. 
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Figure 5: Sequences upstream of bvgAS affect transcription efficiency under Bvg– phase 
conditions. 
 
Figure 5: Sequences upstream of bvgAS affect transcription efficiency under Bvg– phase 
conditions. A, Schematics of RB50PshortbvgAFLP and RB50PlongbvgAFLP showing the 
sequences 5´ to flp (not drawn to scale); B and C, strains were first grown on BG blood agar + 50 
mM MgSO4 + Km and one colony was plated onto BG blood agar + 50 mM MgSO4 (Bvg– phase 
conditions) without Km selection; D and E, strains were grown on BG blood agar + 50 mM 
MgSO4 + Km selection and then one colony of each was plated onto BG blood agar (Bvg+ phase 
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conditions) without selection. Representative white light (left) and fluorescent (right) images are 
shown for panels B, C, D, and E. 
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Figure 6: The genetic architecture of the bvgAS-fhaB intergenic region of strains that do 
and do not produce LCVs. 
 
Figure 6: The genetic architecture of the bvgAS-fhaB intergenic region of strains that do and do 
not produce LCVs. Strains that produce LCVs or demonstrate a defect in bvgAS-flp activation 
have divergent promoters 5´ to the bvgAS-fhaB intergenic region. Schematics for 
RB50PshortbvgAFLP and RB50PlongbvgAFLP represent sequences inserted at the attTn7 site. 
Dotted lines represent non-coding plasmid DNA. Sequence lengths from the ATG of fhaB to the 
nearest 5’ ATG are indicated. 
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Figure 7: Schematic of RBX9cyaAFLP experimental design 
 
204 
 
Figure 7: A, Schematic of RBX9cyaAFLP experimental design, including a data set from one 
replicate. Each pie chart represents the population obtained from plating a single GFP+ colony 
from the previous plate (see text for details). Blue sectors in pie charts represent the frequency of 
GFP– cfu; Green sectors in pie charts represent the frequency of GFP+ cfu; offset regions of pie 
charts represent the frequency of LCVs; Frequencies were determined by counting at least 500 
cfu per condition. B, Comparison of GFP+ cfu frequencies obtained from plating a single GFP+ 
LCV onto Bvg+ and Bvg– phase conditions. C, Comparison of GFP+ cfu frequencies obtained 
from plating a GFP+ LCV grown after 48h and 72h. Background color represents BvgAS 
conditions, where red is Bvg+ phase conditions and blue is Bvg– phase conditions. **, P = 0.005 
by Student’s Unpaired T-test. 
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Figure 8: Comparison of RBX9, RBX9c, RBX9F, and RBX9cF burdens in the mouse lung 
 
Figure 8: Comparison of RBX9, RBX9c, RBX9F, and RBX9cF burdens in the mouse lung after 
3h and 72h p.i. RBX9c and RBX9cF are Bvg+ phase-locked derivatives of RBX9 and RBX9F, 
respectively; four-to eight-week-old BALB/C mice were intranasally infected with 1×105 cfu in 
50µl and lungs were harvested at each time point; each diamond or circle indicates the number of 
cfu recovered from a single animal and each horizontal line indicates the geometric mean for 
each group; these data represent three independent experiments with at least two mice per strain 
per time point. 
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Figure 9. Proposed distribution of BvgA concentration within populations of RBX9 and 
RB50. 
 
Figure 9. Proposed distribution of BvgA concentration within populations of RBX9 and RB50. 
A, In the Bvg– phase, a proportion of RBX9 cells (shaded region) are Bvg– phase-trapped (i.e., 
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have a concentration of BvgA below the threshold [dotted line] necessary to stimulate positive 
autoregulation upon transition to Bvg+ phase conditions). By contrast, all RB50 cells have a level 
of BvgA sufficient to initiate positive autoregulation upon transition to Bvg+ phase conditions. B, 
In the Bvg+ phase, the RBX9 cells that were below the threshold BvgA concentration in the Bvg– 
phase (shaded region as in A) maintain their low concentration of BvgA and are thus unable to 
switch to the Bvg+ phase. These cells are able to initiate LCV formation as described in C. 
Consistent with our in vitro data, all RB50 cells are able to switch to the Bvg+ phase. C, Model 
of LCV formation and propagation illustrated as a lineage diagram (see text for details). RBX9 
bacteria exist as a heterogeneous population under Bvg– phase conditions, with some bacteria 
(white) being below the threshold of BvgA required to initiate positive autoregulation and others 
above this threshold (gray). When bacteria are switched to the Bvg+ phase, the Bvg– phase 
trapped bacteria form LCVs, whereas the other bacteria transition into the Bvg+ phase (black) 
and form Bvg+ phase colonies. Occasionally, Bvg– phase-trapped bacteria “escape” and can 
transition into the Bvg+ phase (indicated by gray cells between white and black cells), resulting 
in LCV formation after 48h. 
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Table 1: LCV recovery frequency 
 
Condition %a LCVs recovered on BG blood agar 
Plating murine lung homogenate after 30 hours 
 
0.39 ± 0.13 
Replating any RBX9 Bvg– phase colony 5.43 ± 0.98 
 
Replating an LCV from BG agar (derived in vitro) 3.90 ± 0.80 
 
Replating an LCV from BG agar (derived in vivo) 
 
6.03 ± 1.26 
Replating any RBX9 Bvg+ phase colony  0 
aValues are means ± standard errors for experiments performed at least in triplicate 
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APPENDIX C. AN IMPROVED RECOMBINATION-BASED IN VIVO EXPRESSION 
TECHNOLOGY-LIKE REPORTER SYSTEM REVEALS DIFFERENTIAL CYAA 
GENE ACTIVATION IN BORDETELLA SPECIES1 
Introduction 
 Bordetella species are Gram-negative bacterial respiratory pathogens. The genus includes 
Bordetella pertussis, an obligate human pathogen and the causative agent of whooping cough, 
and the closely related Bordetella bronchiseptica, which can infect a wide range of mammals 
including several species that are commonly studied in the laboratory (1-3). These bacteria rely 
on the global two-component regulatory system BvgAS for virulence (1-3). The BvgAS 
phosphorelay regulates gene expression patterns according to environmental cues and controls at 
least three distinct phenotypic phases: Bvg minus (Bvg–), Bvg plus (Bvg+), and Bvg intermediate 
(Bvgi) (4, 5). All evidence thus far suggests that the Bvg+ phase is necessary and sufficient for 
infection, and that modulation to the Bvg– or Bvgi phase does not occur in vivo (6-8). Although it 
has been hypothesized that the Bvgi phase and/or the Bvg– phase is required for transmission or 
survival outside of a host (7, 9, 10), a recent study provided evidence that neither of these 
phenotypic phases is required for B. bronchiseptica transmission in swine (8).  
Genes that define these three phenotypic phases have been divided into four classes based 
on their expression profile. Class 1 (late Bvg+ phase) genes include cyaA-E (encoding the 
_______________________ 
1This chapter was previously appeared as an article in Infection and Immunity. The original citation is as follows: Byrd, MS, Mason E, 
Henderson MW, Scheller EV, Cotter PA. “An improved recombination-based in vivo expression technology-like reporter system reveals 
differential cyaA gene activation in Bordetella species” Infect Immun. 2013 Apr;81(4):1295-305. doi: 10.1128/IAI.01445-12. Epub 2013 Feb 4. 
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bifunctional hemolysin/adenylate cyclase toxin ACT) and ptxA-E (encoding the AB5-type 
pertussis toxin) (4). Class 2 (early Bvg+ phase) genes include those encoding filamentous 
hemagglutinin (fhaB), fimbriae (fim2 and fim3), and bvgAS itself (4). bipA is the only class 3 
(Bvgi phase) gene that has been characterized. Class 4 (Bvg– phase) genes include those 
encoding proteins involved in motility (frlAB) and chemotaxis in B. bronchiseptica (4).  
 Expression of genes that define the various Bvg-dependent phenotypic phases is 
determined mechanistically by the location and affinity of BvgA binding sites near the 
transcription start site (4). Class 1 genes contain multiple low affinity BvgA binding sites 5′ 
distal to the start of transcription (4, 11), while class 2 genes contain high-affinity BvgA binding 
sites proximal to the transcription start site (12-14). The promoter region of the class 3 gene bipA 
contains high affinity BvgA binding sites 5′ proximal to the transcription start site and low 
affinity sites 3′ to the transcription start site (10, 15). Although it has been hypothesized that 
BvgAS directly represses transcription of frlAB in B. bronchiseptica (16), BvgA binding to the 
frl promoter has not been demonstrated and BvgAS-mediated repression of at least some genes 
in B. pertussis is indirect (17). 
 In vitro transcription and DNA binding studies indicate that the phosphorylated form of 
BvgA (BvgA~P) is required to activate transcription of Bvg+ phase genes and that a higher 
concentration of BvgA~P is necessary to bind “late” Bvg+ phase promoters than “early” Bvg+ 
phase promoters (11, 18). Although the natural signals that activate the BvgAS system are 
unknown, it is possible to modulate Bordetella spp. to the Bvg– phase in the laboratory by adding 
a chemical modulator (MgSO4 or nicotinic acid) to the growth medium, or by growing bacteria at 
25°C (15, 19-21). When grown under Bvg– phase conditions, class 4 genes are expressed while 
class 1–3 genes are not expressed. When switched from Bvg– phase to Bvg+ phase conditions, 
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transcription of class 4 genes ceases and transcription of class 2 genes, along with the sole class 3 
gene bipA, is immediately activated. After several hours, class 1 genes are expressed and class 3 
(bipA) genes are repressed. These data are consistent with the model in which the concentration 
of BvgA~P within the cell is nearly zero in the Bvg– phase, low in the Bvgi phase, and high in 
the Bvg+ phase (4, 5, 11, 15, 18, 22, 23). 
 By contrast with the extensive in vitro characterization of the steady-state expression 
patterns of BvgAS-regulated genes in both B. pertussis and B. bronchiseptica, as well as kinetic 
analyses of gene expression upon switching from modulating to non-modulating conditions and 
vice versa (5, 10, 11, 15, 22-24), only one study has investigated BvgAS-dependent gene 
regulation in vivo (24). Veal-Carr et al. utilized recombination-based in vivo expression 
technology (RIVET) to analyze the kinetics of BvgAS-activated gene expression in B. pertussis 
both in vitro and following intranasal infection of mice (24, 25). They showed that the in vivo 
activation of Bvg+ phase genes, including ptxA, cyaA, fhaB, and prn, temporally recapitulated the 
activation pattern of these genes upon switching B. pertussis from Bvg– to Bvg+ phase conditions 
in vitro; i.e., fhaB was activated early post-inoculation (~1 h), followed by prn (~4 h), then later 
by cyaA (~12 h) (24). Significantly, the fact that the pattern of gene activation was nearly 
identical in bacteria switched from Bvg– to Bvg+ phase conditions in vitro and post-inoculation 
of mice indicates that the mouse lung is a Bvg+ phase environment (24).  
  We constructed a plasmid, pGFLIP, that encodes a Flp recombinase-based fluorescent 
reporter system to assess the activation kinetics of genes in vivo (26). The region of pGFLIP 
delivered to the chromosome contains gfp and nptII genes, encoding green fluorescent protein 
and neomycin phosphotransferase (conferring kanamycin resistance [Kmr]), respectively, flanked 
by Flp recombinase target (FRT) sites. The plasmid also contains a promoterless flp recombinase 
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gene with a multiple cloning site (MCS) immediately 5′ to the start codon. Upon expression of 
flp under the control of a promoter of interest, the gfp and nptII genes are permanently excised 
from the bacterial chromosome. 
 To test our system, we cloned the promoter regions of several BvgAS-controlled genes, 
including the Bvg-activated genes cyaA, fhaB, and ptxA and the Bvg-repressed gene flaA 
(encoding flagellin) into pGFLIP and evaluated transcription activation in vitro and in vivo in B. 
bronchiseptica. Amongst other results, we found unexpectedly that the cyaA gene is expressed 
differently in B. pertussis and B. bronchiseptica.  
Materials and Methods 
 Strains, reagents, and growth conditions. Escherichia coli were grown in lysogeny 
broth (LB; 10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl) or on LB plates with 1.5% agar at 
37°C. Bordetella were grown in Stainer-Scholte (SS) broth (27) or on Bordet-Gengou (BG) 
plates with 1.5% agar (BD Biosciences, San Jose, CA) supplemented with 7.5% (B. 
bronchiseptica) or 15.0% (B. pertussis) defibrinated sheep’s blood (Colorado Serum Company, 
Denver, CO) at 37°C (28). As required, culture media were supplemented with kanamycin (Km; 
50 or 100 µg/ml), ampicillin (100 µg/ml), streptomycin (25 µg/ml), MgSO4 (20 mM or 50 mM), 
heptakis (1 mg/ml, Sigma), and for the ∆asd ∆aphA mobilizer strain RHO3 (29), diaminopimelic 
acid (DAP; 400 µg/ml). Unless otherwise noted, all restriction enzymes and T4 DNA ligase was 
purchased from New England Biolabs. 
 Construction of pGFLIP and derivatives containing Bordetella promoters. The Tn7 
transposition plasmid pUC18T-mini-Tn7T-Km-FRT (30) was digested with BamHI, resulting in 
fragments of 3636 and 1299 bp in length containing the plasmid backbone and the nptII (Kmr) 
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gene, respectively. Separately, a 797-bp fragment containing gfp driven by the constitutive 
Burkholderia pseudomallei rpsL promoter PS12 was amplified by PCR from mini-Tn7-kan-gfp 
(31) using Pfu Ultra II (Agilent) and primers GFP_UP and GFP_DN. This fragment was blunt-
end ligated into the cloning vector pJET1.2/blunt (Fermentas) and was transformed into E. coli 
DH5α according to the manufacturer’s instructions. Using restriction sites introduced by PCR, 
the PS12-gfp fragment was digested from pJET using BamHI and was ligated together with the 
BamHI-digested pUC18T-mini-Tn7T-Km-FRT backbone and nptII fragment. As the flp gene 
would be sensitive to transcription read-through from either the PS12 or the nptII promoter, 
primers specific to gfp (gfpseqR) and nptII (kanseqR) were used to confirm that both genes 
would be transcribed opposite the promoter of interest and would therefore not drive flp 
expression. Once the orientation of gfp and nptII was verified, the plasmid was digested with 
KpnI and StuI; a fragment containing promoterless flp amplified by PCR from pFLPe4 (30) 
using primers FLP_UP and FLP_DN was likewise digested with KpnI and StuI and was ligated 
into the digested vector. The resulting plasmid, pGFLIP, thus contained an MCS 5′ to flp, the flp 
recombinase gene, and constitutively expressed nptII and gfp genes flanked by FRT sites. 
pGFLIP was fully sequenced using a primer-walking approach with the primers listed in Table 2. 
 Promoters for five Bordetella genes (cyaA, cyaABp, fhaB, ptxA, and flaA) were cloned into 
the MCS of pGFLIP as follows. For cyaA and cyaABp, 605 and 604-bp fragments containing the 
cyaA promoter were amplified by PCR from B. bronchiseptica RB50 and B. pertussis BPSM, 
respectively, using primers cyaA_F and cyaA_R. These fragments were digested with SacI and 
KpnI and ligated into pGFLIP. For fhaB, a 426-bp fragment containing the fhaB promoter was 
amplified by PCR from RB50 using primers fhaprF2 and fhaprR2, digested with SacI and KpnI, 
and ligated into pGFLIP. For ptxA, a 454-bp fragment containing the ptxA promoter was 
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amplified by PCR from BPSM using primers ptxprF and ptxprR, digested with SacI and ApaI, 
and ligated into pGFLIP. For flaA, a 514-bp fragment containing the flaA promoter was 
amplified by PCR from RB50 using primers flaA_F and flaA_R, digested with SacI and KpnI, 
and ligated into pGFLIP. These constructs were delivered to the chromosome by transposase-
mediated insertion as described below. 
 Transposase-mediated delivery of pGFLIP to the B. bronchiseptica attTn7 site. The 
pGFLIP plasmid was delivered to Bordetella by tri-parental mating using a procedure modified 
from (28). B. bronchiseptica strains RB50 and RB52 were grown on BG agar for 48 h, and a 
portion of the cells was co-incubated with conjugation-competent E. coli RHO3 cells (29) 
harboring pGFLIP and RHO3 cells containing the helper plasmid pTNS3 (30), which expresses 
tnsABCD from a constitutive promoter, on BG agar supplemented with DAP for 6 h at 37°C. 
Following incubation, cells were restreaked onto BG/Km agar containing 20 mM MgSO4 (to 
maintain strains containing pGFLIP with Bvg+ phase promoters in the Bvg– phase) or without 
MgSO4 (to maintain RB50flaAFLP in the Bvg+ phase) and were incubated an additional 48 h at 
37°C. Delivery of pGFLIP to BPSM followed the same procedure except that incubations 
required four days at 37°C and plates were supplemented with 50 mM MgSO4. pGFLIP without 
a promoter driving flp was used as a positive control for GFP production and as a negative 
control for flp activation. The delivery of all constructs to the attTn7 site was confirmed by PCR 
using primers glmSF and gfpseqR (data not shown). 
 Evaluation of pGFLIP in vitro. We determined the functionality of pGFLIP using a 
plate-based assay in which RB50cyaAFLP and RB50flaAFLP were modulated between 
promoter-inactive and promoter-active conditions. BG agar containing 20 mM MgSO4 was used 
to de-repress PflaA and to deactivate PcyaA, while BG agar without MgSO4 was used to activate 
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PcyaA and to repress PflaA (7). The pGFLIP strains were grown under promoter-inactive conditions 
for 48 h at 37°C and were determined to be GFP+ using a G:BOX Chemi imaging system with an 
UltraBright-LED Blue transilluminator and a SW06 short-pass filter (495–600 nm; Syngene, 
Frederick, MD). A single GFP+ colony was resuspended in PBS and was diluted and plated on 
BG agar under promoter-active and promoter-inactive conditions. To demonstrate the loss of 
Kmr upon promoter activation, Km (100 µg/ml) was added to some plates. Plates were incubated 
for 48 h at 37°C, and white-light and fluorescent images were obtained using the G:BOX Chemi 
system.  
 For kinetic assays, strains containing pGFLIP were grown overnight with Km selection in 
SS under promoter-inactive conditions (20 mM MgSO4 for RB50cyaAFLP, RB50cyaABpFLP, 
RB50fhaBFLP, and RB50ptxAFLP; no added MgSO4 for RB50flaAFLP). Cells were washed 
twice in PBS with or without 5 mM MgSO4 to prevent the premature activation of Bvg+ phase 
and flaA promoters, respectively, and were added to fresh SS medium under promoter-active 
conditions (20 mM MgSO4 for RB50flaAFLP; no added MgSO4 for RB50cyaAFLP, 
RB50cyaABpFLP, RB50fhaBFLP, and RB50ptxAFLP) at the OD600 that was equivalent to 1 × 109 
cfu/ml. Tubes were incubated on a roller at 37°C for 8 h. At each time point, an aliquot of cells 
was removed, diluted in PBS under promoter-inactive conditions, and was plated on BG agar 
under promoter-inactive conditions. Plates were incubated for 48 h at 37°C, and total cfu were 
enumerated. For kinetic assays with B. pertussis, cultures were inoculated at the cfu/ml 
corresponding to an OD600 of ~ 0.1, and cells were grown overnight in SS containing 50 mM 
MgSO4, 100 µg/ml Km, and 1 mg/ml heptakis. Cells were washed in PBS containing 25 mM 
MgSO4 to prevent premature flp activation. All other aspects of the assay were the same as for B. 
bronchiseptica, except that dilutions were plated on BG agar containing 50 mM MgSO4 and 
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plates were incubated four days at 37°C. GFP fluorescence was quantified using the G:BOX 
Chemi imaging system as described. The percent resolution (the ratio of GFP– colonies to the 
total number of colonies × 100%) was calculated for each strain at each time point. 
Evaluation of pGFLIP in a murine model of infection.  
Five- to seven-week-old BALB/c mice (Jackson Laboratories, Bar Harbor, ME) were 
inoculated intranasally with 1 × 105 cfu of B. bronchiseptica pGFLIP strains in 50 µl of PBS. For 
infections with RB50cyaAFLP, RB50cyaABpFLP, RB50fhaBFLP, and RB50ptxAFLP, bacteria 
were grown overnight in SS medium containing Km (100 µg/ml) and 20 mM MgSO4 to maintain 
cells in the Bvg– phase. For infections with RB50flaAFLP, bacteria were grown overnight in SS 
media containing Km (100 µg/ml) to maintain cells in the Bvg+ phase. Lungs were harvested 
from infected mice at 1 h and 30 h post-inoculation (p.i.). For RB50flaAFLP, right lungs were 
homogenized in 1 mL of PBS, diluted in PBS, and plated in duplicate on BG agar. For strains 
containing Bvg+ phase promoters in pGFLIP, homogenization, dilution, and plating were carried 
out in the presence of 20 mM MgSO4. Percent resolution was calculated for each strain at each 
time point. This study was done in strict accordance with the recommendations in the Guide for 
the Care and Use of Laboratory Animals of the National Institutes of Health. Our protocol was 
approved by the University of North Carolina IACUC (12-307.0). All animals were properly 
anesthetized for inoculations, monitored regularly, euthanized when moribund, and efforts were 
made to minimize suffering. 
Statistical analyses.  
Statistical analyses were performed using Prism 5 (GraphPad Software, Inc.). Statistical 
significance was determined using the unpaired Student’s t-test or analysis of variance 
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(ANOVA). Images were formatted using Adobe Photoshop CS5 and figures were generated 
using Adobe Illustrator CS5 (Adobe Systems, Inc.). 
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Results 
Design and Construction of pGFLIP.  
To study transcription activation of genes both in vitro and in vivo, we engineered a 
reporter system, pGFLIP, that provides both fluorescent and selectable markers. We designed 
our system for simplicity and ease of use. Therefore, all of the components necessary for 
pGFLIP function are contained on a single plasmid. The region of pGFLIP delivered to the 
chromosome includes gfp and nptII, each under the control of a strong constitutive promoter and 
together flanked by FRT sequences (Fig. 1A). The Flp recombinase gene flp is present in the 
opposite orientation from gfp and nptII with an immediate 5′ MCS to facilitate the insertion of a 
promoter of interest. In the absence of promoter activity flp is not transcribed and cells remain 
GFP+ and Kmr. When the promoter of interest is activated, flp is transcribed and the gene product 
mediates recombination between FRT sites, permanently excising gfp and nptII.  
  To test the system, we cloned promoter regions from B. bronchiseptica and B. pertussis 
into the MCS to generate the strains described in Table 1. The region of pGFLIP between Tn7L 
and Tn7R ends was delivered to the attTn7 site 3′ to the glmS gene in Bordetella spp. as 
described in Materials and Methods. Transcription terminators are present near the 5′ end of the 
transposon to prevent transcription read-through from glmS. Delivery of promoterless pGFLIP to 
B. bronchiseptica RB50 and B. pertussis BPSM resulted in strains that were stably GFP+ and 
Kmr. These strains did not lose GFP fluorescence or Kmr when passaged multiple times in vitro 
in the absence of selection (data not shown).  
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Functional evaluation of pGFLIP in vitro.  
To evaluate the functionality of pGFLIP, we used two B. bronchiseptica promoters for 
which activity can readily be induced in vitro: PcyaA and PflaA. In B. bronchiseptica, the flaA 
promoter is highly transcribed in the Bvg– phase, while the cyaA promoter is transcribed strongly 
in the Bvg+ phase (9, 10, 15, 22, 32). Therefore, RB50flaAFLP was constructed under Bvg+ 
phase conditions to prevent expression of flaA, while RB50cyaAFLP was maintained under Bvg– 
phase conditions to prevent expression of cyaA. Km was added to the media during construction 
of these strains to select against any bacteria that had activated flp, thus ensuring that the 
population only contained GFP+ and Kmr cells. To test these strains for pGFLIP functionality, 
we suspended a single GFP+ colony of each strain in PBS and plated on BG, BG/Km, 
BG/MgSO4, and BG/Km/MgSO4 agar and observed colony formation and GFP fluorescence 
after two (B. bronchiseptica) or four (B. pertussis) days incubation at 37°C.  
 When plated under promoter-active conditions (20 mM MgSO4 for RB50flaAFLP; no 
added MgSO4 for RB50cyaAFLP) in the absence of Km, all RB50flaAFLP and RB50cyaAFLP 
colonies examined had lost fluorescence, and when tested subsequently for growth on agar 
containing Km, all colonies had lost Kmr (Fig. 2A and D). As expected, plating either strain 
under promoter-active conditions and in the presence of Km resulted in a lack of growth due to 
loss of nptII from the chromosome (Fig. 2E and H). Conversely, when plated under promoter-
inactive conditions (no added MgSO4 for RB50flaAFLP; 20 mM MgSO4 for RB50cyaAFLP) in 
the presence of Km, all RB50flaAFLP and RB50cyaAFLP colonies maintained fluorescence (Fig. 
2F and G). Likewise, under promoter-inactive conditions in the absence of Km, all 
RB50flaAFLP colonies maintained fluorescence (Fig. 2B), indicating that flaA is not expressed 
under these conditions. Unexpectedly, however, when RB50cyaAFLP was plated under 
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promoter-inactive conditions in the absence of Km selection, approximately 14% of the colonies 
had lost fluorescence at the time of imaging (Fig. 2C). These colonies did not grow when 
restreaked onto BG/Km/MgSO4, indicating that cells in these colonies were not gfp mutants but 
had lost fluorescence and Kmr due to Flp-mediated recombination. These results suggest that the 
transcription activity of PcyaA under Bvg– phase conditions in vitro is close to the threshold level 
of flp transcription required for Flp-mediated recombination between FRT sites. These plate-
based assays for fluorescence and Kmr demonstrated that pGFLIP is indeed functional and that 
both markers (gfp and nptII) can be used to document promoter activation under active and 
inactive conditions. 
 
Kinetic analysis of Bordetella gene activation using pGFLIP.  
We next assessed the ability of this system to monitor gene activation over time in 
bacteria grown in liquid culture. Strains containing pGFLIP plasmids with cyaA, fhaB, ptxA, and 
flaA promoters were grown overnight under promoter-inactive conditions, switched to promoter-
active conditions, and the percent resolution (i.e., loss of GFP fluorescence and Kmr) was 
calculated over 8 h. For the first 4 h after switching from Bvg+ phase to Bvg– phase conditions, 
the percentage of RB50flaAFLP colonies that had lost fluorescence remained below 20% (Fig. 
3A), indicating that less than 20% of the bacteria had reached or surpassed the threshold of flp 
expression to result in recombination during this time. Approximately 75% of cells had lost 
fluorescence at 6 h, and this proportion was maintained at 8 h (Fig. 3A). When grown under 
Bvg– phase conditions for 24 h, greater than 85% of cells demonstrated a loss of fluorescence 
and Kmr (data not shown). The fact that resolution did not reach 100% suggests that the 
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maximum level of flaA expression under in vitro Bvg– phase conditions (SS medium containing 
20 mM MgSO4) is just at or above the threshold of flp expression needed for Flp-mediated 
recombination between FRT sites. The relatively long amount of time required for the majority 
of RB50flaAFLP cells to cross the threshold of flp expression is in agreement with a previous 
study that examined the expression kinetics of the BvgAS-regulated operon frlAB, which 
encodes the E. coli FlhDC homologs FrlAB that are at the top of the flagella transcription 
cascade in B. bronchiseptica (16). Upon shifting from Bvg+ phase to Bvg– phase conditions, a 
frlAB-lacZ fusion strain exhibited a gradual increase in β-galactosidase activity over time, 
reaching approximately 40% of the maximum overnight expression level by 7.5 h (15).  
 In contrast, when RB50fhaBFLP were switched from Bvg– phase to Bvg+ phase 
conditions, the fhaB promoter was apparently activated as early as 1 h, at which time 
approximately 75% of cells had lost fluorescence (Fig. 3A). At 2 h and later time points, nearly 
100% of RB50fhaBFLP cells had lost fluorescence, consistent with the classification of fhaB as a 
class 2 gene requiring a relatively low level of BvgA~P for activation. As a canonical class 1 (or 
“late”) gene, ptxA had only been activated in approximately 8% of cells at 1 h (Fig. 3A). 
Approximately 20% of cells had activated ptxA by 4 h, increasing to 90% of cells by 8 h. 
Surprisingly, cyaA, which is also considered to be a class 1 gene, was activated in over 85% of 
cells at 1 h, and in greater than 95% of cells at 2 h and later time points (Fig. 3A). These data 
suggest that at early time points after switching to promoter-active conditions, the cyaA promoter 
is activated to a level sufficient to drive flp-mediated recombination. This result was unexpected 
based on cyaA transcription results in studies of B. pertussis (5, 11, 18, 23, 24). 
 At the initiation of each kinetic experiment, we observed a consistent background 
resolution (i.e., the percent resolution at 0 h) for each Bvg+ phase promoter in pGFLIP. 
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RB50cyaAFLP displayed the highest background resolution at 8.9%, while the background 
resolution for fhaB and ptxA was significantly lower at 1.54% and 1.99%, respectively (p < 
0.01). The background resolution for RB50flaAFLP was the lowest of the pGFLIP constructs at 
0.23% (Fig. 3A). The fact that a portion of RB50cyaAFLP cells had lost fluorescence at 0 h 
suggests that low-level expression of cyaA might be occurring in a BvgAS-independent manner, 
which could interfere with measuring BvgAS-dependent PcyaA activation over time. Therefore, to 
test the sensitivity of pGFLIP to background resolution we grew RB50cyaAFLP, RB50fhaBFLP, 
and RB50ptxAFLP strains overnight as in Fig. 3A, washed the cells to remove Km, and 
maintained the cultures under Bvg– conditions in the absence of selection for 8 h. At 0, 1, 4, and 
8 h, the percent resolution was determined for each strain. We hypothesized that if PcyaA was 
indeed active under Bvg– conditions we would observe a steady increase in resolution over time 
for RB50cyaAFLP but not for RB50fhaBFLP or RB50ptxAFLP. As expected, RB50cyaAFLP 
displayed the greatest background resolution at 11.9%, increasing to 18.1% at 8 h (Fig. 3B). Loss 
of fluorescence for RB50fhaBFLP and RB50ptxAFLP remained essentially unchanged over 8 h, 
averaging 0.22% and 5.4%, respectively (Fig. 3B). Although cyaA had been activated in 
approximately one-fifth of the population at 8 h, these data do not account for the >85% 
resolution observed for RB50cyaAFLP as early as 1 h following the switch to Bvg+ phase 
conditions.   
Neither the B. bronchiseptica bvgAS allele nor PcyaA accounts for the unexpectedly early 
activation of cyaA.  
As cyaA expression in RB50 was activated unexpectedly early compared to what has 
been observed for B. pertussis (5, 11, 18, 23, 24), we sought to determine whether differences in 
the cyaA promoter or in the bvgAS allele between B. bronchiseptica and B. pertussis accounted 
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for this difference. There are five single nucleotide changes and one nucleotide insertion in the 
sequence 5′ to cyaA in B. bronchiseptica RB50 compared to B. pertussis BPSM. We 
hypothesized that replacing the cyaA promoter of RB50 with that of BPSM would delay the 
activation of PcyaA relative to PfhaB, similar to what was observed by Veal-Carr et al. (24). We 
cloned the cyaA promoter from B. pertussis BPSM into pGFLIP and introduced this plasmid into 
RB50, generating strain RB50cyaABpFLP. When evaluated in the kinetic assay, there was no 
difference in the rate of resolution between RB50cyaAFLP and RB50cyaABpFLP, suggesting that 
differences in the cyaA promoter do not account for the rapid resolution observed in B. 
bronchiseptica (Fig. 4).  
 Some strains of B. pertussis, such as BP338 and BPSM, exhibit decreased sensitivity to 
chemical modulation compared to B. bronchiseptica RB50 due to amino acid differences in 
BvgS, which causes these strains to remain in the Bvg+ phase at a lower concentration of 
modulator compared to RB50 (22). We hypothesized, therefore, that the bvgAS allele from 
BP338 would permit activation of cyaA more quickly and in a greater percentage of cells 
compared to the B. bronchiseptica RB50 bvgAS allele. To assess this, we utilized strain RB52, 
which contains the entire bvgAS locus and bvgA promoter from B. pertussis BP338 in place of 
bvgAS in RB50 (22). RB52 recapitulates the decreased sensitivity to modulation characteristic of 
both BP338 and BPSM, requiring ≥ 40 mM MgSO4 to modulate to the Bvg– phase, in contrast to 
RB50, which requires ≥ 10 mM MgSO4 to fully modulate (15, 22). We introduced pGFLIP 
containing the RB50 cyaA promoter driving flp expression into RB52, producing strain 
RB52cyaABbFLP. We evaluated the kinetics of cyaA activation in RB52cyaABbFLP compared to 
RB50cyaAFLP and did not observe any difference. Likewise, when we evaluated an RB52 
derivative containing the BPSM cyaA promoter driving flp expression (RB52cyaABpFLP) in the 
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kinetic assay, there was no impact on cyaA activation compared to RB50cyaAFLP. Together, 
these data suggest that neither the cyaA promoter nor the bvgAS allele significantly affects the 
kinetics of cyaA activation in B. bronchiseptica as reported by the PcyaA-flp promoter fusion in 
pGFLIP (Fig. 4). 
 
Evaluation of Bordetella promoter activation in vivo.  
Although the kinetics of Bvg+ phase gene activation in vivo have been examined for B. 
pertussis (24), these experiments have not been done in B. bronchiseptica or in the context of a 
natural bacteria-host interaction. To address BvgAS-regulated gene activation in B. 
bronchiseptica in vivo, we infected BALB/c mice intranasally with 1 × 105 cfu of the RB50 
pGFLIP strains shown in Fig. 3A, grown under promoter-inactive conditions (100 µg/ml Km, 20 
mM MgSO4). Mice were sacrificed and lungs were harvested at 1 h and 30 h p.i. Lungs were 
homogenized and dilutions were plated on BG agar containing 20 mM MgSO4 to prevent further 
recombination. Total cfu were enumerated and the percentage of colonies that had lost 
fluorescence (% resolution) was calculated for each strain and time point. The percentage of 
RB50fhaBFLP that had lost fluorescence at 1 h was 95.3 ± 0.60%, while only 5.4 ± 0.69% of 
RB50ptxAFLP had lost fluorescence at this time (Fig. 5). Similar to the in vitro kinetic assay 
(Fig. 3A), the majority (85.3 ± 3.3%) of RB50cyaAFLP cells had lost fluorescence at 1 h. At 30 
h p.i., essentially all cells had lost fluorescence, indicating that the environment in the mouse 
induces the expression of Bvg+ phase genes to a level at or above that required to activate flp 
expression (Fig. 5). The fact that the pGFLIP system functions in vivo much the same as in vitro 
when switched from Bvg– to Bvg+ phase conditions suggests that the pattern of Bvg+ phase gene 
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activation is similar between these two conditions and that the unexpectedly early expression 
from the cyaA promoter in vitro was not due to an artifact of that assay.  
 Although all evidence thus far suggests that the Bvg+ phase is necessary and sufficient for 
Bordetella spp. to cause respiratory infection in rats and mice (6, 7, 22, 33), it is possible that 
rare in vivo environments exist that induce modulation to the Bvg– phase. Therefore, using the 
activation of the flaA promoter as an indicator of the Bvg– phase, we infected mice as described 
above and evaluated the loss of fluorescence at 1 h and 30 h p.i. We did not observe activation of 
flaA in any RB50flaAFLP cells at 1 h, 30 h, 3 d, 5d, or 7 d (Fig. 5). These data suggest that B. 
bronchiseptica do not enter the Bvg– phase in the mouse during the time period that we 
examined.  
 
Kinetic analysis of Bordetella gene activation in B. pertussis reveals delayed activation of 
cyaA compared to B. bronchiseptica.  
Due to the observation that neither the cyaA promoter nor the bvgAS allele affects the 
kinetics of cyaA activation in B. bronchiseptica, we hypothesized that additional, species-specific 
factors account for the differences in the activation of cyaA. To evaluate this possibility, we 
delivered the same pGFLIP plasmids as those used in B. bronchiseptica to the chromosome of B. 
pertussis BPSM and evaluated loss of fluorescence in the kinetic assay. We reasoned that if the 
activation of cyaA, fhaB, and ptxA in B. pertussis resembled the pattern seen in B. 
bronchiseptica, then the discrepancy with was likely due to differences in resolvase/recombinase 
expression sensitivity between pGFLIP and RIVET (i.e., Flp recombinase is activated at a lower 
threshold of PcyaA activity than TnpR, making cyaA appear to be activated sooner in the Flp-FRT 
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system). Alternatively, if activation of cyaA, fhaB, and ptxA was canonical as in Veal-Carr et al. 
(24), then the difference in cyaA activation would be attributed to species-specific gene 
regulation. 
 In contrast to what we observed in B. bronchiseptica, the proportion of BPSMcyaAFLP 
that had lost fluorescence at 1 h was less than 10%, essentially equal to the level of background 
resolution (Fig. 6). There was a steady loss of fluorescence in BPSMcyaAFLP beginning at 2 h 
post-switch and continuing until 6 h, at which time greater than 90% of colonies had lost 
fluorescence. The pattern of PcyaA activation in B. pertussis matched that of PptxA, which displayed 
similar but somewhat earlier activation in B. pertussis compared to B. bronchiseptica (Fig. 6). 
Interestingly, the loss of fluorescence in BPSMfhaBFLP occurred more slowly compared to 
RB50fhaBFLP, with approximately 55% of cells having lost fluorescence at 1 h. At 2 h post-
switch the proportion of GFP– BPSMfhaBFLP equaled that of RB50fhaBFLP at 1 h, indicating 
that the activation of PfhaB may be delayed in B. pertussis compared to B. bronchiseptica; 
however, the background resolution for BPSMfhaBFLP (29.5 ± 11.3%) was substantially higher 
compared to RB50fhaBFLP. At 1.99%, the background resolution for BPSMptxAFLP was 
identical to that seen for RB50ptxAFLP, while the background for BPSMcyaAFLP (4.8 ± 2.2%) 
was not significantly different compared to RB50cyaAFLP (Fig. 6).  
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Discussion 
 Evaluating bacterial gene expression within the host is critical for understanding the 
complex host-pathogen interactions that result in disease, clearance, or asymptomatic 
colonization. One approach that has been developed to evaluate gene expression in the host is in 
vivo expression technology (IVET) (34). In IVET, promoter sequences are cloned 5′ to a gene 
that either confers resistance to an antibiotic or complements a specific auxotrophy (34-36). 
Under conditions in which the promoter is active, these genes are expressed and permit the 
survival of bacteria in hosts that have either been dosed with the relevant antibiotic (for antibiotic 
resistance-based selection) or naturally lack the ability to complement the auxotrophy (for 
auxotrophy-based selection) (34). A drawback of using IVET is that promoters that are activated 
transiently or at a low level may not be identified due to insufficient production of the missing 
survival factor (34). In RIVET, a modification of IVET, a promoter of interest drives the 
expression of a site-specific recombinase that irreversibly excises a genetic marker, often an 
antibiotic resistance gene (24, 34, 37). By selective plating it is possible to determine if the 
promoter of interest was active at some time during infection. Unlike IVET, RIVET permits the 
detection of transiently or weakly expressed genes because the recombinase-mediated loss of a 
marker need only occur once to document promoter activation (34).  
 pGFLIP is a pUC18-based plasmid that, while conceptually similar to RIVET, possesses 
several advantages over this well-characterized genetic tool. The Tn7 transposon system 
specifically delivers sequences to the attTn7 site located 3′ to the highly conserved glmS gene, 
which provides pGFLIP with an especially broad host range that includes many Gram-negative 
bacteria (38). As a result of this specific recombination at the attTn7 site, only one integration 
event is required for all components of pGFLIP to be delivered in single copy to the bacterial 
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chromosome. Single-copy delivery eliminates potential gene dosage issues inherent to multi-
copy plasmid systems, and integration at the attTn7 site does not disturb the native locus of the 
gene to be tested. Once delivered, a Tn7 transposon is stable in the absence of selection, unlike 
suicide plasmids that have been integrated into the chromosome via single-crossover 
homologous recombination, which can spontaneously resolve in the absence of selection. In 
contrast with other published systems, pGFLIP also possesses two markers—gfp and nptII—
allowing either the loss of fluorescence or Kmr to indicate promoter activation.  
 In this study, we used pGFLIP to analyze the transcription activation of Bvg-regulated 
genes in both B. bronchiseptica RB50 and B. pertussis BPSM. Our results showed that, in vitro, 
fhaB and ptxA promoters were activated early and late, respectively, following a switch from 
Bvg– to Bvg+ phase conditions, which is in agreement with previous reports for both Bordetella 
species (15, 23, 24). However, the cyaA promoter was activated unexpectedly early in our assay; 
these results appear to stand in contradiction to the established view that cyaA is transcribed 
solely as a late gene. Using B. bronchiseptica RB50 in a BALB/c mouse model, we found that 
the pattern of gene activation for cyaA, fhaB, and ptxA was nearly identical to that observed in 
vitro at early time points. Veal-Carr et al. reported similar agreement between in vitro and in vivo 
gene activation patterns using RIVET (24), although in that study, maximal activation of fhaB, 
cyaA, and prn occurred over a much greater time scale (approximately 24 h to full activation), 
likely a result of differences in sensitivity between the TnpR-res and Flp-FRT systems. Our use 
of pGFLIP to evaluate gene activation in B. bronchiseptica is both the first kinetic analysis of 
PcyaA and the first in vivo kinetic analysis of any promoter to be reported for this organism.  
Although we expected PcyaA to behave like a class 1 promoter in B. bronchiseptica, based 
on gene activation and expression data obtained by us and others for B. pertussis (5, 11, 18, 23, 
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24), our data nevertheless suggest that PcyaA acts more like a class 2 promoter in this organism. 
However, it is not necessarily the case that cyaA reaches maximal expression at 1–2 h following 
a switch from Bvg– phase to Bvg+ phase; it is possible that cyaA activation occurs in a stepwise 
manner, i.e., PcyaA may rapidly reach a level of expression necessary to activate flp transcription 
in our system, but may not reach maximal expression until much later. This scenario would 
account for the apparently rapid activation of PcyaA without requiring a bacterium to be producing 
and secreting a significant amount of ACT immediately upon switching to non-modulating 
conditions. Evidence exists to support cyaA activation and ACT production, albeit at a reduced 
level, in the Bvgi phase, as strains RB50i and RB53i are slightly hemolytic on BG agar (a 
consequence of the hemolysin activity of ACT), and RB53i produces measurable levels of cyaA 
transcript (9). We were able to determine that neither differences in the cyaA promoter nor in the 
bvgAS allele between the two species accounted for the difference in cyaA activation (see Fig. 4), 
suggesting that other, potentially Bvg-independent, factors may be influencing cyaA activation in 
B. bronchiseptica compared to B. pertussis.  
 In B. pertussis BPSM, PcyaA demonstrated an activation pattern consistent with both 
indirect (RIVET) and direct (RNA hybridization) assessments, reinforcing the conclusion that 
cyaA activation is indeed different between RB50 and BPSM (23, 24). Given the differences in 
host range and the ability of B. bronchiseptica to survive outside of a host (7, 9, 10, 33), it is 
possible that the relatively early activation of cyaA in B. bronchiseptica is advantageous during 
the establishment of infection in a mammalian host or in transmission between hosts. Previous 
studies have shown that RB50 cyaA deletion mutants are more susceptible to clearance from the 
mouse respiratory tract, presumably as a result of neutrophil-mediated killing, and that ACT may 
interact with FHA (an “early” Bvg+ gene) on the cell surface and modulate cytokine production 
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by the host (39, 40). All strains of B. bronchiseptica that have been tested show the same 
modulation characteristics in vitro (i.e., the same relatively low concentration of modulator is 
required for inducing the Bvg– phase), while B. pertussis isolates exhibit variable resistance to 
modulation at concentrations of modulator equal to or greater than for B. bronchiseptica (22). 
These observations suggest that early expression of cyaA may not be detrimental to human-
adapted B. pertussis but may be necessary for B. bronchiseptica to establish an infection.  
 For both B. bronchiseptica and B. pertussis it has been shown that the Bvg+ phase is 
necessary and sufficient for infection (6, 7, 9, 16, 22). Our results do not contradict these 
observations for B. bronchiseptica, but demonstrate that once inside the host, bacteria begin to 
transcribe Bvg+ phase genes within 1 h p.i., with essentially every cell having activated fhaB, 
cyaA, and ptxA by 30 h p.i. The transition of B. bronchiseptica from Bvg– phase to Bvg+ phase 
upon inoculation also indicates that the mouse lung is a Bvg+ phase environment. We likewise 
provided evidence that B. bronchiseptica does not modulate to the Bvg– phase in vivo, supporting 
studies conducted using Bvg– phase-locked mutants that were unable to establish an infection 
and were quickly cleared from the respiratory tract and those using Bvg+ phase-locked mutants 
that displayed no colonization defect (7, 8). Moreover, ectopic expression of flagellin in Bvg+ 
phase B. bronchiseptica results in impaired persistence in the rat respiratory tract, possibly due to 
an immune response to this antigen (16). Therefore, modulation to the Bvg– phase likely does not 
occur in vivo as it would be disadvantageous to bacterial survival. We cannot rule out the 
possibility, however, that some Bvg+ RB50flaAFLP bacteria did modulate to the Bvg– phase and 
were quickly eliminated by the immune response, or were present in a niche other than the lung 
(such as the trachea or nasopharnx) and were not represented in the lung homogenates that we 
analyzed. It is also conceivable that B. bronchiseptica is able to partially modulate, perhaps to 
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the Bvgi phase, which would not be documented using RB50flaAFLP. We are currently 
constructing additional strains to test this possibility.  
  The pGFLIP plasmid has proven to be useful in understanding the regulation of gene 
activation in Bordetella. However, there remain caveats for the use of this system in other 
applications. As with other IVET and RIVET systems, pGFLIP requires that strains be 
manipulated under strict promoter-inactive conditions to prevent unwanted Flp-mediated 
resolution. This requirement poses problems for studying genes for which conditions of 
repression or lack of activation are unknown, genes that are essential for growth, and for genes 
that may not be fully transcriptionally inactive in vitro. And, like other systems that have been 
developed to monitor transcription, pGFLIP cannot provide information about post-
transcriptional or post-translational regulation of target genes. Finally, as was shown by the 
variable background resolution of Bvg-regulated promoters in our study, pGFLIP appears to be 
sensitive to low-level promoter activation even under “repressed” conditions for certain genes. 
Lee et al. were able to modulate the sensitivity of RIVET by mutating the ribosome-binding site 
(RBS) of tnpR, effectively raising the threshold of promoter activity required for resolution (41). 
pGFLIP does not possess an RBS 5′ to flp, instead relying on the RBS of the promoter of 
interest, though it would be feasible to develop a modified pGFLIP plasmid that contains an RBS 
with reduced sensitivity to permit the study of genes that are not fully inactive or are 
constitutively active at a low level. 
 In this study we used pGFLIP to detect the activation of BvgAS-regulated genes in 
Bordetella, but there are additional uses for this system to measure transcription activation at the 
population or single cell level. Using pGFLIP, fluorescence can be used to quickly differentiate 
cells that have activated the promoter of interest from those that have not. Over time, stochastic 
238 
 
and/or transient promoter activation can result in sectoring of fluorescent colonies, permitting 
spatiotemporal observation of gene activation within a single colony (M. S. Byrd and E. Mason, 
unpublished observation). The addition of a second, non-gfp fluorescent label (e.g., a 
constitutively expressed fluorescent protein or a fluorescently labeled antibody) to cells already 
containing pGFLIP would allow cells that had activated the promoter of interest to be 
differentiated from cells that had not. Cells labeled using such an approach could be visualized 
using fluorescence-activated cell sorting or by microscopy. We are currently developing an 
improved pGFLIP plasmid that contains a constitutively expressed fluorescent protein gene not 
flanked by FRT sites that will provide a two-color to one-color readout upon activation of flp by 
the promoter of interest. The development of pGFLIP has resulted in a sensitive genetic tool that 
can be used to document promoter activation in a broad range of Gram-negative bacteria both in 
vitro and in vivo. Our use of pGFLIP to document the activation of Bvg-regulated promoters 
revealed unexpectedly early activation of cyaA in B. bronchiseptica, suggesting a possible 
explanation for the less restrictive host range of this organism compared to B. pertussis, and is 
the first in vivo use of a recombination-based genetic reporter of B. bronchiseptica gene 
activation.  
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Table 1. Strains and plasmids used in this study. 
Strain or Plasmid Description 
Source 
or 
referenc
e 
Strains   
E. coli   
DH5α Molecular cloning strain (28) 
RHO3 Conjugation strain; Kms, ∆asd, ∆aphA (29) 
Bordetella   
RB50 Wild-type B. bronchiseptica strain; Smr (7) 
RB52 RB50 containing bvgAS from BP338; Smr (22) 
BPSM Smr Tohama I derivative (29, 42) 
RB50FLP RB50 with promoterless pGFLIP integrated at attTn7 
This 
study 
RB50cyaAFLP 
RB50 with flp recombinase driven by PcyaA integrated 
at attTn7 
This 
study 
RB50cyaABpFLP 
RB50 with flp recombinase driven by PcyaA from 
Tohama I integrated at attTn7 
This 
study 
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RB52cyaABbFLP 
RB52 with flp recombinase driven by PcyaA from RB50 
integrated at attTn7 
This 
study 
RB52cyaABpFLP 
RB52 with flp recombinase driven by PcyaA from 
Tohama I integrated at attTn7 
This 
study 
RB50fhaBFLP 
RB50 with flp recombinase driven by PfhaB from RB50 
integrated at attTn7 
This 
study 
RB50ptxAFLP 
RB50 with flp recombinase driven by PptxA from 
Tohama I integrated at attTn7 
This 
study 
RB50flaAFLP 
RB50 with flp recombinase driven by PflaA integrated at 
attTn7 
This 
study 
BPSMFLP BPSM with promoterless pGFLIP integrated at attTn7 
This 
study 
BPSMcyaAFLP 
BPSM with flp recombinase driven by PcyaA from RB50 
integrated at attTn7 
This 
study 
BPSMfhaBFLP 
BPSM with flp recombinase driven by PfhaB from RB50 
integrated at attTn7 
This 
study 
BPSMptxAFLP 
BPSM with flp recombinase driven by PptxA integrated 
at attTn7 
This 
study 
Plasmids   
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pUC18T-mini-Tn7T-Km-
FRT 
Mobilizable transposition vector; Apr, Kmr (30) 
pFLPe4 
Site-specific excision vector, source of Flp 
recombinase; Apr, Kmr 
(30) 
mini-Tn7-kan-gfp 
Mobilizable transposition vector, source of gfp driven 
by PS12; Kmr 
(31) 
pTNS3 
Tn7 transposase expression vector containing 
tnsABCD; Apr 
(30) 
pGFLIP 
pUC18-based vector with PS12-gfp and nptII flanked by 
FRT sequences and flp 3′ to the MCS; Apr, Kmr  
This 
study 
pGFLIP-PcyaA 
pGFLIP with flp recombinase driven by the RB50 cyaA 
promoter, Apr, Kmra  
This 
study 
pGFLIP-PcyaABp 
pGFLIP with flp recombinase driven by the BPSM 
cyaA promoter, Apr, Kmra  
This 
study 
pGFLIP-PfhaB 
pGFLIP with flp recombinase driven by the RB50 fhaB 
promoter, Apr, Kmra  
This 
study 
pGFLIP-PptxA 
pGFLIP with flp recombinase driven by the BPSM 
ptxA promoter, Apr, Kmra  
This 
study 
pGFLIP-PflaA pGFLIP with flp recombinase driven by the RB50 flaA This 
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promoter, Apr, Kmra  study 
aKmr only under promoter-inactive conditions 
 
 
Table 2. Primers used in this study. 
Primer Sequence (5′-3′)a Description 
FLP_UP ATCTACGGTACCATGAGCCAGTTCGATATCC Forward and reverse 
primers to amplify flp 
from pFLPe4 
FLP_DN AGGTCCAGGCCTCTATATGCGTCTATTTATG 
GFP_UP ATATATGGATCCCAGCTGTTGACTCGCTTG Forward and reverse 
primers to amplify gfp 
from mini-Tn7-kan-gfp GFP_DN ACCTGGGGATCCTTATTTGTATAGTTCATCC 
Tn7seqF GAGCGCTTTTGAAGCTGATGTGCT 
Forward sequencing 
primer annealing 
within Tn7R 
gfpseqR GATGACGGGAACTACAAGACACGT 
Reverse sequencing 
primer annealing 
within gfp 
kanseqR ATCGCCTTCTATCGCCTTCTTGAC Reverse sequencing 
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primer annealing 
within nptII 
GFLseq1 ACGGTGAAAACCTCTGACACATGC 
Forward sequencing 
primers for sequencing 
pGFLIP by primer-
walking 
GFLseq2 CTGAAATCAGTCCAGTTATGCTGTG 
GFLseq3 AAATCCGCCGCTAGGAGCTT 
GFLseq4 GTCTGCCATGATGTATACATTGTGTG 
GFLseq5 GGGACAACTCCAGTGAAAAGTTCTTC 
GFLseq6 CTGATGCTCTTCGTCCAGATCATC 
GFLseq7 CCTGCGTGCAATCCATCTTGTTCA 
GFLseq8 CAGGGGATCTTGAAGTTCCTATTCCG 
GFLseq9 GCAACAATTCTGGAAGCCTCATT 
GFLseq10 TCTTTAGCGCAAGGGGTAGGATCG 
GFLseq11 TCCAATTGAGGAGTGGCAGCAT 
GFLseq12 TATCAGAGCTTATCGGCCAGCCT 
GFLseq13 ATAAAGATACCAGGCGTTTCCCCC 
GFLseq14 AAACAAACCACCGCTGGTAGC 
GFLseq15 CGCAGAAGTGGTCCTGCAACTTTA 
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GFLseq16 CCGCGCCACATAGCAGAACTTTAA 
gflpmcsF GTTGACAAAGGGAATCAGGGGATC  
Forward sequencing 
primer for inserts in the 
MCS 
gflpmcsR GAACTGGGTGTAGCGTCGTAAGCT 
Reverse sequencing 
primer for inserts in the 
MCS 
glmSF CAGCTGCTGTCGTACCACACGG 
Forward primer to 
confirm Tn7 insertion 
at glmS by PCR 
cyaA_F ATTATAGAGCTCTGCGAGCAGATGCAC Forward and reverse 
primers to amplify 
PcyaA from RB50 and 
BPSM 
cyaA_R TATAATGGTACCGTGGATCTGTCGATAAGTAG 
ptxprF AGCTTCGAGCTCCAAGATAATCGTCCTGCTC Forward and reverse 
primers to amplify PptxA 
from BPSM  
ptxprR ATATATGGGCCCTCCCGTCTTCCCCTCT 
fhaprF2 AGGCCTGAGCTCGATAAGAAGAATATGCTT Forward and reverse 
primers to amplify PfhaB 
from RB50 
fhaprR2 ATATTCGGTACCATTCCGACCAGCGAAGTG 
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flaA_F AATGAGCTCGCCGTGCTCAACGTCA Forward and reverse 
primers to amplify PflaA 
from RB50 
flaA_R ATTATAGGTACCAGGCTCCCAAGAGAGAAA 
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Figure 1. Design and Mechanism of pGFLIP 
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Figure 2. Plate-based validation of pGFLIP 
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Figure 3. Kinetic analysis of Bordetella gene activation in vitro 
 
  
249 
 
Figure 4. Effect of PcyaA and bvgAS alleles on cyaA activation in B. bronchiseptica 
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Figure 5. Analysis of Bordetella gene activation in vivo using pGFLIP 
 
  
251 
 
Figure 6. Kinetic analysis of Bordetella gene activation in vitro in B. pertussis 
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